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In recent decades, obesity has become a worldwide challenge, effecting many people and 
has shown a constant increase since the late 1960s. Over half of the Dutch population is 
overweight (BMI 25-29.99 kg/m2) and 15% is considered to be obese (BMI ≥ 30kg/m2). 
The latter has doubled compared with 19901. The World Health Organization reported 
that in 2016 more than 1.9 billion adults were overweight (39% of the population), of 
which 650 million were obese. Despite all treatments, the worldwide prevalence has 
tripled since 19752. Morbid obesity, also called class III obesity, is defined as a BMI 
≥40 kg/m2, 3, 4. It is estimated that 1-2% of the Dutch population suffers from morbid 
obesity5.
Obesity is associated with a significant increase in mortality, and brings with it added 
health risks such as type 2 diabetes mellitus, hypertension, hypercholesterolemia, 
obstructive sleep apnea syndrome (OSAS), heart disease, diverse forms of cancer and 
musculoskeletal disorders6-11. The risk of diseases and disorders is significantly increased 
by growth in the body mass index (BMI) or the waist circumference12. The risks are not 
only limited to somatic diseases, obesity also comes with a higher risk of psychosocial 
problems, stigmatization and discrimination when compared to people with a healthy 
weight13. Additionally the spread of anxiety disorders and depression increases14.
Furthermore, obesity has severe social and economic effects. The number of unhealthy 
years of life (spent with illness and disabilities) as a result of being overweight increases, 
as well the social costs due to disability and sickness absence and additional health care 
costs1, 15, 16.
Although challenging, it is important to counteract and decrease the number of patients 
with obesity. On an individual level, people can limit energy intake from total fats and 
sugars, increase consumption of fruit and vegetables, whole grains and nuts and engage 
in regular physical activity2. On a societal level, it is important to support individuals in 
following the recommendations above, through sustained implementation of evidence-
based and population-based policies that make regular physical activity and healthier 
dietary choices available, affordable and easily accessible to everyone, particularly for 
the poorest  individuals in our population2. The food industry also plays a significant 
role in promoting (un)healthy dietary behavior. Unfortunately, maintaining weight loss 
on the long-term is difficult and often weight regain occurs17, 18.  
Since conservative treatment is not sufficient to achieve long-term significant weight loss 
in the majority of patients with (morbid) obesity, metabolic surgery or bariatric surgery (the 
Greek words “baros” meaning “weight” and “iatrikos” meaning “medicine”) is regularly 
performed to induce weight loss19. The amount of patients that underwent metabolic surgery 
has increased enormously because it is the only therapy currently achieving successful 
long-term sustained weight loss20-22. Worldwide over 575.000 metabolic procedures 
were performed in 2014 which is a 23% increase compared to 201323. From 2015 up to 
14
and including 2018, the Dutch Audit for Treatment of Obesity (DATO) registered 45582 
bariatric procedures in the Netherlands23. However, metabolic surgery has been taking 
place since 1995, so the estimated total number of patients operated is much higher, 
probably above 100,000 including those who are operated across the border (Belgium). 
To be eligible for metabolic surgery, the patient must have a BMI ≥ 40 kg/m2 or a BMI 
≥ 35 kg/m2 with a comorbidity related to obesity24. Eligible comorbidities are OSAS, 
osteoarthritis, hypertension, hypercholesterolemia and diabetes mellitus type 2. In 
keeping with the policies of some other countries, metabolic surgery is only considered 
when it is a last resort treatment after conservative treatments have failed. This ´last 
resolve´ criterion is frequently debated because conservative treatments for this group 
of patients have often proven to be ineffective in the long term.
This thesis focusses on micronutrient deficiencies after metabolic surgery, so it 
is necessary to give a short overview of the most common procedures performed 
worldwide.
PROCEDURES
In Europe, from the mid-90s till up to 2010, the adjustable gastric band (AGB) procedure was 
performed in most patients. Later the Roux-en-Y gastric bypass (RYGB) became the leading 
procedure, as the AGB showed disappointing results on clinical outcomes and weightloss25. 
Worldwide, the two most commonly performed procedures to alter the normal anatomy 
(figure 1) are now the sleeve gastrectomy (SG, figure 2) and the Roux-and-Y gastric 
bypass (RYGB, figure 3)23. In recent years the procedures showing an increase in numbers 
are the mini-gastric bypass or one anastomosis gastric bypass (MGB and OAGB, figure 
4) and the single anastomosis duodeno-ileal switch (SADI-S, figure 5). More extensive 
interventions are the biliopancreatic diversion with or without a duodenal switch (BPD-
DS, figure 6). These procedures are not performed in large numbers and are mostly 
reserved for extremely morbid obese patients (BMI > 60kg/m2). Many techniques 
have been used in the past and many trials are currently underway to help establish the 
optimal procedure for morbid obesity with the best chances for weight loss, little weight 
regain, minimal complications and good comorbidity outcomes. 
Sleeve Gastrectomy
During a SG procedure, the greater curvature of the stomach is mobilized by dividing 
the gastrocolic omentum up to the angle of His superiorly and inferiorly to the antrum 
approximately 3–6 cm proximal to the pylorus26, 27. A sleeve is created around a 32- 
to 40-French bougie28. A large part of the stomach is removed (figure 2). The tubular 
stomach is small in its capacity (restriction) and resistant to stretching due to the absence 
of the fundus. Compared to other metabolic procedures it is considered a less technically 




after three years is about 60 to 70% in the first years after surgery (percentage total body 
weight loss (TBWL) is 25-30%)26, 29.
 
Figure 1. Normal anatomy (© E.O. Aarts)
Figure 2. Sleeve gastrectomy (© E.O. Aarts)
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Roux-en-Y Gastric Bypass 
During a RYGB procedure in the Rijnstate hospital, the stomach is reduced to a 30-
45cc pouch which causes restriction in dietary intake. Starting from Treitz, the small 
bowel is measured to a length of 75 centimeters. This limb will eventually become the 
biliopancreatic limb. Next, an antecolic antegastric end-to-side gastro-enterostomy is 
created. An alimentary limb (Roux limb) of 150 centimeters of small bowel is measured 
and a entero-enterostomy is created. As a last step, the small bowel is dissected in 
between the gastro-enterostomy and the entero-enterostomy (figure 3). 
The result is a small pouch from which food passes through the gastro-enterostomy into 
the Roux limb. Only after the entero-enterostomy, do the secretions from the gastric 
remnant, liver, and pancreas come into contact with the ingested foods. Major digestion 
and absorption of nutrients only occur in the resultant common channel where pancreatic 
enzymes and bile mix with ingested food. The distal part of the stomach, duodenum and 
the proximal jejunum is bypassed, which induces a change in incretin levels leading to 
anorexia and weight loss27. The percentage EWL after three years is > 70% (30-35% 
TBWL)26, 29. 
Figure 3. Roux-en-Y Gastric Bypass (© E.O. Aarts)
Mini Gastric Bypass/One Anastomosis Gastric Bypass 
A MGB, or OAGB is a gastric bypass with just a single anastomosis (figure 4)30, 31. After 
a tubular gastric pouch is created of 10-15cm in length, a jejunal loop is brought to the 




bowel, to create the loop30, 32. This biliary limb that is created is between 150 and 220 
centimeters. The %-EWL is comparable with the RYGB, ranging from 70 to 85% after 
five years of follow-up (35-40% TBWL)29, 32. The biggest disadvantage are higher rates 
of alkaline bile reflux which can lead to reflux, ulcer formation and theoretically can 
cause malignant changes after many years32, 33.     
                                                    
Figure 4. Mini Gastric Bypass (© E.O. Aarts)
 
Single Anastomosis Duodenal-Ileal bypass with Sleeve gastrectomy
SADI-S can be performed as a primary but also as a revisional procedure34. First a SG is 
created (see SG), followed by post-pyloric division of the duodenum. The terminal ileum 
is then located and from that reference point 250-300 cm of small bowel is measured. An 
anastomosis is made between this point of midway jejunum (250-300 cm) and the post 
pyloric end of the duodenum. The loop is set up so the efferent limb is descending on the 
patient’s right, and the afferent limb was ascending coming up from the left (figure 5)35. 
The estimated %-EWL is 85% at two years (35-45% TBWL)29, 34. 
In the present thesis the MGB and SADI-S procedures are not included because these 
interventions were not part of any of the articles in this thesis
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Figure 5. Single anastomosis duodeno-ileal switch with sleeve gastrectomy(© E.O. Aarts)





Bilio-Pancreatic Diversion with Duodenal Switch
During a BPD-DS, SG is combined with a BPD –like distal bypass procedure of the 
small intestine. First, a cholecystectomy is performed. The duodenum is stapled and 
transected 2-cm post-pyloric and end-to-side connected to the 150-cm alimentary limb. 
The common channel is very short, approximately 75-100 cm (figure 6). This procedure 
gives higher degrees of protein, nutritional, and vitamin deficiencies and more often 
diarrhoea than any other metabolic procedure but results in greater weight loss. The 
procedure is mostly performed in super morbid obese patients, with a resulting %-EWL 
on the long term of approximately 70 to 80% (35-45% TBWL)29, 36.
Since the switch to more extensive metabolic operations after the failure of the gastric 
band, we started to see more deficiencies in vitamins and minerals37. Despite the excellent 
results in weight loss and the good reduction of comorbidities, metabolic surgery causes 
nutritional deficiencies in up to 100% of patients. Vitamin and mineral deficiencies were 
known in medicine but especially after malnutrition and alcohol abuse but not to such 
a dramatic extent.
METABOLIC SURGERY AS A DISEASE MODEL 
Although mainly used as a treatment for morbid obesity, metabolic surgery is a disease 
model as well. It has many theoretical benefits compared to other research strategies 
to investigate for example weight(loss). Another example is that it can be used to look 
into the reversibility of obesity and its related comorbidities. In comparison with the 
most obvious alternative, dieting, the success rate in terms of sufficient weight loss and 
the reduced timeframe required are fine examples why metabolic surgery is a desired 
disease model. One thus does require less patients and less follow-up time to come in 
conclusions. Another reason why there is so much interest in metabolic surgery, is that 
it gives us the opportunity to investigate the biological routes and (hormonal) changes 
that are required to challenge obesity. Some of these are promising and hopefully lead to 
an alternative obesity treatment. Although not as effective as metabolic surgery, GLP-1 
analogs are for example one of these. 
Unfortunately, it is also these changes induced by metabolic surgery that sometimes 
make it hard to extrapolate these results to the general population. It can be used 
however to look into the separate parts of the digestion system and research uptake. 
However, promising insights and strategies may not work in non-surgical patients at 
all because of the number of bias factor involved. One downside is also, that metabolic 




Vitamins and minerals play an important role in enzymatic reactions for homeostasis, 
metabolism, and neuronal functions. Nutritional deficiencies can cause serious 
hematological, neurological and musculoskeletal complications when left untreated38.
Prior to metabolic surgery, many patients with morbid obesity already have a 
deficient (micro)nutrient status mostly due to an inadequate diet(51%)39-43. There is an 
overconsumption of unhealthy foods, low in nutritional values and a low intake of fruits 
and vegetables44. The most common deficiency preoperatively is found for vitamin D 
(72-100%), due to very limited exposure to natural sun, low milk consumption and a high 
amount of body fat which reduces the bioavailability45-47. Other existing preoperative 
deficiencies are folic acid (0-63%), vitamin B12 (4-37%), ferritin (1-10%), vitamin A 
(2-17%) with raised parathyroid levels (2.8-30.2%) probably all due to low nutritional 
valuable intake43, 48, 49. Results clearly show that after metabolic surgery the number of 
micronutrient deficiencies increases. 
During metabolic surgery the stomach is reduced and is often combined with a form of 
bypass. The most important uptake sites in the intestine are skipped and micronutrient 
deficiencies can easily occur. Reduced availability of acid and intrinsic factor required to 
convert micronutrients to a soluble form and to be absorbed, are considerably reduced 
or lacking. Another reason for the development of deficiencies is that patients consume 
fewer foods and many patients report a intolerance for certain foods such as red meat50, 
51.
Other contributing factors for developing deficiencies include vomiting, poor dietary 
habits, the use of proton pomp inhibitors, noncompliance to multivitamin supplements 
and a change in taste52-54. After a BPD, the part where absorption can take place is even 
shorter.  
The most common deficiencies after metabolic surgery, depending of the type of 
procedure, cut-off value and time after surgery, are ferritin (66%), vitamin B12 (50%), 
folic acid (15%) vitamin B1 (49%), vitamin D (25-73%) and calcium (10%). BPD-DS 
has an additional risk of protein, fat-soluble vitamins A (5-69%), D, E, and K (50-60%), 
as well as calcium deficiency50, 51, 55, 56. 
To prevent nutritional deficiencies and /or to detect them as early as possible, it is 
essential to follow up patients after metabolic surgery. In accordance with international 
guidelines, all patients should be screened preoperatively for vitamin and mineral 
deficiencies because of the high rate of preoperative deficiencies as mentioned above24. 
If deficiencies occur preoperatively, patients are supplemented so that they undergo their 
surgery with corrected values. Postoperatively all patients are advised to use life-long 




In order to diagnose postoperative deficits, patients are invited for follow-up during 
which a list of laboratory tests are performed after 6, 12, 24 and 36 months including 
hemoglobin, sodium, potassium, kidney function, albumin, ferritin, calcium, vitamin 
B12, folic acid, 25-OH-vitamin D and PTH. In addition, less frequent deficits may 
also occur such as vitamins A, B1, B6, B11, K and zinc, depending on the procedure 
performed. These can be measured when a deficiency is suspected, based on clinical 
signs.
After the first two years, patients are advised to continue their laboratory assessment 
on an annual basis for the rest of their lives by their general practitioner. Over time, 
experience shows that patients often discontinue their follow-up visits or simply stop 
using multivitamins58. Not only patients, but also doctors often lose the discipline 
to perform regular nutritional status checks. The focus of the follow-up moments is 
still more on weight loss, weight retention and other/ technical complications than 
on nutritional status. Vitamin and mineral deficiencies are unjustly underestimated 
complications.
Deficiencies may increase unnoticed, until patients get clinical symptoms, which can 
have major consequences38. The deficiencies with their consequences are listed below. 
Iron and anemia
Iron is a trace mineral and is essential in the execution of cellular function. It is required 
for adequate erythrocyte function, muscular function, oxidative metabolism, and 
cellular immune responses59. Iron can occur in the human body in two forms: the divalent 
iron (Fe2+) and the trivalent iron (Fe3+). The Fe2+ is more soluble than the Fe3+ and is 
therefore better absorbed54, 60. In addition, a distinction can be made between heme and 
non-heme iron. Heme iron is for the most part Fe2+ and has (partly) therefore a higher 
bioavailability compared to non-heme iron. Heme iron can only be found in animal 
products. Non-heme iron is found in animal and vegetable products60. The majority of 
consumed iron is non-heme iron and only 10% is heme iron60. 
Although iron can theoretically be absorbed in the whole intestine, the main absorption 
sites are the duodenum and proximal jejunum (figure 7). Gastric acid is necessary to 
reduce Fe3+ to Fe2+ so that iron can be absorbed. Iron deficiency occurs in up to 66% 
after RYGB and has several causes56. As mentioned earlier, the stomach is reduced 
which results in less total gastric acid. In bypass configurations (e.g. RYGB, MGB/
OAGB and BPD-DS) the duodenum and a various part of the jejunum are bypassed. 
A reduced intake and an intolerance for red meat causes less intake of heme iron50, 51. 
Also gastric emptying is increased which causes less time to make contact between the 
nutrients and the intestine61. Added to that are other factors, for example premenopausal 
morbid obese patients tend to lose more iron via their menses on average which leads to 
greater losses. A resulting iron deficiency might lead to a microcytic anemia. But even 
without anemia patients can get complaints. Symptoms besides anemia are dysphagia, 
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glossitis, koilonychia, enteropathy, decreased immune function, fatigue, rapid heart rate/ 
palpitations, decreased work performance and impaired learning ability38, 54, 57.
 
Vitamin B9/B11 (folate) and B12 (cobalamin)
Folate, also known as folic acid or vitamin B11 plays a critical role in the prevention 
of congenital neural tube defects27. It is included in green leafy vegetables, whole-grain 
products, bread, organ meat and dairy. The absorption takes place in the whole small 
intestine and colon (figure 7). Therefore, a deficiency is often caused by reduced intake 
of products containing folate or bad compliance to multivitamins postoperatively27, 
62. Rarely it is caused by malabsorption or by interaction with other medication 
(anticonvulsants, oral contraceptives, and cancer treating agents)54, 62. Symptoms 
common in folate deficiency are changes in pigmentation or ulceration of skin, nails, or 
oral mucosa57.
Vitamin B12 and folate are critical for DNA synthesis, RNA synthesis and DNA 
methylation.  A deficiency can lead to problems in the hematopoiesis with megaloblastic 
anemia as a result.  Other clinical symptoms are glossitis, fatigue, numbness and 
paresthesia in extremities, ataxia, changes in reflexes, demyelination and axonal 
degeneration, especially of peripheral nerves, spinal cord, and cerebrum. Light-
headedness or vertigo, shortness of breath and tinnitus have also been identified27, 57.
Vitamin B12 in food is bound to proteins, which are dissociated in the acid environment 
of the stomach with the help of pepsin. Additionally, vitamin B12-binding proteins bind 
to the vitamin B12 in the stomach. Gastric parietal cells produce intrinsic factor (IF). 
Pancreatic proteases secreted into the duodenum, where the pH is higher, cleave off 
the vitamin B12-binding proteins allowing the vitamin B12 to bind IF. The vitamin 
B12-IF complex is then taken up by mucosal receptors in the ileum and is transported 
into the bloodstream (figure 7). All metabolic surgery patients have both an incomplete 
digestion and release of vitamin B12 from protein foods. With a significant decrease 
in stomach acid, pepsinogen is not converted into pepsin, which is necessary for the 
release of vitamin B12 from protein. Due to restriction of the stomach, fewer parietal 
cells are available to produce IF. 
Calcium, vitamin D and parathormone (PTH)
One of the main functions of calcium is to keep the bone and teeth strength adequate, 
thereby supporting skeletal structure and function. Cell signaling, blood clotting, muscle 
contraction and nerve function are all dependent on calcium. Dietary sources include 
dairy products, leafy vegetables, and fish. Calcium is absorbed passively in the ileum 
and jejunum, where the highest concentration of calcium transporters is present and 
actively by 1,25 OH vitamin D in the duodenum in the presence of acid27, 62 (figure 7). 




excitability, secondary hyperparathyroidism and osteoporosis57. Deficiencies occur as a 
result of the altered anatomy and inadequate intake of dietary products. 
Vitamin D is absorbed preferentially in the jejunum and ileum62 (figure 7). Sun exposure 
on the skin produces vitamin D3 and supplies 90% of the vitamin D. It is important for 
calcium and bone metabolism, regulating parathyroid hormone functions. The specific 
reasons for deficiencies in metabolic patients remain unknown but may be attributed to 
various factors like dietary intake, sun exposure, thicker epidermis, season of the year, 
and socioeconomic status. A deficiency can cause osteomalacia, osteoporosis, arthralgia, 
myalgia, fasciculation, and depression27.
The international guideline from the American Society for Metabolic and Bariatric Surgery 
(ASMBS) showed an overview with recommendations for preventive daily dosage of 
micronutrients and how to treat deficiencies57. The recommended preventive daily dosage 
of micronutrients is higher than in standard available multivitamins and it is not easy to 
achieve these doses with the standard supplements that are currently available. There was 
no specialized multivitamin per procedure available for metabolic patients. Dogan and 
colleagues researched and developed specialized multivitamin supplements and concluded 
less deficiencies in iron, vitamin B12 and folic acid over a 12 month postoperative period63. 
 
Due to the lack of available literature on how to treat deficiencies after metabolic 
surgery, the international guidelines often referred to small studies or expert opinions 
and lacked information on compliance. Gradually, over the years we have learned that 
these guideline recommendations have frequently proved to be insufficient for metabolic 
patient in daily practice58. It remains challenging to prevent nutritional deficiencies and 
to treat these deficiencies adequately.
Further research is necessary to address deficiencies after metabolic surgery. The main 
research questions remains: How can nutritional deficiencies be prevented and treated 
once developed after metabolic surgery?
First, we hypothesized that the daily use of a specialized multivitamin supplement 
lowers the amount of deficiencies in comparison to general multivitamin supplements63. 
Second, the uptake of micronutrients is changed after metabolic surgery. Additionally, 
we hypothesized that treatment strategy of newly developed nutritional deficiencies 
(iron and vitamin B12) is different after metabolic surgery in comparison to non-bariatric 
patients, due to the changed uptake.
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Figure 7. Micronutrient absorption places (© E.O. Aarts)
 
To address our hypothesis, patients were elected who were subjected to metabolic 
surgery as a disease model. In practice, preventive measures and treatment of nutritional 
deficiencies as done in the general population are insufficient for metabolic patients. 
This is due to the anatomical and physiological changes described earlier. It often 
leads to undertreatment of patients leading to suboptimal care. For this reason, it is 
eminent to specifically perform scientific micronutrient research in the metabolic patient 
population. This does however come with an additional challenge while every type of 
metabolic surgery requires its own prevention  and treatment strategy. 
Unfortunately, although fit for research on weight loss, the outcomes of research 
metabolic surgery as a disease model for micronutrient deficiencies cannot be easily 




and patient specifics are so typical for this surgery, that other types of comparable 
surgeries can be expected to have different outcomes. 
AIM OF THE THESIS
The overall aim of this thesis is to optimize prevention of micronutrient deficiencies 
after metabolic surgery and to optimize treatment strategies when these deficiencies 
develop.
Table 1 shows an overview of the research questions, aims, main findings and 
conclusions per chapter.
Table 1. Research question, aim, study design and measures
Chapter Research 
question
Aim(s) Study design Measures
2 •  Do specialized         
multivitamins 




•  Examine  the 
effectiveness 


















3 • Do specialized 
multivitamins 
lead to less 
deficiencies after 
SG patients?
• Examine the 
effectiveness 
of a specialized 
multivitamin 
supplement for 
SG patients on 
micronutrient 













• Registration of 
medication, AE’s
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scores, also called 

















• Registration of 
medication
5 • How should 
nutritional 
deficiencies after 
BPD or BPD/DS 
be treated?















6 • What are the 
effects on 
efficacy of oral 
and intravenous 
treatment of iron 
deficiency (ID) 
after RYGB?












• To compare the 
efficacy of oral 
FF, oral FG, and a 
single intravenous 
infusion of FCM 













• Registration of 
medicatio
7 • Is oral treatment 
with vitamin 
B12 effective for 
deficiencies after 
RYGB?
• Investigate the 
effectiveness of 
oral vitamin B12 
• supplementation 
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One of the side effects of bariatric surgery is the risk of vitamin and mineral deficiencies. 
Vitamin B12, vitamin D, folate and iron deficiencies are especially common among 
Roux-en-Y gastric bypass (RYGB) patients. 
Objective
Examine the effectiveness of a specialized multivitamin supplement for RYGB patients 
on deficiencies the first three postoperative years. A retrospective cohort study. 
Setting
Large specialized bariatric hospital 
Results
1160 patients were included, 883 users and 258 who were non-users of the specialized 
multivitamin. Patient characteristics and total body weight were comparable. Higher 
serum concentrations of ferritin (124.7 ± 96.2 µg/L versus 106.0 ± 83.0 µg/L, p=0.016), 
vitamin B12 (347.3 ± 145.1 pmol/L versus 276.8 ± 131.4 pmol/L, p < 0.001), folic 
acid (34.9 ± 9.6 nmol/L versus 25.4 ± 10.7 nmol/L, p < 0.001) and vitamin D (98.4 ± 
28.7 nmol/L versus 90.0 ± 34.5 nmol/L, p=0.002) were observed in users compared to 
non-users after one year. Less new deficiencies were found for ferritin (1% versus 4%, 
p=0.029), vitamin B12 (9% versus 23%, p < 0.001) and vitamin D (0% versus 4%, p 
< 0.001) in users compared to non-users. Two and three years after the surgery these 
findings remained almost identical.
Conclusions
The use of specialized multivitamin supplements resulted in less deficiencies of vitamin 
B12, vitamin D, folic acid and ferritin. The study showed that RYGB patients benefited 
from the specialized multivitamin supplements and it should be advised to this patient 
group.





Obesity is a chronic condition affecting 600 million adults worldwide, according to the 
World Health Organisation (WHO). Relatively, this is 13% of the total world population, 
forming a major burden for global healthcare1. The only proven long-term strategy to 
treat obesity is bariatric surgery such as the Roux-en-Y gastric bypass (RYGB)2-5.
Besides the benefits, bariatric surgery also has to contend with the common complications 
of vitamin and mineral deficiencies. Deficiencies in vitamin B12 (37-50%), vitamin D 
(20-51%), folate (15-38%) and iron (47-66%) are frequently found6. The RYGB is no 
longer regarded as a malabsorptive procedure for macronutrients, but it is a malabsorptive 
procedure for micronutrients. New vitamin and mineral deficiencies post RYGB are a 
result of this caloric restriction, malabsorption of micronutrients and bypassing the first 
part of the small intestine. To prevent these vitamin and mineral levels from declining 
after RYGB surgery, lifelong supplementation is needed and recommended7. Standard 
multivitamin supplements (sMVS) showed to be ineffective to restore deficiencies on 
the long term8, 9. A supplement was therefore developed, that had been adjusted to the 
needs of RYGB patients6. The doses for the most common deficient vitamins after 
RYGB surgery in the specialized supplement are shown in table 1.
Previous studies already reported on the efficacy of this specialized bariatric multivitamin 
supplement in a controlled setting6, 9. These studies concluded that the use of this 
specialized multivitamin resulted in significantly less deficiencies of ferritin, vitamin 
B12 and folic acid compared to a sMVS after one and three years. The purpose of the 
present study was to examine if this effect was also shown in a bigger population on the 
long-term. Patients had the choice whether or not to use the specialized multivitamin 
supplement and pay for these themselves, which better reflects the real life situation of 
postoperative RYGB patients.
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Table 1. Supplement recommendation by the American Society for Metabolic and Bariatric Surgery 
(ASMBS) after RYGB and the amount of nutrients with % of the RDA in often used standard 
multivitamin supplements and the specialized multivitamin supplement6
ASMSB Standard MVM1 Standard MVM2 Specialized MVM
Vit A (µg) 1500-3000 800 (100%) 800 (100%) 1000 (125%)
Vit B1 (mg) 12 1.1 (100%) 1.1 (100%) 2.75 (250%)
Vit B11 (µg) 400-800 200 (100%) 200 (100%) 600 (300%)
Vit B12 (µg) 350-500 2.5 (100%) 2.5 (100%) 350 (14000%)
Vit D3 (µg) 75 5 (100%) 5 (100%) 12.5 (250%)
Vit E (mg) 15 12 (100%) 12 (100%) 24 (200%)
Vit K (µg) 90-120 - 75 (100%) 120 (160%)
Copper (mg) 1-2 1 (100%) 1.5 (150%) 3 (300%)
Iron (mg) 45-60 14 (100%) 14 (100%) 70 (500%)
Zinc (mg) 8-22 10 (100%) 15 (150%) 22.5 (225%)
Calcium (mg) 1200-1500 160 (100%) 160 (100%) -
ASMBS, American Society for Metabolic and Bariatric Surgery; RYGB, Roux-en-Y Gastric Bypass; Vit, 
vitamin; %, percentage; RDA, recommended dietary allowances; MVM1, standard multivitamin supplement 
brand 1; MVM2, standard multivitamin supplement brand 2; MVM, multivitamin supplement. 6, reference 
number 6. Conversion factors Vit A: 1µ=3.3IU; Vit D3, 1µg=40IU.
METHODS
 
Study design, subjects and data collection
In this single-centre retrospectively cohort study with prospectively collected data, 
patients themselves were responsible for their choice of multivitamin, but were 
encouraged and advised to use the specialized multivitamin supplement (WLS Forte™, 
FitForMe, Rotterdam the Netherlands). At six months postoperative and then annually, 
patients were asked about their multivitamin use and serum blood values and total body 
weight (TBW) were determined.
The subjects included in this study all underwent primary RYGB surgery in a large 
specialized bariatric hospital between June 2012 and July 2015, to ensure at least one 
year of follow-up. For this study, the general inclusion criteria for bariatric surgery 
were applicable7. Exclusion criteria were conditions of patients which could cause 
serious metabolic changes, for example cancer, hemochromatosis or high serum ferritin 
concentrations in combination with elevated serum C-reactive Protein.
The specialized multivitamin is available in its current form since 2011 and for this study 
our institution had access to the online ordering data. Patients were then classified as 
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users or non-users, since regular ordering of the specialized multivitamin in appropriate 
amounts (one tablet per day) suggested that the patient was a user (at least 6 times 
per week intake). Patients were considered non-users when they stopped ordering 
the specialized multivitamin after the first test package or ordered it at  irregular time 




This study was approved by the national and local ethnical committees as part of the 
VITAAL II study.
Surgical procedure and medication
All patients underwent the RYGB surgery following a standardized operating technique 
with a gastric pouch of 30 mL and a biliopancreatic and Roux limb of 150/150 cm. All 
patients received Omeprazole (20 mg/day) for six months, Fraxiparin (5700 units/day) 
for four weeks and all patients received lifelong Calci Chew D3 tablets 3 times a day 
(Calcichew 500 mg calcium and 880 IU vitamin D) together with the advice to take 
lifelong multivitamin supplementation. 
Reference values and outcomes
The primary outcome was the number of deficiencies and mean serum concentrations 
for the most common deficiencies: vitamin D, folate, vitamin B12 and ferritin and 
parathormone (PTH) Deficiencies were defined as a serum concentration below the lower 
bound of the normal range. A deficient patient was treated according to our standard 
protocol6 and was from that moment onwards excluded from any further analyses for 
that variable Secondary outcomes were BMI, percentage excess weight loss (%EWL) 
and percentage total body weight loss (%TBWL).
 
Statistical analysis 
Two groups were compared in the analysis, the users and the non-users group, 
preoperatively and 1, 2 and 3 years after surgery. Numerical data were analysed with 
an unpaired t-test and mean ± SD was shown correspondingly. The Chi-square test was 
used to analyse binary data or Fisher’s Exact test was used when counts were < 5. 
Linear Mixed Models was used to analyse differences between changes in mean serum 
values of the micronutrients over time for all the years of follow-up available. Gender 
and age-groups of ≤35 years, 36-59 years, ≥60 years were included in the model as 
confounders. A 2-sided p-value < 0.05 was considered to be indicative of a significant 




The total study population included 1160 subjects, 883 were classified as users and 258 
as non-users and these were included in the analysis (figure 1). 
Seven hundred-and-five users were classified as consistent users and 175 were classified 
as inconsistent users Of the non-users, 121 used a non-specialized multivitamin 
from several brands. Patients baseline characteristics are shown in table 2 and were 
comparable although non-users had on average less comorbidities. The mean follow-
up time was 2.1 ± 1.2 years for users and 2.6 ± 1.6 years for non-users. Preoperatively 
and during follow-up, TBW, BMI, %TBWL and %EWL were almost identical between 
users and non-users (appendix).  
 
Figure 1. Flow chart of the subjects in this study. 
N, number; MVS, multivitamin supplement; preop., preoperative.
Iron (Hb, Ht, MCV and ferritin)
One year after surgery, higher mean serum ferritin concentrations were found for users 
(124.7 ± 96.2 µg/L) compared to non-users (106.0 ± 82.9 µg/L, p=0.016) (figure 2, 
table 3) and serum level changes were positive for users (7.8 ± 73.7 µg/L) and negative 
for non-users (-6.7 ± 58.4 µg/L) (p= 0.020). Fewer users developed a new ferritin 
deficiencyone year post-surgery when compared to non-users (1% for users versus 4% 
for non-users, p=0.029*). Relatively fewer users who were preoperatively deficient were 
still deficient  one year after surgery compared to non-users (27% vs. 71%, p=0.002) 
(table 4). 
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The total number of premenopausal women was 358, of whom 40 (11%) were diagnosed 
with a ferritin deficiency, compared to 53 (12%) of the 451 postmenopausal women. 
Table 2.  Baseline characteristics of the study population for users and non-users of the specialized 
multivitamin supplements

















Joint complaints 26 15
Dyslipidemia 4 4
Mean ± SD Mean ± SD
N=881 N=257
TBW (kg) 126.6 ± 19.6 126.8 ± 17.8
BMI (kg/m2) 44.1 ± 5.4 44.4 ± 5.3
Age (years) 46.0 ± 9.8 46..0 ± 11.0
DM, diabetes mellitus type 2; HT, hypertension; OSAS, obstructive sleep apnoea syndrome; Hb, Hemoglobin; 
Ht, Hematocrite; PTH, parathormone; %, percentage; SD, standard deviation; N, number; TBW, total body 
weight; BMI, body mass index;*, significant difference.
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Figure 2. Mean serum concentrations (with SEM) over the time in users and non-users 
Mean serum concentrations (with SEM) over the time. For users (grey line) and non-users (black line) of 
the specialized multivitamin supplement. Hemoglobin, Hematocrit, MCV, ferritin, vitamin B12, Folate acid, 
vitamin D and Parathyroid hormone (PTH). * = p < 0.05
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Table 3. Mean serum concentrations 1, 2 and 3 years post-surgery for users and non-users, and changes 




Years N Mean ± SD Δ ± SD N Mean ± SD Δ ± SD
PTH 1 734 4.2 ± 2.3 0.5 ± 2.4 198 4.6 ± 2.7 1.0 ± 2.4*
(1.3-6.8 pmol/L) 2 283 4.1 ± 2.3 0.3 ± 2.3 130 4.4 ± 2.3 0.8 ± 2.2*
3 87 4.4 ± 2.6 -0.1 ± 2.7 42 5.2 ± 3.3 1.4 ± 3.0*
Vitamin D 1 739 98 ± 29 57 ± 28 199 90 ± 35* 47 ± 32*
(> 50 nmol/L) 2 287 101 ± 32 59 ± 33 130 91 ± 41* 49 ± 36*
3 87 96 ± 27 54 ± 31 42 84 ± 32* 43 ± 28*
Folic acid 1 735 35 ± 10 16 ± 11 193 25 ± 11* 8 ± 11*
(6-28 nmol/L) 2 285 35 ± 10 17 ± 12 128 25 ± 12* 8 ± 12*
3 89 34 ± 11 18 ± 11 42 23 ± 11* 7 ± 11*
Vitamin  B12 1 655 347 ± 145 47 ± 147 172 277 ± 131* -20 ± 140*
(200-570 mol/L) 2 257 363 ± 169 58 ± 175 113 285 ± 133* -7 ± 159*
3 74 372 ± 175 59 ± 191 35 296 ± 138* -2 ± 146
Ferritin 1 711 125 ± 96 8 ± 74 184 106 ± 83* -6 ± 58*
(20-300 µg/L) 2 266 118 ± 105 -5 ± 90 107 106 ± 87 -21 ± 80
3 70 77 ± 80 -24 ± 71 28 74 ± 53 -42 ± 71
Normal ranges of the serum concentrations for morbid obese patients are shown behind the serum variable. 
Hb, haemoglobin; Ht,haematocrit; MCV, mean corpuscular volume; PTH, parathyroid hormone; N, number; 
SD, standard deviation; Δ, serum level change; *, significance by p < 0.05.
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PTH 1 734 8 4 198 7 3
2 283 6 8 130 7 5
3 88 3 14 42 10 10
Vitamin D 1 741 72 0 199 65 4**
2 287 69 1 130 66 5**
3 87 74 2 42 64 10
Folic acid 1 735 0 0 193 0 0
2 288 0 0 128 0 6**
3 90 0 9 42 0 14**
Vitamin B12 1 665 17 9 172 19 23*
2 257 18 14 114 20 38*
3 74 22 16 35 17 49*
Ferritin 1 711 8 1 184 8 4**
2 266 7 4 108 7 10*
3 72 10 14 28 7 4
Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; Preop, preoperative; PTH, parathyroid 
hormone; New, new deficiencies; N, number; %, percentage; *, p < 0.05; **, p-value < 0.05 from Fisher’s 
exact test.
 
Vitamin B12 and folic acid
Preoperatively, no significant differences between users and non-users were found 
for mean serum vitamin B12 concentrations and deficiencies (table 4, figure 2). 
One year after surgery, significantly higher mean serum concentrations of vitamin 
B12 were found in users (347.3 ± 145.1 pmol/L) compared to non-users (276.8 
± 131.4 pmol/L, p < 0.001) (table 3) and this was still evident three years after the 
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surgery (371.5 ± 175.1 pmol/L and 296.4 ± 138.4 pmol/L, p=0.028). For vitamin 
B12, a significant difference in new deficiencies between users and non-users was 
observed after three years (16% in users and 49% in non-users, p < 0.001) (table 4). 
For folic acid, the mean serum concentration for users was significantly higher compared 
to non-users preoperatively (18.9 ± 8.2 nmol/L for users versus 17.6 ± 6.8 nmol/L, 
figure 2) (table 4). Three years after surgery, the mean serum folate concentration was 
significantly higher for users (34.1 ± 11.2 nmol/L) compared to non-users (23.2 ± 11.3 
nmol/L, p < 0.001) (table 3) and the percentage of new deficiencies was 0% in users and 
14% in non-users (p < 0.001) (table 4).
Vitamin D and PTH
Preoperatively, the mean serum concentration and percentage of deficiencies for vitamin 
D and PTH were both not significantly different between users and non-users (table 4, 
figure 2). After three years, a significantly higher mean serum concentration of vitamin 
D was found in users (95.6 ± 27.2 nmol/L) compared to non-users (83.6 ± 32.2 nmol/L, 
p=0.029) (table 3). Less new developed deficiencies were found in users for vitamin D 
after one year (0% in users versus 4% in non-users, p < 0.001**)  and after three years 
(2% in users versus 10% in non-users, p=0.088*) (table 4). Of the patients who were 
preoperatively deficient, relatively fewer users stayed deficient after one year compared 
to non-users (5% in users versus 13% in non-users, p < 0.001*).
For PTH, the change from baseline to three years was significantly greater in the 
non-users group (1.4 ± 3.0 pmol/L) compared to the users group (-0.1 ± 2.7 pmol/L, 
p=0.004) (table 3). Cumulative percentages of the most common deficiencies (vitamin 
B12, vitamin D, folic acid and ferritin)  increased from 9% for users versus 28% for 
non-users at one year post surgery to 26% for users versus 67% for non-users at three 
years post-surgery (figure 3).
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Figure 3. Cumulative deficiency of the most common deficiencies (vitamin D, vitamin B12, folic acid 
and ferritin) one, two and three years post-operatively for users (grey line) and non-users (black line). 
Long-term 
Mean serum concentrations of folic acid, vitamin B12, vitamin D and PTH over the 
three years of follow-up, were significantly different between users and non-users at all 
post-surgery time points (figure 2). 
DISCUSSION
In this study, we have confirmed that specialized bariatric multivitamins were more 
effective in preventing deficiencies in patients in comparison to sMVS and no 
multivitamin-use. This has been proven effective in a large population and in a real-life 
setting. Usage of these multivitamins resulted in higher mean serum concentrations of 
vitamin B12, vitamin D, folic acid and ferritin and in less deficiencies.
Serum ferritin concentrations declined over time after RYGB surgery. This is to be 
expected since, firstly, iron intake is reduced and many patients experience intolerance 
for meat10. Secondly, iron is normally cleaved from dietary proteins by gastric acid, 
of which the secretion is reduced11. To be absorbed, iron has to be transformed into 
the ferrous state. This reduction is negatively affected by the decreased amount of 
hydrochloric acid12. Furthermore, iron is absorbed in the duodenum and proximal 
jejunum, which are bypassed and it’s the iron deficiencies that are the main cause 
of anemia11, 13. In comparison to 25% anaemic patients in the study of Aarts et al., 
before sMVM were available, this study only found 12%14. An increase in ferritin 
concentration was however, observed in users in the first year, the decrease in mean 
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serum ferritin concentration became larger over the years. This suggests that the dose 
of 70 mg elementary iron should be slightly higher for some patients to prevent ferritin 
deficiencies after a longer time period which is in line with the study of Madan et al.15. 
After RYGB surgery, the size of the stomach and thereby the amount of gastric acid 
producing cells is reduced, leading to a reduced gastric acid production and less 
cleavage and absorption of vitamin B12. The amount of intrinsic factor, required to 
absorb vitamin B12, is also reduced10, 13, 16, 17. A deficiency leads to macrocytic anemia, 
glossitis, leukopenia, paraesthesia, thrombocytopenia and irreversible neuropathies13. 
The preoperative prevalence of vitamin B12 deficiency in this study was 17% in users 
and 19% in non-users. In comparison, the prevalence in other studies was estimated to 
be between 5% and 30%, but is partially explained by the use of other reference values11, 
15. One year after surgery, the percentage of patients with a vitamin B12 deficiency was 
9% in users and 23% in non-users in comparison to 12-75% in literature, where the 
mean prevalence is reported at 35%10, 14, 18. In this study, fewer users developed a de novo 
vitamin B12 deficiency compared to non-users and the mean serum concentration of 
users was significantly higher for users compared to non-users after three years. This is 
in accordance with Dogan et al. and Homan et al.6,9 This implies that the dose of 14000% 
RDA of vitamin B12 in the specialized multivitamin is sufficient to prevent most 
vitamin B12 deficiencies and is in accordance with the recommendation on vitamin B12 
supplementation of 350-500 µg/d by the American Society for Metabolic and Bariatric 
Surgery19 (ASMBS). 
All patients in this study showed an increase in mean serum folic acid concentrations, 
while folate deficiencies were more common in non-users than in users. Developing 
a folate deficiency is less common than vitamin B12 and D deficiencies in RYGB 
patients, since folate can be absorbed along the whole small intestine. However, 
vitamin B12 deficiency could contribute to folate deficiency since vitamin B12 is 
required for the conversion of folate to its’ active form13. Folate deficiencies could 
cause megaloblastic anemia, leukopenia, glossitis, thrombocytopenia and increased 
homocysteine concentrations13. In this study, after three years, significantly higher 
mean serum folic acid concentrations were found in users compared to non-users and 
0 versus 14% of deficiencies. Since a large part of the studied population were women 
(84%) and of whom 45% were of child-bearing age, inclusion of folic acid in the 
specialized multivitamin is important to prevent neural tube defects in new-borns. No 
preoperative folate deficiencies were found, in contrast to another study which reported 
< 2% preoperatively and 8% in the first year6, 9, 14, 15. It is suggested that synthetic folic 
acid intake might increase the risk for colorectal cancer in some individuals, however 
two large prospective cohort studies found an inverse association between the intake of 
dietary folate and the risk for colorectal cancer20, 21.
Vitamin D deficiencies are common after RYGB surgery because it is absorbed in 
the proximal small intestine, which is bypassed after RYGB surgery. Obese patients 
in particular, are known to have low vitamin D levels preoperatively22-23. Bone 
46
demineralization could be a result of vitamin D and calcium deficiency. Vitamin D 
is also involved in cardiovascular health, cancer prevention and immunity13. High 
percentages of preoperative vitamin D deficiencies were found in both users and non-
users, which was also found in other studies6, 15, 22-26. One year after surgery, no new 
vitamin D deficiencies were diagnosed in the users group compared to 4% in the non-
users group. One year after surgery, Madan et al., found that 19% of the patients in their 
population was deficient in vitamin D. In the present study, three years after the surgery 
users had significantly better vitamin D status as compared to non-users, which can be 
attributed to the use of the specialized multivitamin supplement15. 
PTH is one of the regulators of calcium, together with vitamin D and calcitonin. As 
the concentration of serum calcium decreases, PTH levels increase. This stimulates 
resorption of calcium in the kidneys and bone resorption. PTH also stimulates the 
formation of active vitamin D in the kidneys14. Preoperatively, 8% of the users in this 
study had elevated PTH levels, which was in line with the findings of Gehrer et al.26. 
In the present study, users showed a lower serum concentration of PTH compared to 
non-users, which was as expected since serum vitamin D concentrations increased. In 
contrast, increased PTH levels one year after RYGB were reported by another study in 
which less additional cholecalciferol was administered28. Ruiz-Tovar et al., showed a 
declining trend in PTH levels, parallel to a positive trend in vitamin D levels during two 
years after a bariatric sleeve gastrectomy29. 
In this cohort, the number of patients in the users groups was over three times as large 
as the number of patients in the non-users group. The percentage of patients who used 
a multivitamin supplement in general was 88% and the percentage of patients who used 
the specialized multivitamin supplement was 78%. This is much higher than what is 
reported from other clinics worldwide (33-59%)30-32. The high number of multivitamin 
users in the present study is likely to be due to the fact that patients are encouraged to 
use the specialized bariatric multivitamin supplement.
Lifelong compliance to a daily supplement is hard to maintain, especially when the 
effect of the supplement is not directly noticeable to the patient. However, when patients 
choose to undergo bariatric surgery they also realize that they have chosen for a change 
in lifestyle, which includes lifelong daily multivitamin supplement use.
A strength of this study was the large population size, which facilitated power to detect 
differences between the groups and provided a better mean so that the influence of outliers 
was reduced. The sample size was sufficiently large for both users and non-users, even 
though the number of users was higher than the number of non-users. Furthermore, this 
study was complementary to clinical studies to better reflect the real life supplement use 
of bariatric patients. Finally, the classification of users and non-users was objectively 
confirmed by the online ordering data.
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A limitation of this study was that the only confounders that were taken into account 
in the linear mixed model were ‘gender’ and ‘age group’. These confounders were not 
included in any of the other analyses. There is a variation of vitamin and supplement 
concentrations in the vitamins used by the 258 non-users. These differences in 
concentrations may play a role in patients developing deficiencies. In table 1 we have 
shown the concentrations of two often used standard multivitamins and the specialized 
multivitamin. 
Furthermore we did not know the length of the common channel in the studied patients. 
Tacchino et al. demonstrated that the common channel length is highly variable in patients, 
and most likely play an important role in the incidence of vitamin and mineral deficiencies33. 
Another possible confounder could be the social economic status of the patient, since the 
supplement had to be purchased by the patients themselves. This specialized supplement 
is approximately 1.6 times as expensive as a generic sMVS and costs could well be a 
reason for a patient to use cheaper supplements or not taking any at all, thereby creating 
selection bias in the data. This does however not take into account the price-efficiency 
capacity of the supplements. Due to the lower number of new deficiencies there is less 
replacement therapy necessary resulting in less consultancy time and theoretically less 
treatment costs.
CONCLUSION
The use of the specialized bariatric multivitamin supplements resulted in less deficiencies 
of vitamin B12, vitamin D, folic acid and ferritin and higher mean serum concentrations 
after RYGB surgery. The study clearly showed  that RYGB patients benefited from the 
specialized multivitamin and should be advised to this patient group.
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ABSTRACT
Background: Since a few years, the laparoscopic Sleeve Gastrectomy (SG) has become 
the most performed bariatric operation worldwide. However, as with all bariatric 
procedures, SG also leads to vitamin and mineral deficiencies post-operatively and 
standard multivitamin supplements are probably not sufficient.
Objective: The present study evaluates the effectiveness of a specialized multivitamin 
supplement for SG patients (WLS Optimum 1.0, FitForMe, Rotterdam, the Netherlands), 
compared to a standard multivitamin supplement (sMVS).
Design: A double-blind randomized controlled trial was performed. For 12 months, 
patients in the intervention group received WLS Optimum, containing elevated doses of 
multiple vitamins and minerals. Patients in the control group were provided with sMVS, 
containing 100% of the recommended dietary allowance.
Results: In total, 139 patients were available for analysis (WLS Optimum; n = 69, 
sMVS; n = 70). Intention-to-treat analyses revealed more folic acid deficiencies and 
higher serum vitamin B1 levels in the WLS Optimum group. Per protocol analyses 
showed that in patients using WLS Optimum; serum folic acid and vitamin B1 levels 
were higher, serum PTH levels were lower, and only one patient (2.6%) was anemic 
compared to 11 patients (17.5%) using a sMVS (p < 0.05 for all). No differences were 
found in prevalence of deficiencies for iron, vitamin B12, vitamin D and other vitamins 
and minerals.
Conclusions: This optimized multivitamin supplement only affected serum levels of folic 
acid, PTH and vitamin B1, and anemia rates compared to a sMVS. There is a clear need to 
further optimize multivitamin supplementation for SG patients. Besides, non-compliance 
with multivitamin supplements remains an important issue that should be dealt with. 




Originally designed as the first step of a biliopancreatic diversion with duodenal switch, 
the sleeve forming gastrectomy (SG) was technically improved and implemented as a 
standalone procedure1. Since a few years, the laparoscopic SG has become the most 
performed bariatric operation worldwide2. It is considered to be an easy, quick and safe 
procedure3 that provides significant weight loss and improvement of obesity-related 
comorbidities by reducing food intake and hormonal changes3, 4.
Perhaps one of the reasons why the Roux-en-Y gastric bypass (RYGB) is no longer 
the preferred procedure for many surgeons is because it is associated with vitamin and 
mineral deficiencies and lifelong use of supplements5, 6. Since the anatomy of the intestinal 
tract remains unaltered when performing a SG, the risk of developing deficiencies is 
theoretically considered lower7. Some authors even state that a SG has minimal impact 
on nutrient status3 and taking multivitamin supplements (MVS) for more than three 
months postoperatively is unnecessary8. However, short and midterm studies found 
that in SG patients, deficiencies are as common as in RYGB patients9-12. Especially 
deficiencies for iron, folic acid, vitamin B12 and vitamin D are frequently reported7, 
13-17. Standard MVS are probably not sufficient to prevent nutritional deficiencies after 
SG. However, specific MVS, that contain higher doses of vitamins and minerals, were 
not available at the time of this study. Based on literature and studies performed in our 
hospital, a customized MVS for SG patients was developed in 2012 (WLS Optimum; 
FotForMe, Rotterdam, the Netherlands). The present study evaluates the effectiveness 





The present study was a double-blind randomized controlled trial. All patients who 
underwent a primary laparoscopic SG (LSG) operation at Rijnstate Hospital Arnhem 
(RHA; > 1200 bariatric cases a year) between November 2011 and October 2014 were 
eligible for the study. Exclusion criteria were a secondary LSG, creatinine > 150 µmol/L, 
liver enzymes > 2 times the upper limit, concomitant diseases (e.g. gastrointestinal 
diseases), psychiatric illness, use of drugs that affect bone metabolism and known 
pregnancy. The study was approved by the Medical Ethics Review Committee of the 
Radboud University Medical Centre and Local Ethical Committee of RHA, and was 
conducted in concordance with the principles of the Declaration of Helsinki. The study 
protocol was registered at the clinical trials registry of the National Institutes of Health 
(ClinicalTrials.gov; identifier NCT01609387). 
Included patients were randomized into two groups: the intervention group received 
the customized MVS for SG patients (WLS Optimum) and the control group received a 
standard MVS (sMVS). 
Surgical procedure 
A standardized operating technique was performed by three experienced bariatric 
surgeons (> 500 cases each). First, the greater omentum was dissected from the greater 
curvature of the stomach using Enseal® (Ethicon, Somerville USA). Then, the stomach 
and angle of His were mobilized, using a posterior approach. This was completed 
by dissection of the anterior part of the angle of His and small gastric vessels. Next, 
transection of the stomach was performed using lengthwise stapling along a 40 French 
calibration bougie positioned along the lesser curvature, starting 4 cm proximal of the 
pylorus until the cardia (Echelon FlexTM Powered Plus Stapler, Ethicon, Somerville 
USA). A bougie size of 40 Fr is associated with a significant lower leak rate and similar 
weight loss results compared to smaller bougie sizes18,19. The remnant of the stomach 
was retrieved through an enlarged port incision in the left flank. This port was closed 
with Vicryl (Ethicon, Somerville USA) using a suture retriever. Finally, the skin was 
closed with agraves.
Intervention and Control
WLS Optimum version 1.0 is a customized MVS for SG patients and contains elevated 
doses of multiple vitamins and minerals (table 1). A sMVS, similar to an over the counter 
MVS, served as a control and contained most micronutrients in a dose equivalent to 100% 
of the RDA. To prevent bias, both supplements had the exact same raw base compounds 
and cherry flavor, and were similar in color and size (figure 1). Both supplements were 
dosed as one capsule per day. 




All patients received fraxiparin (nadroparin, 0.6 mg/5700 IU daily) for six weeks and 
proton-pump inhibitor (omeprazole, 20 mg daily) for six months, as part of the standard 
postoperative protocol. All patients were additionally prescribed calcium/cholecalciferol 
500/800 three times a day.
Figure 1. Standard multivitamin supplement and WLS Optimum
Randomization and blinding
The allocation sequence was computer generated, using a variable block schedule. 
Besides an independent pharmacist, no one had access to the randomization list to 
ensure allocation concealment. All supplements were packaged in nonmarked blisters 
with the same expiration date, each containing 12 capsules. The blisters were packaged 
in a nonmarked sealed box, and numbered according to the randomization list. After the 
last visit of the last study patient, the unblinded randomization list was available to the 
research team. No earlier unblinding occurred
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Table 1. Content of intervention and control supplement
sMVS WLS Optimum
Ingredients Dose RDA (%) Dose RDA (%)
Vitamins
   Vitamin A, mg 0.60 75.0 1.00 125.0
   Vitamin B1, mg 1.10 99.7 2.00 182.0
   Vitamin B2, mg 1.40 100.0 2.00 143.0
   Vitamin B3, mg 16.00 100.0 25.00 156.0
   Vitamin B5, mg 6.00 100.0 9.00 150.0
   Vitamin B6, mg 1.40 100.2 2.00 143.0
   Biotin, µg 25.00 50.0 150.00 300.0
   Folic acid, µg 200.00 100.0 300.00 150.0
   Vitamin B12, µg 2.50 100.0 10.00 400.0
   Vitamin C, mg 80.00 100.0 100.00 125.0
   Vitamin D, µg 4.00 80.0 7.50 150.0
   Vitamin E, mg 10.00 83.4 12.00 100.0
   Vitamin K1, µg 25.00 33.3 90.00 120.0
Minerals
   Chrome, µg 40.00 100.0 40.00 100.0
   Iron, mg 14.00 100.0 21.00 150.0
   Iodine, µg 153.70 102.5 150.00 100.0
   Copper, mg 1.00 100.0 1.00 100.0
   Chloride, mg 0.14 0.0 0.00 0.0
   Magnesium, mg 30.00 8.0 30.00 8.0
   Calcium, mg 91.43 11.4 0.00 0.0
   Manganese, mg 2.00 100.1 3.00 150.0
   Molybdenum, µg 50.00 100.0 50.00 100.0
   Selenium, µg 55.00 100.0 55.00 100.0
   Zinc, mg 10.00 100.0 15.00 150.0
Other ingredients 
   Choline, mg 0.00 - 10.00 -
sMVS = standard multivitamin supplement, RDA = recommended daily allowance.
The true story on deficiencies after sleeve gastrectomy: Results of a double-blind RCT
3
57
Data collection, follow-up and outcome
Standard laboratory blood tests were performed at baseline (T0), and 6 (T6) and 12 
months (T12) after surgery. This included mean corpuscular volume (MCV), hemoglobin, 
iron, ferritin, folic acid, vitamin B12, vitamin D, PTH, calcium, magnesium, phosphate, 
albumin, vitamin B1, vitamin B6 and zinc (reference values in tables). Calcium levels 
were corrected for albumin using the following equation: Cacorr = total calcium – (0.025 
x albumin) + 1.
Iron deficiency was the primary outcome measure. Secondary outcome measures 
included vitamin D and vitamin B12 deficiencies developed during the first twelve 
months after LSG.
Excess weight loss (EWL) was calculated as [weight loss/excess weight based on ideal 
body weight at BMI 25 kg/m2 x 100%]. Total body weight loss (TWL) was calculated as 
[weight loss/initial weight x 100%].
Correction of deficiencies
Preoperative vitamin B12 and vitamin D deficiencies were treated with predefined 
medication. If a deficiency occurred after surgery, it was recorded for the purpose of this 
study where after the deficiency was treated according to local protocol. After additional 
supplementation, subsequent data of the corresponding parameter was excluded to not 
bias mean serum level data. Moreover, follow up measurements of patients who were 
pregnant at T6 and/or T12 were removed from the analyses.
Sample size calculation and statistical analyses
Sample size calculation was performed using Openepi.com20. To detect a 25% reduction 
of iron deficiency at twelve months after surgery, with 95% sensitivity and a power of 
90%, a minimum of 56 patients per group was required. Taking into account a 10% 
dropout rate and 15% of cases excluded because of iron deficiency diagnosed and 
treated at 6 months, this resulted in 75 patients per group.
An intention-to-treat analysis was used as the primary analysis. Additionally, per 
protocol analyses were performed. Differences between groups at baseline, T6 and T12 
were calculated using independent samples t tests for continuous data and Chi-Square 
tests for discrete data (or Fisher’s Exact test when > 20% of expected counts were < 5). 
Linear Mixed Models were used to assess if serum levels changed differently over time 
between the groups. 
Log transformations were performed to normalize the following data: serum levels of 
ferritin, PTH, vitamin B1 and vitamin B6.
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All statistical analyses were performed using IBM SPSS Statistics 25 for Windows 
(IBM Corp., Armonk USA)
RESULTS
Eleven patients were excluded from analysis because they underwent a RYGB 
(n=1), were pregnant during follow-up (n=1) or did not complete any of the follow-
up measurements (n=9). In total, 139 patients were available for analysis: 69 patients 
receiving WLS Optimum and 70 patients receiving sMVS. 
Both groups were similar at baseline with respect to age, gender, weight and BMI, 
deficiencies (table 2). The groups differed on the prevalence of dyslipidemia, which 
was three times higher in the sMVS group compared to the WLS Optimum group (p = 
0.047).
In six patients (three in each group), a gastric band had to be removed before conversion 
to LSG (‘Redo’ surgery). 
Weight loss
The degree of weight loss after 12 months was similar in both groups. Mean BMI at 
T12 was 32.7 kg/m2 in the WLS Optimum group and 33.8 kg/m2 in the sMVS group. 
Furthermore, patients using WLS Optimum showed 70.5 ± 22.7 %EWL and 31.3 ± 8.6 
%TWL compared to 68.5 ± 23.2 %EWL and 30.5 ± 8.4 %TWL for patients using sMVS 
(p > 0.05 for all).
Pre-operative deficiencies
The number of pre-operative deficiencies and mean serum levels at baseline were 
comparable between the groups (table 3, 4 and 5). Pre-operative deficiencies for vitamin 
D (76.1%), phosphate (34.1%) and albumin (12.2%) were most prevalent.
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Table 2. Baseline characteristics of the study population
WLS Optimum (n 69) sMVS (n 70)
Age, year 38.2 ± 12.4 39.7 ± 10.8
Weight, kg 141.3 ± 26.1 140.4 ± 31.2
BMI, kg/m2 47.6 ± 9.0 48.4 ± 9.9
Male 18 (26.1) 16 (22.9)
Redo surgery 3 (4.3) 3 (4.3)
Comorbidities
   T2DM 9 (13.0) 7 (10.0)
   Hypertension 15 (21.7) 19 (27.1)
   Dyslipidemia 3 (4.3) 10 (14.3)
   OSAS 7 (10.1) 7 (10.0)
Data are presented as mean ± standard deviation and counts (percentages).
MVS = multivitamin supplement, OSAS = Obstructive Sleep Apnea Syndrome, T2DM 
= Type 2 Diabetes Mellitus. P > 0.05 for all.
Post-operative deficiencies 
Mean serum levels and prevalence of deficiencies regarding hemoglobin metabolism, 
calcium and vitamin D metabolism, and vitamin B1, B6 and zinc can be found in table 
3, 4 and 5.
At T6, mean serum vitamin B1 levels were significantly higher in patients using WLS 
Optimum, compared to sMVS users: 148.0 ± 27.6 nmol/L vs 134.8 ± 24.8 nmol/L, (p = 
0.011). Mean serum levels for all other parameters were comparable between the groups 
at six and twelve months of follow-up.
During the entire study period, overall significantly more patients in the WLS Optimum 
group were deficient for folic acid: 10 patients (14.5%) versus 2 patients (2.9%) in 
the sMVS group (p = 0.016). No differences were found in prevalence of anemia, and 
deficiencies for iron, vitamin B12, vitamin D and other vitamins and minerals.
Elevated serum B1 and B6 levels were found in 11 (18.0%) and 20 patients (32.8%) 
using WLS Optimum, and 5 (7.9%) and 13 patients (20.6%) using sMVS (p > 0.05). 
For PTH, elevated serum levels were more frequent in the sMVS group (11 patients, 
15.7%) compared to the WLS Optimum group (4 patients, 5.8%), but this was also not 
significant (p = 0.060).
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Table 3. Evaluation of Hemoglobin Metabolism 
Parameter Cases Mean serum levels Deficiencies
WLS Optimum sMVS WLS Optimum sMVS
Hemoglobin: F: 7.4-9.9 mmol/L, M: 8.4-10.8 mmol/L (US: F:11.9-16.0 g/L, M: 13.5-17.4 g/L)
T0 138 (69/69) 8.7 ± 0.8 8.8 ± 0.7 4 (5.8) 4 (5.8)
T6 134 (67/67) 8.6 ± 0.8 8.7 ± 0.8 3 (4.5) 6 (9.0)
T12 130 (66/64) 8.4 ± 0.7 8.5 ± 0.7 7 (10.6) 7 (10.9)
T0–T12 129 (65/64) -0.25 ± 0.61 -0.28 ± 0.52
MCV: 80-100 fL 
T0 136 (68/68) 88.7 ± 4.1 88.9 ± 4.7 1 (1.5) 2 (2.9)
T6 134 (67/67) 90.5 ± 3.3 90.6 ± 4.8 0 - 1 (1.5)
T12 130 (66/64) 91.8 ± 4.4 91.7 ± 4.7 0 - 1 (1.6)
T0–T12 128 (65/63) +3.20 ± 4.16 +2.68 ± 2.94
Iron: 9-31 µmol/L (US: 50.3-173.1 µg/dL)
T0 128 (61/67) 10.8 ± 4.4 11.0 ± 4.7 18 (29.5) 24 (35.8)
T6 105 (48/57) 13.7 ± 4.2 14.1 ± 5.2 7 (14.6) 8 (14.0)
T12 108 (55/51) 15.1 ± 5.3 16.1 ± 7.0 7 (12.7) 3 (5.9)
T0–T12 98 (50/48) +4.56 ± 5.64 +4.90 ± 6.20
Ferritin:20-300 ng/mL 
T0 139 (69/70) 127.6 ± 96.4 128.8 ± 97.7 2 (2.9) 3 (4.3)
T6 112 (53/59) 149.0 ± 114.0 133.1 ± 73.6 0 - 4 (6.8)
T12 131 (65/64) 139.4 ± 104.7 129.1 ± 74.5 2 (3.1) 3 (4.7)
T0–T12 131 (65/64) +8.09 ± 55.36 -2.95 ± 78.59
Folic acid: 9.1-36 nmol/L  (US: 4.0-15.9 ng/mL)
T0 137 (68/69) 16.6 ± 6.7 16.7 ± 6.0 2 (2.9) 4 (5.8)
T6 132 (66/66) 22.3 ± 9.5 19.8 ± 6.9 5 (7.6) 0 -
T12 131 (66/65) 21.8 ± 10.0 19.2 ± 6.7 5 (7.6) 2 (3.1)
T0–T12 129 (65/64) +5.07 ± 9.16 +2.72 ± 7.28
Vitamin B12: 145/200a-570 pmol/L (US: 197/271a-773 pg/mL)
T0 137 (67/70) 289.8 ± 96.4 315.9 ± 110.1 1 (1.5) 0 -
T6 112 (52/60) 276.1 ± 84.6 291.7 ± 92.3 11 (21.2) 11 (18.3)
T12 122 (59/63) 267.3 ± 80.0 284.4 ± 85.7 15 (25.4) 14 (22.2)
T0–T12 122 (59/63) -32.93 ± 76.25 -34.17 ± 91.11
Data are presented as mean ± standard deviation and counts (percentages). 
a Normal range before the operation (baseline) was 145 – 570 pmol/L (US:197-773 pg/mL ).
F female, M male, US United States (units), MCV mean corpuscular volume, sMVS standard multivitamin 
supplement. p > 0.05 for all. 
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Table 4. Evaluation of Calcium and Vitamin D Metabolism
Parameter Cases Mean serum levels Deficiencies
WLS Optimum sMVS WLS Optimum sMVS
Vitamin D: > 50 nmol/L (US: > 20 ng/mL)
T0 138 (69/70) 36.5 ± 21.8 34.0 ± 16.7 51 (73.9) 54 (77.1)
T6 133 (66/67) 86.7 ± 27.6 93.8 ± 36.8 5 (7.6) 4 (6.0)
T12 129 (64/65) 84.5 ± 32.3 89.7 ± 28.8 7 (10.9) 4 (6.2)
T0–T12 128 (63/65) +48.68 ± 29.21 +55.62 ± 28.85
PTH: 1.3 – 6.8 pmol/L (US: 12.3-64.1 pg/mL)
T0 139 (69/70) 3.7 ± 2.0 4.0 ± 2.5 1 (1.4) 4 (5.7)
T6 134 (66/68) 3.4 ± 1.6 3.8 ± 1.9 2 (3.0) 5 (7.4)
T12 130 (65/65) 3.5 ± 2.0 4.0 ± 2.3 2 (3.1) 0 -
T0–T12 130 (65/65) -0.30 ± 2.10 -0.09 ± 2.57
Calciuma : 2.10-2.55 mmol/L (US: 8.42-10.22 mg/dL)
T0 130 (62/68) 2.35 ± 0.11 2.35 ± 0.09 1 (1.6) 0 -
T6 133 (65/68) 2.40 ± 0.08 2.39 ± 0.08 0 - 0 -
T12 130 (65/65) 2.40 ± 0.08 2.38 ± 0.07 0 - 0 -
T0–T12 121 (58/63) +0.05 ± 0.11 +0.03 ± 0.10
Magnesium: 0.70-1.10 mmol/L (US: 1.70- 2.67 mg/dL)
T0 130 (63/67) 0.80 ± 0.07 0.80 ± 0.06 3 (4.8) 3 (4.5)
T6 85 (40/45) 0.82 ± 0.05 0.83 ± 0.05 1 (2.5) 0 -
T12 86 (43/43) 0.83 ± 0.06 0.83 ± 0.04 1 (2.3) 0 -
T0–T12 80 (40/40) +0.03 ± 0.07 +0.03 ± 0.06
Phosphate: 0.87-1.45 mmol/L (US: 2.70-4.50 mg/dL )
T0 129 (62/67) 0.95 ± 0.18 0.93 ± 0.16 22 (35.5) 22 (32.8)
T6 106 (49/57) 1.01 ± 0.15 0.95 ± 0.15 10 (20.4) 14 (24.6)
T12 106 (55/51) 1.02 ± 0.20 1.02 ± 0.15 10 (18.2) 7 (13.7)
T0–T12 99 (51/48) +0.07 ± 0.20 +0.07 ± 0.23
Albumin: 35-50 g/L
T0 131 (63/68) 37.8 ± 3.8 37.8 ± 2.6 9 (14.3) 7 (10.3)
T6 133 (65/68) 38.8 ± 3.4 39.0 ± 3.0 6 (9.2) 5 (7.4)
T12 133 (65/65) 38.5 ± 3.2 38.8 ± 2.7 8 (12.3) 3 (4.6)
T0–T12 122 (59/63) +1.00 ± 3.50 +1.03 ± 2.99
Data are presented as mean ± standard deviation and counts (percentages).
US United States (units), sMVS standard multivitamin supplement.
a Corrected for albumin levels (total calcium – (0.025 x albumin) + 1).p > 0.05 for all. 
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Table 5. Vitamin B1 and B6 and Zinc
Parameter Cases Mean serum levels Deficiencies
WLS Optimum sMVS WLS Optimum sMVS
Vitamin B1: 95-175 nmol/L (US: 3.2-5.9  µg/dL)
T0 128 (61/67) 167.8 ± 29.5 162.3 ± 31.1 0 - 1 (1.5)
T6 104 (49/55) 148.0* ± 27.6 134.8 ± 24.8 1 (2.0) 4 (7.3)
T12 106 (54/52) 145.4 ± 29.8 144.1 ± 44.1 2 (3.7) 2 (3.8)
T0–T12 99 (50/49) -19.35 ± 40.61 -17.24 ± 45.05
Vitamin B6: 25-100 nmol/L (US: 0.62-2.47 µg/dL)
T0 127 (61/66) 79.3 ± 24.0 75.3 ± 29.5 0 - 0 -
T6 104 (49/55) 91.7 ± 36.1 88.1 ± 63.0 0 - 0 -
T12 105 (54/51) 82.9 ± 27.3 78.2 ± 25.9 0 - 0 -
T0–T12 97 (49/48) +3.06 ± 26.59 5.85 ± 30.77
Zinc (9.2-18.4 µmol/L (US: 60-120 µg/dL)
T0 127 (61/66) 12.2 ± 1.6 12.2 ± 2.0 1 (1.6) 4 (6.1)
T6 105 (48/57) 11.7 ± 1.6 12.1 ± 1.9 3 (6.3) 2 (3.5)
T12 102 (53/49) 11.7 ± 1.9 11.8 ± 1.7 2 (3.8) 4 (8.2)
T0–T12 95 (50/45) -0.44 ± 2.25 -0.81 ± 2.15
Data are presented as mean ± standard deviation and counts (percentages).
US United States (units), sMVS standard multivitamin supplement.
* p < 0.05
Compliance
Of the 69 patients in the intervention group, only 44 patients (63.8%) reported using 
the WLS Optimum supplement after 6 months. This number decreased to 38 patients 
(55.1%) after 12 months. The main reported reason for discontinuation was nausea. 
Most patients switched to an over the counter MVS. Others did not tolerate any MVS 
and therefore stopped using multivitamin supplementation. Based on self-reported 
compliance, the total group of patients was redivided into WLS Optimum users and 
sMVS-users. Results are shown in table 6. 
At T6 and T12, mean serum folic acid levels were significantly higher in patients using 
WLS Optimum, compared to patients using a sMVS: 24.1 and 24.4 mmol/L vs 20.2 
and 19.6 mmol/l (p < 0.05 for both). This was also true for mean vitamin B1 levels at 
6 months: 150.2 ± 27.6 nmol/L for WLS optimum users and 137.9 ± 23.3 nmol/L for 
sMVS users (p = 0.028).
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At 12 months, mean serum PTH levels were significantly lower in the group using 
WLS Optimum (3.2 ± 1.7 pmol/L) compared to the group using a sMVS (4.0 ± 2.1) (p 
= 0.026).
Throughout the entire study period, overall only one patient (2.6%) using WLS Optimum 
was anemic compared to 11 of the patients (17.5%) using a sMVS (p = 0.029). No 
significant differences were found for other vitamins and minerals.
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Table 6. Results of the per protocol analyses
Parameter Cases Mean serum levels Deficiencies
WLS Optimum sMVS WLS Optimum sMVS
Hemoglobin: F: 7.4-9.9 mmol/L, M: 8.4-10.8 mmol/L (US: F:11.9-16.0 g/L, M: 13.5-17.4 g/L)
T6 110 (44/66) 8.7 ± 0.7 8.7 ± 0.8 0 - 5 (8.2)
T12 100 (38/62) 8.5 ± 0.6 8.5 ± 0.7 1 (2.6) 8 (12.9)
T0–T12 99 (37/62) -0.34 ± 0.66 -0.20 ± 0.54
Ferritin:20-300 ng/mL
T6 93 (37/56) 148.3 ± 116.4 136.3 ± 74.2 0 - 2 (3.6)
T12 99 (37/62) 150.0 ± 116.5 130.5 ± 75.9 1 (2.7) 2 (3.2)
T0–T12 99 (37/62) +2.65 ± 60.33 -3.61 ± 80.05
Folic acid: 9.1-36 nmol/L  (US: 4.0-15.9 ng/mL)
T6 109 (44/65) 24.1* ± 8.7 20.2 ± 7.0 0 - 0 -
T12 101 (38/63) 24.4* ± 10.3 19.6 ± 6.6 1 (2.6) 3 (4.8)
T0–T12 100 (37/63) +6.84* ± 9.73 +2.42 ± 7.05
Vitamin B12: 200-570 pmol/L (US: 271-773 pg/mL)
T6 93 (36/57) 278.9 ± 90.0 300.0 ± 88.8 8 (22.2) 8 (14.0)
T12 94 (33/61) 277.5 ± 77.8 286.0 ± 87.6 7 (21.2) 14 (23.0)
T0–T12 94 (33/61) -25.27 ± 83.19 -29.30 ± 83.69
Vitamin D: > 50 nmol/L (US: > 20 ng/mL)
T6 110 (44/66) 87.4 ± 25.2 91.6 ± 32.8 1 (2.3) 4 (6.1)
T12 99 (37/62) 88.0 ± 28.4 86.9 ± 27.7 2 (5.4) 5 (8.1)
T0–T12 99 (37/62) +48.24 ± 28.22 +53.77 ± 25.53
PTH: 1.3 – 6.8 pmol/L (US: 12.3-64.1 pg/mL)
T6 111 (44/67) 3.1 ± 1.4 3.7 ± 1.7 2 (4.5) 4 (6.0)
T12 100 (37/63) 3.2* ± 1.7 4.0 ± 2.1 1 (2.7 0 -
T0–T12 100 (37/63) -0.32 ± 1.90 -0.10 ± 2.66
Vitamin B1: 95-175 nmol/L (US: 3.2-5.9  µg/dL)
T6 86 (36/50) 150.2* ± 27.6 137.9 ± 23.3 0 - 2 (4.0)
T12 82 (33/49) 146.9 ± 33.2 146.2 ± 44.4 2 (6.1) 1 (2.0)
T0–T12 78 (30/48) -20.97 ± 46.62 -14.02 ± 43.87
Zinc (9.2-18.4 µmol/L (US: 60-120 µg/dL)
T6 87 (35/52) 11.9 ± 1.65 12.1 ± 1.82 2 (5.7) 1 (1.9)
T12 79 (33/46) 11.8 ± 2.0 11.7 ± 1.5 0 - 2 (4.3)
T0–T12 75 (31/44) -0.22 ± 2.23 -0.68 ± 2.27
Data are presented as mean ± standard deviation and counts (percentages).
Information about compliance was missing for 17 patients at T6 and 23 patients at T12. These patients were 
excluded from analysis for that time point. Non-users of multivitamin supplements were also excluded.
US United States (units), sMVS standard multivitamin supplement.* p < 0.05.




The present study demonstrated that the specialized multivitamin supplement WLS 
Optimum 1.0 had no clear advantages over standard supplementation as it was not 
associated with fewer micronutrient deficiencies after SG. Therefore, the content of this 
first version of WLS Optimum should be further optimized. 
More importantly, the present study illustrates that nutritional deficiencies are highly 
prevalent after SG, despite the anatomy of the intestinal tract remaining unaltered. There 
are several factors that put patients at risk for developing nutritional deficiencies after 
SG, including reduced food intake, decreased hydrochloric acid and intrinsic factor 
secretion, vomiting, poor food choices and food intolerance7, 21. Yet, others believe that 
SG has minimal impact on nutrient status3 and that maintenance of MVS more than three 
months postoperatively seems to be of no benefit8. According to Ruiz-Tovar et al., once 
a patient is able to eat all kinds of food, additional vitamin and mineral supplementation 
can be discontinued8. In the present study, about three-quarters of the patients showed 
at least one micronutrient deficiency during the first year post-sleeve, despite the use 
of multivitamin supplements. In view of our findings, a specialized multivitamin 
supplement for SG patients should at least contain higher doses of elementary iron, 
vitamin B12, vitamin D, vitamin B1 and zinc to prevent nutritional deficiencies post-
operatively.
Anemia and Iron deficiency 
In total, 17 patients (12.3%) were anemic during the study. Additionally, three patients 
(2.2%) had iron deficiency anemia. This is in line with the prospective cohort study of 
Hakeam et al., who also found a low prevalence of iron deficiency anemia (1.6%) 1 year 
after SG22. In contrast, Abdulrahman and colleagues reported that 36% of their patients 
developed iron deficiency anemia23. However, the latter study most likely used serum 
iron concentrations to define iron deficiency anemia as they did not report on ferritin 
levels. 
Post-bariatric anemia is in most cases due to iron deficiency, along with vitamin B12 
deficiency as a secondary cause5. We observed iron deficiency, expressed in low serum 
ferritin levels, in seven patients (5.1%). After surgery, reduced secretion of HCl, use of 
proton-pump inhibitors (PPI) and faster gastric emptying may limit absorption13, 14, 21, 24. 
Besides low absorption, reduced oral intake and intolerance to iron-rich sources such as 
red meat might be a cause of iron deficiency post-sleeve14, 21.
The dose of 21 mg elementary iron in WLS Optimum 1.0 should be increased to 
prevent iron deficiencies post-sleeve. Yet, considering the low number of deficiencies 
observed in the present study, the recommended dose of 45-60 mg for WLS preventative 
supplements according to the ASMBS guidelines25 is probably overestimated. 
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Vitamin B12 deficiency
Occurrence of vitamin B12 deficiency after SG is mainly due to the reduction of HCl 
and intrinsic factor as a consequence of the surgery, which is even more pronounced 
with PPI intake14, 26. In the present study, a marked decrease in mean serum vitamin 
B12 levels over the first year post-operatively was found in both groups, indicating 
that the dose of 10 μg vitamin B12 in the WLS Optimum supplement was insufficient. 
In the study of Al-Mutawa and colleagues (2018), patients were prescribed additional 
B-complex tablets for 1-3 months, including 200 μg vitamin B12 (next to 100 mg 
vitamin B1 and 200 mg vitamin B6)14. This high dose of vitamin B12 (8400% RDA) 
significantly improved serum vitamin B12 levels during the early post-operative period 
in comparison to baseline. Thereafter, patients continued with a daily multivitamin 
supplement that provided only 1 μg (42% RDA) of vitamin B12, which was insufficient 
to prevent deficiencies14. 
These findings indicate that SG-specific MVS do not need to contain more than 100 μg of 
vitamin B12 to prevent deficiencies. This is not in line with the ASMBS recommendation 
of 350-500 μg per day25, probably because they do not make a distinction between the 
different types of weight loss surgery.
Vitamin D deficiency
Vitamin D deficiency was the most prevalent micronutrient deficiency at baseline 
(76.1%). During the study, 10 percent of the patients was deficient. This is not in line 
with other studies, reporting between 16 and 89 percent of patients being deficient7, 27, 
28. Next to supplementation and monitoring post-surgery, the improvement in vitamin 
D status is probably due to our preoperative supplementation protocol. According to 
the systematic review of Dix et al., only 3 of the 17 included studies used additional 
supplementation to improve vitamin D status before SG27. Prevalence rates of post-
operative vitamin D deficiencies in studies using a preoperative treatment protocol 
range from 14 to 36%9, 15, 17, 29, being closer to our observation.
Calcium and magnesium deficiencies were rare during the first year post-sleeve, but low 
levels of phosphate were found more frequently. Hypophosphatemia is usually due to 
vitamin D deficiency30. However, because of the low prevalence of vitamin D deficiencies 
we could not confirm this in the present study. Nevertheless, the dose of vitamin D in a 
SG-specific supplement should be increased to the levels advised for RYGB patients by 
the ASMBS (75 μg per day) to also improve post-operative phosphate levels25. 
Vitamin B1 deficiency
Vitamin B1 deficiencies are not commonly reported after SG, probably because they 
are not routinely measured. We found lowered vitamin B1 levels in nine patients (7.3%) 
throughout the study period, but none showed clinical symptoms. This differs from the 
RYGB patients in whom such deficiencies hardly occur7, 8. Theoretically, this could be 
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explained by the higher risk of minimized intake and vomiting after SG compared to 
a RYGB. When thiamin levels are below the adequate level, this can result in serious 
cardiovascular and neurologic consequences such as Wernicke’s encephalopathy 
(WE) and beriberi31, 32. Risk factors known to cause post-bariatric WE include alcohol 
consumption, vomiting and rapid weight loss, but also poor compliance with vitamin 
supplementation is an important predisposing factor28, 32, 33. 
For non-vomiting patients, the dose of thiamin required to prevent deficiencies post-
sleeve should be increased from 2 mg to ± 3 mg. In our opinion, the recommended dose 
of 12 mg per day by the ASMBS25 is thus highly overestimated.
Zinc deficiency
As with thiamin, only a few studies have evaluated zinc status after bariatric surgery, 
mainly focusing on one type of surgery (RYGB). In the present study, prevalence of zinc 
deficiency was 13%, which is quite low compared to the wide range of 5–39% described 
in the available literature12, 17, 34-36. It is suggested that initially, zinc deficiency may be 
caused by malabsorption and protein malnutrition35. In our study, the only marker for 
protein status was albumin. About half of the patients that were deficient for zinc also 
had low albumin levels and at 12 months, serum zinc levels were significantly correlated 
with serum albumin levels (r = 0.496). Other factors associated with zinc deficiency 
include a reduction of gastric HCl limiting zinc absorption, and inadequate intake of 
dietary zinc because of intolerance to foods rich in zinc such as red meat35, 37.
The dose of 15 mg of zinc in WLS Optimum 1.0 was not sufficient to prevent deficiencies. 
However, this dose was already higher than the recommended dose of 8-11 mg per day 
according to the ASMBS25. For SG patients, recommendations should be increased to at 
least the levels advised in RYGB patients (8-11 mg/day to 16-22 mg/day). 
Hypervitaminosis
Some patients showed excess serum levels of vitamin B1 (13%) and vitamin B6 (27%) 
throughout the study period. For both vitamins, excess cases were more prevalent than 
deficient ones. Complications of high doses of vitamin B1 are rare as the body can 
excrete excess amounts of thiamin in the urine13, 31. However, excessive serum levels of 
vitamin B6 can cause neuropathic symptoms38. Despite the higher dose of vitamin B6 
in WLS Optimum (143% RDA) compared to the sMVS (100% RDA), no difference in 
prevalence of hypervitaminosis was found between the two groups. In three patients, 
extremely high serum levels (> 200 nmol/L) of vitamin B6 were found. Clinical 
manifestations of vitamins toxicity have not been actively investigated in the present 
study. Consequently, it is difficult to ascertain whether the observed excess levels are 
clinically relevant. High serum vitamin B6 levels can also occur due to over-use of 
vitamin supplements. As serum folic acid concentrations rapidly increase after intake39, 
these concentrations can be used as a marker for compliance of MVS intake in countries 
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where it is not a food additive. In our study, serum vitamin B6 levels were significantly 
correlated with serum folic acid levels at 12 months (r = 0.494), but it is unclear if 
patients indeed overdosed the MVS.
Limitations
The present study has some limitations, especially the relatively high rate of incompliant 
patients which most likely led to underpowering. Even when provided free of charge, 
about one third of the patients were not compliant to the supplement protocol. With 
respect to product optimization, this finding is very important as it indicates that this 
version WLS Optimum was probably not well tolerated. 
In addition, information on compliance was subjective (via questionnaires and medical 
files) and incomplete which might have led to an overestimation of compliant patients. 
Yet, comparing self-reported intake to blister counting in a previous study showed 
that the majority of the patients are honest in their self-reports. Besides, presuming 
that serum folic acid levels can serve as a marker for compliance, the absence of folic 
acid deficiencies in the per protocol analyses implies that these patients were indeed 
compliant. 
Furthermore, only preoperative deficiencies for vitamin B12 and vitamin D were 
treated. Not correcting for all preoperative deficiencies could have affected our findings 
regarding the efficacy of both multivitamin supplements in relation to the observed 
nutritional status.
Despite these limitations, we believe that we can draw important conclusions about 
nutritional status of the investigated micronutrients after SG and the need for long-term 
nutritional follow-up and maintenance of routine multivitamin supplementation.
CONCLUSION
This randomized controlled study showed that nutritional deficiencies are prevalent 
after sleeve gastrectomy. Despite the fact that the investigated, specialized multivitamin 
supplement contained elevated doses of multiple vitamins and minerals, it only 
significantly affected serum levels of folic acid, PTH and vitamin B1, and anemia 
rates compared to a standard MVS. This indicates that there is a clear need to further 
optimize multivitamin supplementation for sleeve patients. These supplements should 
contain higher doses of elementary iron, folic acid, vitamin B12, vitamin D, vitamin 
B1 and zinc to prevent deficiencies post-operatively. However, caution is needed to 
prevent oversupplementation as we found that most of the recommended doses for WLS 
preventive supplements according to the ASMBS guideline might be overestimated.
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Besides, non-compliance with multivitamin supplements was frequently encountered. 
More research is needed to identify which factors affect (non-)compliance and how this 
can be improved.
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Loose and frequent stools and PTH levels
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surgery due to less efficient intestinal calcium
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ABSTRACT
Background: After Roux-en-Y Gastric Bypass (RYGB) calcium and vitamin D 
deficiencies are frequently reported. In the presence of adequate vitamin D levels, 
calcium deficiency is caused by a lower efficacy of the intestinal calcium transport.  
Objective: To investigate whether the use of a simple clinical score quantifying bowel 
habits (Fecal Score; FS) correlates with the degree of secondary hyperparathyroidism 
(SHPT) that arises to compensate for calcium deficiency post-surgery.  
Setting: Large peripheral hospital
Methods: Seventy-five calcium and vitamin D supplemented patients were 
prospectively studied before RYGB surgery, and at 6 and 12 months of follow up. FS, 
calcium (mmol/l), phosphate (mmol/l), magnesium (mmol/l), vitamin D (nmol/l) and 
parathyroid hormone (PTH; pmol/l) were measured in each patient. 
Results: Mean BMI was 44.7±5.4 kg/m2 preoperatively and decreased to 34.3±5.0 
kg/m2 at 6 months and 30.8±4.8 kg/m2 at 12 months, with a Total Body Weight Loss 
(%TBWL) of 23.2±5.9% and 30.9±8.3%. There were no significant changes in serum 
calcium levels. Mean PTH levels rose from 3.5 pmol/l at baseline to 4.1pmol/l at 6 
months (P=0.01) and 4.9 pmol/l at 12 months (P < 0.001). Nine patients (12%) had 
increased PTH levels at 6 and 14 patients (19%) at 12 months. A significant positive 
correlation between FS and PTH at 12 months was found, which persisted after adjusting 
for vitamin D levels.  
Conclusion: FS is positively correlated with SHPT using vitamin D-adjusted PTH levels 
as biochemical marker. The present study in humans confirms the relation reported in 
animal studies. These results emphasize that managing stool habits are important after 
bariatric surgery. 
Loose and frequent stools and PTH levels are positively correlated post-Gastric Bypass surgery due to less 




Although the Roux-en-Y Gastric Bypass (RYGB) is the most frequently performed 
bariatric procedure worldwide, it is accompanied by a number of complications1. While 
it provides the excellent results on weight loss and reduction of comorbidities, vitamin 
and mineral deficiencies often arise postoperatively. A common deficiency, that can 
easily be overlooked as changes are subtle, is in the calcium and phosphate metabolism. 
This deficiency is recognized biochemically as secondary hyperparathyroidism 
(SHPT), the body tries to compensate for the calcium deficit by reabsorbing calcium 
from the skeleton2. When SHPT persists, it contributes to increased bone turnover and 
subsequently to bone loss. Several reports have shown that gastric bypass surgery can 
lead to SHPT and thus to increased risk of osteoporotic fractures3-5.
To prevent SHPT after RYGB surgery,  dietary calcium and vitamin D intake, which 
is impaired because of bypassing the proximal part of the jejunum, will have to be 
supplemented. One clinical challenge is the issue of patients’ adherence to prescribed 
calcium and vitamin D formulations. More than one third of patients is inadequately 
compliant in taking their daily portion of supplements1, 6-8.
In addition to inadequate dietary intake and/or adherence, postoperative changes 
in bowel habits may also affect calcium metabolism9. Many patients complain that 
postoperatively their stools are of lowered frequency and hardened consistency than 
preoperatively. Even more common is the opposite situation of patients who have 
looser stools than before operation10-12. In case of RYGB surgery, it is the bypass of 
the proximal part of the small intestine and the resulting increased transit time, which 
impairs the intestinal transport of calcium13. 
The aim of the present study was to investigate, in a prospective study, the relationship 
between semi-quantified stool scores, also called fecal score (FS) as previously reported 
by our group9, calcium and phosphate metabolism in the first year after RYGB surgery 
in a prospective study. 
78
PATIENTS AND METHODS
As part of the prospective VITAAL I study1 toward multivitamin supplementation, this 
study was conducted at the Bariatric Surgery Unit of the Rijnstate Hospital Arnhem 
(RHA), the Netherlands, after approval of the institutional review board. The study was 
registered at clinicaltrials.gov (NCT01609387). 
A total of 75 patients who were eligible for RYGB surgery, participated in this study 
(for demographics see table 1). After written informed consent, each participant 
was requested to complete a questionnaire about his/her bowel habits prior to and 
at 6 and 12 months after surgery, and FS was calculated from each questionnaire9. 
Fecal Score
The Fecal Score  was based on fecal frequency and consistency. Fecal frequency was 
scored on a five-point scale ranging from less than twice a week (1 point), every two 
days (2 points), once a day (3 points), twice a day (4 points) to more than twice a 
day (5 points). In addition, fecal consistency was scored on a five-point scale ranging 
from watery stools (5 points), loose stools (4 points), normal stools (3 points), firm 
stools (2 points) to hard stools with concomitant constipation (1 point). Summation of 
fecal consistency and frequency scores yields the Fecal Score (FS), as introduced for 
the first time by our group. Validation of FS was based on comparative data pre- en 
postoperative. Thus far, there are no validated data with regard to the FS. 
Preoperative management
All patients were screened by a multidisciplinary team, including a bariatric surgeon, 
a nutritionist, a psychologist and a physiotherapist. Patients who met the criteria for 
bariatric surgery of the International Federation for the Surgery of Obesity (IFSO) 
(Body Mass Index (BMI) > 40 kg/m² or > 35 kg/m² with at least 1 comorbidity), were 
invited for individual consultation with one of the bariatric surgeons. Preoperatively 
routine blood tests were performed, including calcium (mmol/l) corrected for albumin 
(mmol/l), phosphate (mmol/l), magnesium (mmol/l), 25-OH-vitamin D (nmol/l) and 
PTH (pmol/l). Patients without 25-OH-vitamin D deficiency were eligible for enrolment 
into the study. Patients with 25-OH-vitamin D deficiency or insufficiency, defined as 
25-OH-vitamin D < 50nmol/l, received cholecalciferol; these patients were then enrolled 
into the study if their 25-OH-vitamin D levels  became sufficient.  
Postoperative management
Each patient included was advised to take calcium carbonate and vitamin D 3 
(Calcichew 500/400) t.i.d., a multivitamin formulation containing 350ug vitamin B12 
(FitForMe WLS Forte), esomeprazol 40mg (once daily for 6 months to protect the 
gastro-enterostomy) and low molecular heparin SC (fraxiparine ® 5700 IU) once daily 
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for 6 weeks to prevent thrombo-embolism)1. Because FitForMe WLS Forte doesn’t 
contain calcium, patients were instructed to take the Calcichew 500/400 2 hours after 
the multivitamin supplement at 2 different time points.
Compliance for taking Calcichew 500/400 was arbitrarily defined as daily use with at 
most one day of non-use a week. Patients who reported taking the supplement 5 days a 
week or less were categorized as non-compliant. Patients were asked to return (empty) 
Calcichew 500/400 containers during control visits. Routine blood tests were performed 
at 6 and 12 months postoperatively, including calcium (mmol/l) corrected for albumin 
(mmol/l), phosphate (mmol/l), magnesium (mmol/l), 25-OH-vitamin D (nmol/l) and 
PTH (pmol/l). 
Statistical analysis
Data were analyzed using IBM® SPSS® (version 21.0 for Windows). Results are 
presented as mean values ± standard deviation (SD). Differences between groups were 
analyzed by related-samples t-test and Mann-Whitney U-test for continuous variables. 
Multivariate linear regression analysis was used to study the association between PTH at 
0, 6, 12 months and FS at 0, 6 and 12 months adjusted for calcium and 25-OH-vitamin 
D. Wilcoxon Signed Ranks Tests were performed between FS at 0, 6 and 12 months 
postoperatively, including correction for Bonferroni error. Results with p < 0.05 were 
considered as statistically significant. 
A power analysis was performed: Patients included in this study were a subgroup of 
the original VITAAL I study, aiming to study the differences in deficiency outcomes 
between two types of multivitamins after RYGB surgery1. The original sample size of 
this study (VITAAL I study) was 150 patients in total. Before the start of the VITAAL 
I study an additional sample size was calculated for this fecal score trial. Based on our 
previous study on fecal scores we calculated the required number of patients based on 
the difference in PTH levels between the high fecal score group and the average PTH 
value of the intermediate and low fecal score groups combined (a mean of 5.4 ± 2.8 
and 8.0 ± 3.4, respectively)9. With a confidence interval of 95% and a power of 90%, a 
minimum of 62 patients were required. Taking into account that usually 10% of patients 
drop out during the study, we aimed to include a total of 70 patients. All patients in 
the VITAAL I study completed 3 questionnaires on fecal scores. In order to minimize 
supplementation bias and improve homogeneity in the present study group, we excluded 
those patients who were known, after the randomization code was broken after one year, 
to have  received the suboptimal standardized multivitamins (100% RDA) and standard 
calcium supplementation (75 patients). The remaining 75 patients, who were optimally 
supplemented, were all included in this study.
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RESULTS
Seventy-five patients (68% female) participated in the study. Demographics and 
laboratory data prior to gastric bypass surgery are shown in table 1. Sixty-seven patients 
underwent primary RYGB surgery; the remaining 8 patients underwent redo-RYGB 
surgery because of failed adjustable banding. Diabetes mellitus type 2 was present in 25 
patients (33.3%), hypertension in 38 (50.7%), obstructive sleep apnea syndrome in 12 
(16.0%), osteoarthritis in 27 (36.0%) and abnormal lipids in 18 (24.0%). The percentage 
Excess Weight Loss (EWL%) postoperatively was 54.7 ± 15.6% at six months and 
72.1±19.8% at 12 months corresponding to a Total Body Weight Loss (%TBWL) of 
23.2±5.9% and 30.9±8.3%, respectively. The mean BMI at baseline was 44.7±5.4 kg/
m2 and decreased to 34.3±5.0 kg/m2 at six months and further to 30.8 ± 4.8 kg/m2 at 12 
months.
Changes in bowel habits were reported by 21 out of 75 patients (28%) at 6 months and 
56 patients (75%) at 12 months postoperatively. Nine out of 75 (5.3%) patients reported 
to be non-compliant in taking additional Calcichew 500/400.
Table 1. Demographics and laboratory data prior to Roux-en-Y Gastric Bypass surgery
Parameters
Patient number 75                                 
Males/Females        24/51 
Age (yr)    47.1 ± 9.8 
BMI (kg/m2)     44.7 ± 5.4 
Bodyweight (kg) 132.6 ± 17.8 
Patients with abnormal lab. values 
Calcium    (mmol/l)1        2.32 ± 0.08                           1   (high 1%)2
Phosphate            (mmol/l) 0.99 ± 0.22 21 (low 28%) / 3 (high 4%)
Magnesium       (mmol/l) 0.78 ± 0.06 6   (low 8%)
Albumin          (g/l) 39.0 ± 3.3 5   (low 7%)
Vitamin D             (nmol/l)          43.2 ± 18.1    
Deficiency        < 30  (nmol/l)                                                               21 (28%)
Insufficiency    < 50  (nmol/l)                                                               27 (36%)
PTH                        (pmol/l)                  3.5 ± 2.2                                10 (low 13%) / 5 (high 7%)
Yr, year; BMI, body mass index; kg, kilogram; PTH, parathyroid hormone; lab, laboratory. 1, Serum calcium 
was adjusted for albumin concentrations. 2, One patient had a corrected serum calcium of 2.57 mmol/l. 
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Preoperatively, all vitamin and mineral deficiencies (for instance, calcium, 25-OH-
vitamin D, folate, phosphate, vitamin B12, ferritin) were corrected. There were no 
significant differences between calcium levels corrected for serum albumin concentration 
at baseline, 6 or 12 months. 25-OH-vitamin D levels increased significantly both at 6 and 
12 months, (P < 0.001). In spite of increasing 25-OH-vitamin D levels plus Calcichew 
500/400 supplementation, mean PTH levels increased from 3.5 pmol/l at baseline to 4.1 
pmol/l at 6 months (P=0.01) and 4.9 pmol/l at 12 months (P < 0.001).
An analysis was performed comparing patients with normal PTH levels (3.6±1.6 pmol/l 
at 6 months and 3.9±1.4 pmol/l at 12 months) vs. increased PTH levels (7.5±0.5 pmol/l 
at 6 months and 9.1±2.1 at 12 months) (table 2). Nine patients (12%) had increased 
PTH levels at 6 months and 14 (19%) patients at 12 months. Of note, 25-OH-vitamin D 
levels were lower in the high-PTH group than in the low-PTH group; 59±19 vs. 77±23 
nmol/l (p=0.03) at 6 months  and 61±17 vs. 80±24 nmol/l (p=0.002) at 12 months, while 
corrected calcium levels were similar (table 2). 
Table 2. Biochemical data categorized according to normal or increased parathyroid hormone levels at 
6 and 12 months after Roux-en-Y Gastric Bypass surgery
6 Months 12 Months
PTH≤6.8 PTH > 6.8 PTH≤6.8 PTH > 6.8
Patients       (N) 66 9 61 14
Calcium      (2.10 - 2.55 mmol/l) 2.32 ± 0.08 2.28 ± 0.11 2.33 ± 0.08 2.30 ± 0.10
Phosphate   (0.8-1.4 mmol/l) 1.07 ± 0.21 0.99 ± 0.21 1.05 ± 0.16 1.04 ± 0.20
Magnesium (0.70-1.10 mmol/l) 0.80 ± 0.05 0.78 ± 0.04 0.81 ± 0.06 0.84 ± 0.82
Vitamin D   (30 - 100 nmol/l) 77 ± 23* 59 ± 19* 80 ± 24# 61 ± 17#
Albumin      (35 - 50 g/l) 39.4 ± 3.2 37.0 ± 3.7 39.0 ± 2.7 40.2 ± 3.8
PTH             (1.3 - 6.8 pmol/l) 3.6 ± 1.6** 7.5 ± 0.5** 3.9 ± 1.4** 9.1  2.1**
PTH; parathyroid hormone. Laboratory results are represented as mean ±1 Standard deviation. Significant by 
*p=0.03,  **p < 0.0001 and # p=0.002. p, p-value.
Fecal score
Changes in bowel habits with respect to stool frequency and consistency scored at 
baseline, 6 and 12 months after RYGB surgery are shown in table 3a, table 3b and 
figure 1.
There was a significant shift towards more frequent and less consistent stools, yielding 
a significantly higher overall FS at 12 months post-RYGB (p=0.024) (significance 
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remained after correction for Bonferroni error).
Table 3a. Changes of bowel habits according to frequency and consistency scores before and after Roux-
en-Y Gastric Bypass surgery
Frequency Consistency
Baseline 6 Months 12 Months Baseline 6 Months 12 Months
Patient number 75 75 75 75 75 75
Frequency/Consistency
< 2 Per week/Constipated 3 0 1 5 3 0
3 Times per week/Firm 13 16 7 11 13 9
1 Day/Normal 35 45 41 48 34 40
2 Per day/Solid to watery 16 8 19 6 19 21
> 2 Per day/Liquid 8 6 7 5 6 5
Number of patients with stool frequency and consistency scores ranging from 1-5 points. (See text for scoring).
Table 3b. Fecal scores before and after Roux-en-Y Gastric Bypass surgery expressing patient numbers
Fecal Score Baseline 6 Months 12 Months
2 2 0 0
3 3 3 1
4 4 4 1
5 15 14 9
6 24 27 32
7 16 15 14
8 5 7 11
9 2 2 4
10 4 3 3
Fecal Scores are the summation of stool frequency and consistency ranging from 2-10 points and show a 
significant increase post-surgery (chi 2-test: P < 0.01).
 
Loose and frequent stools and PTH levels are positively correlated post-Gastric Bypass surgery due to less 
efficient intestinal calcium absorption
4
83
Figure 1. Changes in bowel habits reflected in Fecal Score before Roux-en-Y Gastric Bypass surgery 
and 12 months postoperatively in 75 patients
Six months after surgery, FS was lowered at baseline in 23 patients (30.7%), similar in 
21 (28.0%) and higher in 31 patients (41.3%). After 12 months FS was lowered in 18 
(24.0%),  similar in 19 (25.3%) and higher in 38 (50.7%). 
No correlations were found between FS and PTH at 0 and 6 months (p=0.61 and 
p=0.43); however, at 12 months there was a significant positive correlation (p=0.028, 
β coefficient=0.479; see table 4). This positive correlation remained significant after 
adjusting for 25-OH-vitamin D levels and calcium. Thus, using PTH level as a marker 
for SHPT, FS correlated with SHPT at 12 months.
Table 4. Correlations between Fecal Score and parathyroid hormone
Fecal score PTH












Output of linear regression analysis between Fecal Score and laboratory values before, and 6 and 12 months 
after Roux-en-Y gastric bypass surgery, adjusted for calcium and 25-OH-vitamin D. β Coeff, β coefficient;, 




In the present study about the fecal transit time post-RYGB surgery, changes in bowel 
habits occurred in 75% of patients. Moreover, stool frequency increased and consistency 
decreased reflected in higher FS. These data are in line with an earlier reported 
retrospective study by our group9. Increased fecal transit hampers intestinal calcium 
transport, creating an increased drive for the parathyroid gland to compensate for low 
serum calcium concentrations (secondary hyperparathyroidism; SHPT)2. Importantly, at 
the same time PTH levels are relatively suppressed as substantial bone loss results in a 
rise of serum calcium levels. Bone loss after surgery mostly affects the weight bearing 
bones, i.e. hip and pelvis14, 15. SHPT arises due to insufficient intake and/or intestinal 
absorption capacity, as a way to compensate for increased fecal calcium loss. Intestinal 
calcium transport is mainly actively mediated by vitamin D receptors, as opposed to 
passive transport, by intestinal diffusion16. Active calcium transport takes place primarily 
in the duodenum and upper jejunum while passive (gradient-based) calcium transport 
occurs in the jejunum, ileum and to a much lesser extent in the colon. It is widely 
accepted that the combination of anatomical changes and increased fecal transit impairs 
calcium absorption. In this prospective study, FS used as a clinical marker for fecal transit 
time correlated independently with SHPT, a sensitive biochemical marker of impaired 
intestinal calcium transport. This confirms the relation established retrospectively in an 
earlier study by our group9. Additionally, preclinical research supports with the view that 
fecal transit is an independent determinant of the level of intestinal calcium transport. 
Moreover, it has been shown previously that intestinal calcium kinetics depend on 
intestinal transit time17. Similar observations were also found in vivo after RYGB in rats 
due to the inability of the small intestine to bind and absorb calcium13. The current study 
is a prospective study in humans who were dedicatedly treated with calcium carbonate 
1500 mg and vitamin D3 1200 i.e. per day as a fixed dose18. 
After malabsorptive bariatric surgery, calcium deficiency arises in up to 10-25% of 
patients at 2 years and 25-48% at 4 years of follow up. Moreover, low vitamin D levels 
are found in 17-52% of patients at 2 years and 50-63% at 4 years19. These data should 
encourage clinicians not only to supplement calcium and vitamin D to sufficiency 
post-surgery but also to monitor FS. For constipated patients (low-FS group), the 
supplementary calcium may worsen their constipation problem: on the contrary, for 
patients with diarrhea (high-FS group) the supplementary calcium will improve stool 
frequency and consistency. Thus, it appears beneficial to tailor calcium supplementation 
to the individual patient so as to normalize the FS. We hypothesize that optimal calcium 
dosing combined with vitamin D supplementation based on serum levels will result in 
the lowest level of SHPT. Obviously, this hypothesis needs to be proven by prospective 
dose-finding studies. 
Due to the lack of dedicated studies on bowel habits after bariatric surgery, no 
recommendations exist the quantification of bowel habits and how this should affect 
calcium and vitamin D supplementation. Existing recommendations relate only 
Loose and frequent stools and PTH levels are positively correlated post-Gastric Bypass surgery due to less 
efficient intestinal calcium absorption
4
85
to excessive bloating, flatulence and/or foul-smelling stools with oral neomycin, 
metronidazole or pancreatic enzymes20. 
The weakness of the current prospective study is that it did not include a placebo group. 
However, inclusion of a placebo group would face opposition from Medical Ethical 
Committees as supplementation of calcium and vitamin D is considered a critical 
part of the post-operative management of bariatric patients20. A confounding factor 
is the inclusion of men and women (68%) with a mean age of 47.1±9.8 years. Since 
menopause was not an exclusion criterion for the study, the higher calcium levels found 
in menopausal women may have affected correlations. However, since high calcium 
levels due to increased bone turnover suppress PTH levels, correlations between FS 
and PTH levels are even more solid. Second, all data were collected during 12 months 
post-surgery. It is questionable whether this timing was appropriate in terms of FS-
PTH correlations. Yet, no prospective FS data beyond 12 months have been reported. 
In addition, calcium levels are increased particularly during massive bone loss in the 
first year after surgery, which suggests that calcium levels will decrease afterwards15. 
Therefore the existence of positive correlations between FS and PTH levels in the first 
year is considered positive proof of principle that FS is genuinely related to calcium 
metabolism. Based on the result of the current study, we believe that a future study 
should address the implementation of FS scoring and the FS-based individualization of 
calcium supplementation. This will improve both patient  convenience and bone safety 
issues such as SHPT. 
CONCLUSION
In this prospective study among 75 patients (all being calcium and vitamin D sufficient 
prior to surgery), it was shown that FS is independently correlated with the degree of 
SHPT 12 months postoperatively. In spite of supplementation with a high fixed dose of 
calcium carbonate (1500 mg) combined with vitamin D3 (1200 i.e.), SHPT was found 
in 9 patients at 6 months and in 14 patients at 12 months. Of note, it was also found that 
FS correlated positively and significantly with PTH after adjusting for 25-OH-vitamin 
D concentrations, suggesting a contributory role for the fecal transit time in SHPT post-
surgery. 
The present study emphasizes the importance of using semi-quantified bowel habits 
(represented by the Fecal Score [FS]) in post-surgery bariatric care. No official 
recommendations exist on individualized calcium supplementation based on bowel 
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ABSTRACT
Background: Vitamin and mineral deficiencies are a major concern after biliopancreatic 
diversion (BPD) and BPD with duodenal switch (BPD/DS). Evidence based guidelines 
how to prevent or how to treat deficiencies in these patients are currently lacking. The 
aim of the current study is to give an overview of postsurgical deficiencies and how to 
prevent and treat these deficiencies.
Methods: Retrospective evaluation of a 1-year structured monitoring and treatment 
schedule for various deficiencies in 34 patients after BPD or BPD/DS. 
Results: Patients were introduced into the program 12-90 months after surgery. 
Vitamin B1, B6, B9 and B12 deficiencies could be prevented by mean daily doses of 
2.75 mg, 980 µg, 600 µg, and 350 µg, respectively. However, many patients continued 
to develop deficiencies of vitamin A, D, Iron Calcium and Zinc despite major dose 
adjustments. Current observations suggest that at least total daily doses of 200 mg Fe in 
premenopausal women and 100 mg in men, 100 mg of Zinc, 3000 mg of Calcium, and 
weekly doses of at least 50,000 IU solubilized vitamin A and vitamin D are needed to 
prevent the occurrence of major deficiencies. 
Conclusion: Exceptionally high supplementation doses are needed to prevent and 
treat vitamin and mineral deficiencies in patients after BPD or BPD/DS. Further 
refinement and simplification of treatment schedules is needed. Focus on improvement 
of compliance to treatment is recommended. 
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Vitamin and mineral deficiencies are a major concern after biliopancreatic diversion 
(BPD) and BPD with duodenal switch (BPD/DS). Up to 90% of these patients develop 
any kind of vitamin or mineral deficiency within three years after surgery1. This is 
related to the profound malabsorptive character of these procedures, a result of the very 
short common channel of approximately 75 cm for BPD and 100 cm for BPD/DS. 
The international guideline of the American Society for Metabolic and Bariatric Surgery 
(ASMBS)2 advises daily intake of two multivitamin supplements (MVS), 1200-1500 
mg calcium citrate, and at least 3000 IU of vitamin D per day after BPD or BPD/DS. 
These recommendations are not very specific and do not cover all potential deficiencies. 
The exact requirements to maintain nutritional health after BPD or BPD/DS remain 
unclear. Although several studies have evaluated nutritional status after BPD or BPD/
DS1, 3, 4, only two focused on multivitamin and mineral supplementation5, 6. Topart et al.5 
concluded that a basic MVS was not sufficient to cover the requirements after BPD/
DS and gave some recommendations in addition to a basic multivitamin supplement, 
such as a daily oral intake of at least 3000 mg calcium, 7000 IU of vitamin D, 50,000 
IU vitamin A (tablet), 200 mg of iron and 30 mg Zinc. Nett et al. concluded that despite 
200% micronutrient supplementation on a daily base over 80% of patients with a 
BPD/DS developed micronutrient deficiencies within 5 years. Readjustments of the 
micronutrient supplementation were necessary and included an increase of the initial 
dosage varying from about 50% for folate to about 300% for vitamin B12.
To date, there is no single multivitamin supplement (MVS) that meets all the nutritional 
requirements after BPD or BPD/DS. The present study summarizes our attempts to treat 
nutritional deficiencies in patients after BPD and BPD/DS. These experiences may help 
to increase the basic information that is needed to develop rational supplementation 




Study design and ethics
This is a retrospective, one-year observational study of structured monitoring and 
treatment of nutritional deficiencies in patients after BPD or BPD/DS. The study 
was approved by the ethical committee, and informed consent was obtained from all 
participants.
Surgical procedures
BPD: A laparoscopic operation with a distal two-thirds resection of the stomach, an 
alimentary limb of 150 cm, and a common channel of 75 cm with a side-to-side stapled 
anastomosis with the biliopancreatic limb. 
BPD/DS: The laparoscopic BPD/DS is performed as a second-stage procedure after an 
earlier laparoscopic sleeve gastrectomy (LSG). First, a cholecystectomy is performed. 
The duodenum is stapled and transected 2-cm post-pyloric and end-to-side connected to 
the 150-cm alimentary limb. The common channel is 100 cm. 
Standard postoperative supplementation
After BPD or BPD/DS all patients were advised to take multivitamins to ensure at least 
200% of the recommended dietary allowance (RDA), plus 1500 mg calcium and 2400 
IU vitamin D3 daily, and a minimal protein intake of at least 60 g per day, up to a 
maximum of 1.5 g/kg ideal body weight. 
Patient selection and outcome
Initially, all patients were primarily monitored by bariatric surgeons. If patients developed 
a specific vitamin or mineral deficiency despite routine post-operative supplementation 
they were referred for internal medicine consultation. After the realization that virtually 
all patients developed various deficiencies in due time it was decided to focus on 
prevention and refer patients systematically to the department of internal medicine 
at an earlier stage for structured monitoring and treatment. As a result of this change 
in regimen the interval between the date of BPD or BPD/DS surgery and the time of 
permanent referral to the department of internal medicine varied from 12 – 90 months, 
with a median of 44 months). Baseline nutritional screening was performed at referral 
(T0), and then repeated six (T6) and 12 (T12) months later. In between, additional blood 
withdrawals were performed to evaluate the effects of dose adjustments or changes in 
treatment. Nutritional screening consisted of a complete blood count, vitamin A, vitamin 
B1, B6, B9 (i.e. folic acid), and B12, 25-hydroxyvitamin D (25-OHD), albumin, calcium 
corrected for albumin, parathyroid hormone (PTH), Zinc, and 24-hour urinary calcium 
excretion. 
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After T0 all patients an optimized multivitamin supplement (oMVS) specifically 
developed for patients after RYGB (WLS Forte®, FitForMe, Rotterdam, the Netherlands) 
was provided to each patient as one tablet per day, combined with calcium carbonate/
cholecalciferol 500 mg/800 IU tablets three times daily (a total of 1500 mg calcium and 
2400 IU vitamin D). The oMVS composition has been described by Dogan et al, and is 
summarized in table 17. 
Table 1. Content of the optimized multivitamin supplement (oMVS) used in this study
Content Amount RDA
Vitamin A 600 µg 75%
Vitamin B1 2.75 mg 250%
Vitamin B2 3.5 mg 250%
Vitamin B3 32 mg 200%
Vitamin B5 18 mg 300%
Vitamin B6 980 µg 70%
Vitamin B8 100 µg 200%
Vitamin B9 (folic acid) 600 µg 300%
Vitamin B12 350 µg 14.000%
Vitamin C 120 mg 150%
Vitamin D3 25 µg 500%
Vitamin E 24 mg 200%
Chrome 160 µg 400%
Iron 70 mg 500%
Iodine 225 µg 150%
Copper 3 mg 300%
Manganese 3 mg 150%
Molybdenum 112.4 µg 225%
Selenium 105 µg 191%
RDA = Recommended Daily Allowance. Conversion factors: Vitamin A: 1 µg = 3.3 IU; Vitamin D: 1 µg = 
40 IU
During follow-up, data on body weight and supplementation were documented. Primary 
endpoints were vitamin and mineral deficiencies at baseline, six and 12 months follow-
up. Vitamin and mineral deficiencies were defined as serum levels falling below the 
lower normal limit (LNL). These LNL’s are summarized in table 3. Changes in serum 
levels were evaluated in relation to the mean supplementation dosage prescribed for that 
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vitamin or mineral. Poor compliance to treatment was common. Therefore, the effects 
of interventions were evaluated as by per protocol analysis. Maintenance of weight 
reduction, expressed as percentage excess weight loss (%EWL, defined as weight loss 
divided by excess weight based on Body Mass Index (BMI) 25 kg/m2), and percentage 
total weight loss (%TWL, defined as weight loss divided by pre-operative body weight) 
were secondary endpoints.
Laboratory assays 
The following analyses were routinely performed on random access analysers: 
complete blood count (XN-10 Sysmex, Kobe, Japan), erythrocyte sedimentation rate 
(StaRRsed Auto-Compact, Mechatronics Manufacturing B.V., Hoorn, the Netherlands), 
and ferritin, vitamin B9, B12, 25-OHD and PTH (Modular E170, Roche Diagnostics, 
Basel, Switzerland), and albumin, calcium (Modular P800, Roche Diagnostics, Basel, 
Switzerland). Zinc was analysed by inductively coupled plasma mass spectrometry 
(Shimadzu Corp., Kyoto, Japan), vitamin B1 and vitamin B6 analysed on a HPLC with 
fluorescence detector (Shimadzu Corp., Kyoto, Japan), and retinol was analysed on a 
HPLC with UV-vis detector (Shimadzu Corp., Kyoto, Japan). 
Statistical analysis
Data were analysed using IBM® SPSS® (version 21.0 for Windows). Results are 
presented as mean values with standard error of the mean (SE) unless specified otherwise. 
Differences between groups were analysed by Mann–Whitney U-test for continuous 
variables and Fisher’s exact test for categorical data. All tests were two-tailed, and the 
results with p < 0.05 were considered statistically significant.
RESULTS
Patient selection and characteristics
Thirty-four patients were included; 15 had undergone BPD and 19 had a BPD/DS. No 
patients were lost to follow-up. Surgery had been performed 44 months (range 12 – 90) 
before referral to the department of internal medicine (T0). Baseline characteristics at T0 
are described in table 2. No significant differences regarding sex, age and weight were 
observed between BPD and BPD-DS patients. Sixteen women were premenopausal.
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Table 2. Baseline patient characteristics at the time of referral to the department of 
internal medicine (T0)
Total BPD BPD/DS
Number of patients 34 15 19
Female (N, %) 23 (67) 11 (73) 12 (63)
Age (years) 45 ± 2 48 ± 2 42 ± 2 
Weight (kg) 109 ± 5 112 ± 6 108 ± 7
BMI (kg/m2) 37 ± 2 37 ± 3 37 ± 2
Follow-up after surgery (months) 44 ± 3 42 ± 4 47 ± 5
There were no differences between patients with BPD or BPD/DS. BMI = body mass index, BPD = 
biliopancreatic diversion, BPD/DS = biliopancreatic diversion with duodenal switch.
Body Weight
At the time of referral (T0) the mean percentage EWL was 62 ± 5%, i.e. 53 ± 5% for 
BPD and 68 ± 7% for BPD/DS respectively (p = 0.09). This corresponded with an 
overall mean percentage TWL of 33 ± 3%, i.e. 29 ± 16% for BPD and 37 ± 15% for 
BPD/DS, respectively (p = 0.17). During the 1-year observation period after referral 
mean body weight remained stable (109 ± 5 kg at T0 and 110 ± 5 kg at T12,  p = 0.47).
Nutritional status
Table 3 summarizes the mean serum levels for all minerals and vitamins that were 
monitored during the one-year observation period. An overview of the percentage of 
patients with deficiencies at various time points during the study period and the daily 
supplementation doses during the period are shown in table 4. At baseline (T0) 94% 
of the patients were using a MVS and 38% used calcium and vitamin D as prescribed 
according to protocol (calcium 1500 mg/day, cholecalciferol 2400 IU/day). Many 
patients had already been started on additional supplements: 13 patients used oral iron, 
4 used folic acid, 15 used vitamin B12 (12 by injections, 3 on oral supplements), 15 used 
cholecalciferol, 5 used zinc, and 2 used vitamin A supplements. The mean daily doses 
of these supplements are described in table 4. At T12 all patients (100%) were using a 
MVS, and 32 (94%) were using the recommended oMVS. In addition, 82% was using 
calcium and vitamin D as prescribed. 
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Table 3. Mean blood levels monitored throughout the study
Normal 
Range
Baseline 6 months 12 months ∆0-12
Haemoglobin (mmol/L) 7.4 & 8.4# 7.9 ± 0.2 8.0 ± 0.1 8.2 ± 0.2 0.3 ± 0.1
Albumin (g/L) 35 - 50 37 ± 1 37 ± 1 37 ± 1 0
Ferritin (μg/L) 20 - 300 93 ± 16 104 ± 17 141 ± 25 48 ± 17
Folate (nmol/L) 9.0 – 28.0 21.0 ± 1.5 26.1 ± 1.87 25.2 ± 1.8 4.2 ± 1.7
Vitamin B12 (pmol/L) 200 - 640 569 ± 53 600 ± 65 565 ± 59 -2 ± 59
Calcium$ (mmol/L) 2.20 -260 2.28 ± 0.02 2.27 ± 0.02 2.28 ± 0.02 0 ± 0.01
Vitamin D (nmol/L) 50 – 150 51 ± 6 46 ± 5 47 ± 4 -4 ± 5
PTH (pmol/L) 1.3 - 6.8 6.9 ± 0.6 8.1 ± 0.6 7.9 ± 0.6 1.0 ± 0.5
U-Calcium (mmol/24h) 4.0 – 10 - - 1.6 ± 0.4 -
Zinc (μmol/L) 9.2 – 18.4 10.3 ± 0.4 10.5 ± 0.4 10.5 ± 0.4 0.2 ± 0.5
Vitamin A (μmol/L) 1.05 – 2.80 1.54 ± 0.12 1.42 ± 0.15 1.33 ± 0.10 -0.21 ± 0.11
Vitamin B1 (nmol/L) 95 – 175 169 ± 7 175 ± 7 163 ± 6 -6 ± 5
Vitamin B6 (nmol/L) 25 - 100 110 ± 8 95 ± 6 86 ± 5 -24 ± 9
The mean changes after 12 months (∆0-12) are shown on the right. PTH, parathyroid hormone; 
#,lower normal 
limit for females 7.4 mmol/L, for males 8.4 mmol/L; $,calcium corrected;
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Table 4. Percentages of patients with vitamin or mineral deficiencies, and concomitant oral 









Hb < 7.4 or 8.4# 38% 32% 35%
Albumin < 30 g/L 3% 0 3%
Ferritin < 20 ug/L 24% 12% 3%
Oral Iron (mg/d) 66 ± 14 103 ± 11 116 ± 14 1.8x
Vitamin B1 < 95 nmol/L 0% 0% 0%
Vitamin B1 (mg/d) 0.65 ± 1.18 2.67 ± 0.48 2.61 ± 0.67 4.0x 
Vitamin B6 < 25 nmol/L 0% 0% 0%
Vitamin B6 > 100 nmol/L 53% 23% 35%
Vitamin B6 (mcg/d) 231 ± 422 963 ± 188 959 ± 271 4.2x
Vitamin B9 < 9.0 nmol/L 0% 0% 0%
Oral Folate (µg/d) 712 ± 276 1036 ± 256 1153 ± 284 1.6x
Vitamin B12 < 200 pmol/L 3% 3% 0%
Vitamin B12 (µg/d) (total) 92 ± 26 357 ± 13 382 ± 34 4.1x
Vitamin B12 (µg/d) (inj) 9.8 ± 2.2 9.2 ± 2.3 9.9 ± 2.3 1.0x
Calcium* < 2.20 mmol/L 3% 0% 6%
PTH > 6.8 pmol/L 35% 51% 51%
Oral Calcium (mg/d) 1301 ± 206 1680 ± 233 1786  ± 222 1.4x
Vitamin D < 50 nmol/L 56% 71% 56%
Vitamin D (IU/d) 7160 ± 1840 11120 ± 1880 16640 ± 2240 2.3x
Vitamin A < 1.05 μmol/L 24% 29% 27%
Oral Vitamin A (IU/d) 1417 ± 693  4590 ± 1090 8000 ± 1743 5.6x
Zinc <  9.2 μmol/L 32% 21% 29%
Zinc (mg/d) 24 ± 11 78 ± 19 103 ± 20 4.3x
Hb, haemoglobin; *, calcium corrected for albumin;
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At T0 no significant differences in serum levels were found between BPD and BPD/DS 
patients. Therefore all analyses were performed on the total cohort of patients. Although 
26 (76%) patients had already started treatment for deficiencies diagnosed before 
referral, a new or a recurrent deficiency at referral was diagnosed in as much as 25 
(74%) patients. The most common deficiencies at T0 were vitamin D (56%), zinc (32%), 
iron (24%), and vitamin A (24%) deficiency (table 4). During the one-year observation 
period as much as 29 (85%) patients developed a new deficiency or had a recurrent 
deficiency despite prescription of specific supplements. 
Correction of deficiencies
Iron deficiency (ID): At T0, 13 patients were already on oral iron supplementation at a 
mean daily dose of 137 ± 74 mg (provided as 200 mg ferrofumarate tablets containing 
65 mg Fe), and an additional 5 were diagnosed with de novo ID. During the one-year 
follow up another two patients raised the total number of patients with ID to 20 (59%). 
ID was diagnosed in 13 (65%) women and in 7 (35 %) men. It led to anaemia in 4 patients 
(Haemoglobin 6.0 – 7.3 mmol/L). Patients responding to oral iron supplementation (N 
= 12) needed 119 ± 17 mg/day orally to maintain ferritin levels above 20 ug/L. Eight 
patients (6 females, 2 males) had ID resistant to oral supplementation, defined as lack of 
improvement on a daily iron dose of 195 mg. They were treated with a single intravenous 
infusion of ferric carboxymaltose containing 1000 mg iron (Ferinject®, Vifor Pharma, 
Glattbrugg, Switzerland). This raised serum ferritin to a level > 20 ug/L for a period of 
at least one year in 7 out of 8 patients.  
In summary: The incidence of ID after BPD or BPD/DS is at least 60%. An oral dose of 
100 mg/day started immediately after surgery appears to be the minimal requirement to 
prevent the development of ID in men and postmenopausal women. For postmenopausal 
women we suggest a daily starting dose of 200 mg iron. Finally, Ferinject® 1000 mg IV, 
once a year, appears to be sufficient in the majority of patients with ID resistant to oral 
iron supplementation.
Vitamin B12 deficiency: at T0 15 patients (44%) were already using hydroxycobalamin 
1000 µg by intramuscular injection, with intervals varying from every 4 weeks to every 3 
months (mean 1.7 months). In the 4 patients on vitamin B12 1000 µg every three months 
the mean serum level at T0 was 677 ± 275 pmol/L. The 11 patients with a higher injection 
frequency had a mean vitamin B12 level of 750 ± 102 pmol/L (range 250 – 1307).  One 
patient was diagnosed with vitamin B12 deficiency de novo at T0. The introduction of the 
oMVS at T0, a multivitamin containing 350µg vitamin B12, increased the group’s mean 
oral daily dose from 82 ± 26 µg at T0 to 382 ± 34 µg at T12 (p < 0.001), and this stabilized 
their mean serum vitamin B12 around 550 pmol/L. None of the 18 patients on oMVS 
developed a de novo vitamin B12 deficiency during the one year observation period, and 
only three patients exceeded the UNL (highest vitamin B12 level: 769 µg/L). 
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In summary: oral vitamin B12 in a daily dose of 350 µg appears to be sufficient to prevent 
the development of vitamin B12 deficiency after BPD or BPD/DS. As an alternative 
intramuscular injections of 1000 µg every three months may suffice. 
Vitamin A deficiency: at T0 2 patients had a prior diagnosis of vitamin A deficiency, 6 
patients were diagnosed with de novo vitamin A deficiency at T0, and an additional 6 
patients developed a de novo vitamin A deficiency during the one year study period. 
This raised the total number of patients with vitamin A deficiency to 14 (41%). One 
patient achieved normal levels without supplementation of Vitamin A. The remaining 
13 patients started vitamin A supplementation with an oral solution of 50,000 IU/ml, at a 
starting dose of 50,000 IU/week. This proved to be insufficient in all but one patient, and 
thus the maintenance dose was increased to 100,000 IU/week. Two patients needed an 
even higher dose: one needed 150,000 IU/week and one needed 200,000 IU/week. Poor 
long-term compliance was a major issue. Most patients explained that they believed 
that supplementation was needed only temporarily and discontinued supplementation 
before the next follow-up. This may explain why 9 (27%) patients still had vitamin A 
deficiency at T12. 
In summary: vitamin A deficiency occurred in at least 40% of patients. A weekly dose 
of 50,000 IU/week appears to be insufficient in most patients to achieve normal serum 
levels. Most patients needed 100,000 IU/week and some even required a higher dose. 
Limited compliance was a major issue and this may have affected the accuracy of 
our findings. To avoid over-supplementation we therefore recommend to start with a 
dose of 50.000 IU solubilised vitamin A, with subsequent dose adjustments based on 
measurement of serum levels at 3-month intervals during the first year after surgery.   
Vitamin D deficiency: 19 Patients were diagnosed with vitamin D deficiency at T0, 
despite a mean daily dose of 7,168 ± 1,836 IU/day. Seven of these patients only used 
the recommended standard dose of 2,400 IU/day, and six had already started additional 
supplementation with oral Cholecalciferol. Vitamin D deficiency was treated by adding 
solubilised oral Cholecalciferol 50,000 IU/ml once weekly, on top of the standard 
advice of 2,400 IU/day. Sixteen patients required higher supplementation doses. At T12 
one patient used 75,000 IU once a week, three 50,000 IU twice a week, six 50,000 IU 
trice a week, one 50,000 IU four times a week, three 50,000 IU five times a week, one 
50,000 IU six times a week, and one 50,000 IU seven times a week. Figure 1 gives an 
overview of the vitamin D serum concentrations plotted against the supplementation 
dose. Despite progressive increases in oral Cholecalciferol supplementation, 19 patients 
still had 25-OHD levels < 50 nmol/L at T12 despite a mean daily dosage of 16,654 ± 2,244 
IU (range 2200 – 51,000 IU/day). This suggests that intestinal uptake of Cholecalciferol 
is frequently insufficient or that compliance towards oral Cholecalciferol intake is very 
poor. 
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In summary: vitamin D deficiency is a major issue after BPD or BPD/DS, and rather 
difficult to treat with oral supplementation. It appears that 50,000 IU/week is the 
minimal requirement to achieve at least some improvement. It may be better to switch 
to the parenteral route in patients who remain vitamin D deficient despite high oral 
supplementation.
Figure 1. Serum vitamin D concentrations plotted against the oral Cholecalciferol dose , shown as IU/
week
The bars represent the mean and 95% confidence interval, and interrupted lines represent the upper and lower 
normal limits.
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Hypocalcaemia, secondary hyperparathyroidism and hypocalcuria: Hypocalcaemia, 
defined as an albumin corrected serum calcium level < 2.20 mmol/L was rare, whereas 
secondary hyperparathyroidism (SHPT) was very common. Despite a mean daily 
calcium supplementation of 1300 mg (range 0 – 5000 mg/day), 14 (41%) patients were 
diagnosed with SHPT at T0, whereas only one patient (3%) had concomitant 
hypocalcaemia. The mean serum calcium concentrations remained stable throughout 
the study period (table 3). However, the number of patients developing SHPT rose from 
14 (41%) at T0 to 20 (59%) at T12, despite an increase in mean calcium dose up to 1800 
mg/day. Persistence of the negative calcium balance is also apparent as judged by the 
24-hour urinary calcium excretion that was assessed in nine (26%) patients. They all 
had a urinary calcium excretion < 4.0 mmol/24 hours despite a mean daily calcium 
intake of 2444 mg. 
In summary: SHPT is a frequent finding after BPD or BPD/DS, despite a mean calcium 
supplementation dose of 1800 mg/day. This suggests that the postoperative standard 
supplementation dose should be at least 2000 mg/day, and that correction of vitamin D 
deficiency is of utmost importance.
Zinc deficiency: At T0 four (12%) patients had already started oral zinc supplementation 
in a daily dose of 435 ± 135 mg zinc sulfate. An additional 11 (32%) patients were newly 
diagnosed with zinc deficiency at T0, and during the study period the total number of 
patients with Zinc deficiency increased to 21 (62%). Zinc deficiency was treated by an 
oral zinc sulphate solution (10 mg/ml containing 2.27 mg per ml), with a starting dose 
varying between 440 – 660 mg/day divided in two to three doses. Most patients with 
a daily dose of 440 mg or 660 mg achieved normal zinc levels. This raised the group’s 
mean daily dose from 14 ± 6 mg to 44 ± 11 mg (p < 0.010), and decreased the number 
of patients with zinc deficiency to 7 (21%) at T6. Additional patients starting zinc 
supplementation increased the daily dose to 58 ± 11 mg at T12 (p < 0.001). Nevertheless, 
the number of patients with a serum zinc < 9.2 µmol/L rose to 10 (29%) at T12. 
Vitamin B6: during the study period no vitamin B6 deficiencies occurred. However, 18 
(53%) out of 34 patients had developed hypervitaminosis B6 at T0. Most of these patients 
(67%) had been using a non-standardized MVS that commonly contained at least 100% 
RDA of vitamin B6. After introduction of the oMVS the number of patients with a 
hypervitaminosis decreased to 12 (35%) at T12. Also the overall serum levels for vitamin 




The present study should be regarded as a summary of the learning curve we went 
through in the treatment of vitamin and mineral deficiencies in patients after BPD and 
BPD/DS. It is important to note that many deficiencies occurred despite the prescription 
of basic multivitamins and calcium and vitamin D supplements as recommended by 
the ASMBS2. Even after the switch to a single, standardized oMVS at T0, de novo 
deficiencies still developed over the subsequent 12 months. This supplement has been 
specifically developed for patients after Roux-en-Y gastric bypass (RYGB) and contains 
a large number of vitamins in doses exceeding normal daily requirements by a factor 
0.7 for vitamin B6 to 14 for vitamin B12 (table 1). Its efficacy has been evaluated in 
patients after RYGB, but not yet in patients after BPD or BPD/DS7. In the present study 
we observed that patients on this specific oMVS did not develop vitamin B1, B6, B9 or 
B12 deficiencies. Apparently, the mean daily doses of 2.75 mg, 980 µg, 600 µg, and 
350 µg, respectively, are sufficient for patients after BPD or BPD/DS (table 1 and 4). 
However, patients continued to develop deficiencies of vitamin A, D, Calcium and Zinc. 
Therefore, adjustment of the oMVS with higher basic doses for these compounds will 
be needed for this specific patient population. 
At the time we started structured monitoring of patients after BPD or BPD/DS evidence-
based recommendations for the treatment of specific deficiencies in these patients were 
not available. To prevent over-supplementation we started with schedules comparable 
to those employed in patients after gastric bypass. Gradually we learned that most of 
these doses were far too low and that substantial increments were needed to reach target 
levels. Based on these experiences we now have some background data to formulate 
regimens that may result in better and more rapid corrections of deficiencies. It is well 
recognized that many of these regimens will need further refinement and confirmation 
by prospective validation.
Vitamin A deficiency was initially treated by oral administration of vitamin A in a dose of 
50,000 IU/week. This proved to be insufficient in all but one patient. A dose of 100,000 
IU/week was sufficient to raise and maintain vitamin A levels into the normal range in 
80% of the patients with a documented vitamin A deficiency. None of these patients 
developed vitamin A levels exceeding the upper limit of normal. Twenty percent of 
patients needed a dose higher than 100,000 IU/week. As long-term compliance was 
poor this may have caused an overestimation of the required supplementation dose. We 
therefore recommend starting supplementation with 50,000 IU/week, with blood level 
checks after three months to perform dose adjustment if necessary. Our estimate is that 
prevention of vitamin A deficiency after BPD or BPD/DS is likely to require an oral 
dose of at least 7500 – 15,000 U/day. Although this is 875 to 1250 % higher than the 
normal RDA it is much lower than the daily dose of 50,000 IU recommended by Topart 
et al5. The discrepancy may be explained by the formulation, Topart et al used tablets 
whereas we prescribed solubilised vitamin A. In our experience solubilised medication 
is better absorbed than tablets in these patients (data not shown).  
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Vitamin B12 deficiency was relatively easy to treat. Treatment with a loading dose of 
1000 µg weekly for three weeks followed by a maintenance dose of 1000 µg every three 
months led to normal serum levels. This schedule is commonly used in patients without 
bariatric surgery and as expected it also appears to be an effective regimen after BPD 
or BPD/DS. In patients using vitamin B12 injections more frequently serum vitamin B12 
levels were unnecessarily high, with levels often exceeding the ULN of 1500 pmol/L. 
Our data also indicate that vitamin B12 deficiency can be prevented by oral dose of 350 
µg per day.
Treatment of vitamin D deficiency proved to be a major challenge. Initially, vitamin D 
deficiency was treated with an additional 50,000 IU solubilised cholecalciferol once 
a week, on top of the basic supplementation of 2400 IU/day. This regimen was not 
sufficient to raise vitamin D levels above 50 nmol/L in the majority of patients, and 
despite major additional dose increments the prevalence of vitamin D deficiency did 
not decrease at 12 months. Poor compliance may be part of the explanation. In view 
of the limited efficacy of these high oral doses we have now begun to replace oral 
supplementation by intramuscular cholecalciferol in doses of 300.000 IU per injection. 
Preliminary data suggest that the injection interval to maintain vitamin D levels within 
the normal range varies between three to six months among subjects (data not shown).
Zinc deficiency is associated with alterations in immune function, cognitive function, 
hair loss, and dermic lesions8-11. It was observed in 62% of the patients, and an even 
higher rate can be expected after a longer post-operative follow-up. Our data suggest 
that zinc sulfate in a dose of approximately 440 mg/day (equivalent to 100 mg zinc) will 
be required to prevent zinc deficiency. 
Hypocalcaemia was rare in our series, despite the high rate of severe vitamin D 
deficiency. Apparently, most patients are capable of maintaining calcium levels in 
the low normal range by PTH-mediated calcium mobilization from bone. Secondary 
hyperparathyroidism was present in 59% of our patients at T12, despite a mean calcium 
supplementation dose of 1800 mg/day. As intestinal calcium absorption is highly 
dependent on vitamin D, deficiencies in vitamin D should be treated first before raising 
oral calcium doses.
At baseline, 62% of the patients were diagnosed with a Vitamin K1 deficiency. As 
reported recently this is usually not accompanied by major deficiencies of vitamin K 
dependent coagulation factors, probably because vitamin K stores can be maintained 
by vitamin K2 produced in the colon
12. Routine oral vitamin K supplementation does 
not appear to be necessary. However, in case of bleeding or lengthening of vitamin K 
dependent clotting times vitamin K supplementation should be started. 
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Limitations
The current study was performed in a small group of patients with heterogeneous 
nutritional characteristics at baseline. The interval between surgery and the start of 
structured monitoring varied widely and more than 90% of patients had been using non-
standardized multivitamins before entering the study. This will have affected the timing 
of onset of deficiencies, their degree of severity, and the magnitude of the doses needed 
for treatment. The limited and variable compliance will also have increased the variability 
of our observations. Therefore, any recommendation of supplementations based on the 
results of this study should be regarded as preliminary and in need of validation in a 
prospective study. With these limitations in mind, we nevertheless would recommend 
to consider adjustment of supplementation regimens, and to start immediately after 
BPD or BPD/DS surgery without waiting for deficiencies to develop. If we combine 
our observations with those of Topart et al.5 this should include a basic multivitamin 
with a composition comparable to the oMVS used in the current study (table 1), with 
additional supplementation to achieve total daily doses of 200 mg Fe in premenopausal 
women and 100 mg in postmenopausal women and in men, 100 mg of zinc, 3000 mg 
of calcium in three divided doses at mealtime, and 50,000 IU of solubilized vitamin A 
and vitamin D per week. In addition we would recommend a vitamin and mineral check 
every 3 months during the first year, and every 6 months during the second year to 
enable timely adjustment of supplementation. With accumulating experience over time 
these laboratory check-ups may be simplified. The proposed regimen will not prevent 
all deficiencies, need of higher doses are to be expected, in particular for correction of 
vitamin A and D deficiencies. We did not address deficiencies of magnesium, selenium, 
copper, and vitamin E because of limited data that were available in the present study, 
however, there is sufficient evidence in the literature to propose measurement of these 
compounds once a year6, 13, 14. Magnesium should be measured more frequently in 
patients on proton pump inhibitors as these compounds may inhibit intestinal magnesium 
absorption15. Finally, careful patient instruction with repeated emphasis on the need of 
high compliance will be extremely important to reduce the prevalence of micronutrient 
deficiencies. 
CONCLUSION
Vitamin and mineral deficiencies are major adverse effects of BPD and BPD/DS. To 
achieve and maintain normal mineral and vitamin levels high supplementation doses 
will be needed, combined with a high degree of patient compliance. This study provides 
the basic information to develop and test an optimized multivitamin supplement for 
patients after BPD or BPD/DS.
Treatment of vitamin and mineral deficienciesmafter biliopancreatic diversion with or without duodenal 
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ABSTRACT
Background: Iron deficiency (ID) is one of the most common postoperative deficiencies 
that may develop after Roux-en-Y gastric bypass (RYGB). The optimal mode of 
treatment is uncertain.
Aim: To compare the efficacy of oral ferrous fumarate (FF), oral ferrous gluconate (FG), 
and a single intravenous infusion of ferric carboxymaltose (FCM) in women with ID 
after RYGB. 
 
Methods: multicenter randomized controlled trial including 120 women with a serum 
ferritin < 20µg/l during follow-up after RYGB. They were randomized into three groups: 
41 patients were treated with FF 200mg three times a day (total daily dose: 195mg 
elemental iron), 39 received FG 695mg twice a day (total daily dose: 160mg elemental 
iron) for three months, and 39 patients were treated with a single intravenous dose of 
FCM (1000mg elemental iron). Serum ferritin levels were measured at six weeks, and 
three, six and twelve months after the start of supplementation. 
 
Results: At three months, persistence of ID was observed in 29.4% and 42.4% of the 
patients treated with FF and FG, respectively, but in none of those treated with FCM (p 
< 0.001). Over the next nine months, recurrence of ID was observed in 56.5% of patients 
treated with FF, in 52.9% treated with FG, and in 27.8% of those treated with FCM. 
Adverse effects were most common during oral treatment.
Conclusion: In women developing ID after RYGB, a single dose of intravenous FCM 
is more effective and better tolerated than the standard treatment with either FF or FG. 






Metabolic surgery for morbid obesity has many beneficial effects, but is also associated 
with various adverse effects such as a high rate of micronutrient deficiencies. Calcium, 
vitamin B12, vitamin D, and iron deficiencies (ID) are the most common1. Postoperative 
ID has been reported in up to 66% of patients after Roux-en-Y Gastric Bypass (RYGB)2. 
Its prevalence depends on definition, the type of multivitamins used, menstrual status, 
and the duration of follow up. Even preoperatively, obese patients are already at an 
increased risk of developing iron deficiency, mainly because of their use of high calorie 
food with low iron content2. Postoperatively, the incidence of ID may increase further 
due to a reduction in oral intake, and a decrease in iron absorption due to the decline in 
gastric acid production and the bypass of the proximal small intestine3, 4. Premenopausal 
women are at the highest risk because of their menstrual blood loss. 
Current knowledge about the optimal dose and route of iron supplementation for the 
prevention and treatment of ID after metabolic surgery is still limited. The American 
Society for Metabolic and Bariatric Surgery (ASMBS) recommends to treat post-bariatric 
ID with 150-200 mg elemental iron daily, up to 300 mg maximum5. No distinction is 
made between RYGB and other bariatric procedures, and no advice is given how to 
adjust the iron maintenance dose, once they have finished their superimposed course of 
iron supplementation for the treatment of ID.
Treatment of ID can be performed orally or intravenously (IV). The intramuscular route 
is usually avoided because of skin discoloration due to local iron accumulation6. In 
the Netherlands, the most commonly used oral supplementations are ferrous fumarate 
(FF) and ferrous gluconate (FG). Ferric carboxymaltose (FCM), iron sucrose, iron (III) 
isomaltoside and iron dextran are available for IV treatment. Oral iron supplementation 
is currently the preferred choice of treatment in most countries, despite frequent gastro-
intestinal side-effects5, 7, limited compliance, and possible interference with other 
medication. IV treatment is usually considered as a second step, after failure of oral 
treatment. However, the situation is changing and intravenous iron repletion is rapidly 
gaining in popularity, in non-bariatric as well as in bariatric patients8, 9. Onken et al 
demonstrated the safety and efficacy of FCM as treatment for ID in 1011 non-bariatric 
patients during a follow-up of 35 days8. Malone et al performed a retrospective review 
analysis of five phase three studies using FCM supplementation in 281 bariatric patients 
with a 6-week follow-up after FCM infusion and showed that FCM is effective in raising 
hemoglobin and ferritin levels in this particular group of subjects. Adverse effects were 
similar to other IV iron products9.
The aim of the current study is to compare the long-term efficacy of oral and intravenous 





Trial design and participants
This is an open multicenter, randomized, intervention trial to compare the effects of 
oral and intravenous iron supplementation in 120 women who had undergone RYGB 
surgery and developed ID postoperatively. ID was defined as a postoperative serum 
ferritin level < 20 µg/l, as described in the ASMBS international guideline5 (see table 
1 for normal ranges). The primary endpoint of the study was defined as the percentage 
of patients with a ferritin level ≥ 20 µg/l at 3 and 12 months after the start of treatment. 
The study was performed in three, large volume, bariatric centers in the Netherlands 
(Rijnstate Arnhem, Rode Kruis Ziekenhuis Beverwijk, and OLVG Amsterdam). These 
centers were chosen because they had an identical protocol for gastric bypass surgery 
and follow up. All patients received a biliopancreatic limb of 150 and an alimentary limb 
100 centimeters, as previously described10. To ensure study population homogeneity, 
only women were included. 
Inclusion criteria
Women, aged 18 - 65 years, with preoperative ferritin levels > 20 µg/l, who had 
undergone a standardized RYGB (150 cm biliary limb and a 100 cm alimentary limb), 
and then developed ID postoperatively during follow-up were eligible for inclusion in 
the study. The presence of anemia was not a requirement for inclusion.
 
Exclusion criteria
Exclusion criteria were: Blood transfusion during the study period, use of iron 
containing supplements in addition to the standardized multivitamin supplement 
(FitForMe Forte®, Rotterdam the Netherlands, containing 70mg of elemental iron a 
day11-13), metrorrhagia, anemia due to other factors than a ID (e.g. macrocytic anemia), 
hypersensitivity to substances in the iron supplements, glomerular filtration rate below 
30 ml/min, psychiatric illness, pregnancy, acute or chronic infection, liver dysfunction, 
and immune- or inflammatory diseases.
 
Intervention and measurements
Patients who were included were randomized in one of the three treatment groups: 
1. FF-group: ID was treated with oral tablets containing ferrous fumarate 
(Ferrofumaraat®,Pharmachemie BV, the Netherlands), 200 mg three times a 
day. This is equivalent to a total daily dose of 195 mg of elemental iron.
2. FG-group:  ID was treated with oral effervescent tablets of ferrous gluconate 
(Losferron®,Will-Pharma BV, the Netherlands), 695 mg two times a day, 
equivalent to a total daily dose of 160 mg of elemental iron.




3. FCM-group: ID was treated with a single dose of 1000 mg of intravenous 
iron(III) carboxymaltose (Ferinject®,Vifor, the Netherlands), containing 1000 
mg of elemental iron, which is common practice in the Netherlands. 
Randomization was performed by the trial pharmacy, using block randomization 
stratified by center (Research Manager version 5.12.1.0 for Windows). Daily oral 
treatment by FF and FG was continued for 90 consecutive days. Tablets were taken at 
home, unsupervised. All patients on iron tablets were instructed to take their tablets as 
recommended, to report any adverse effects at the follow-up appointments, and to return 
their empty blisters at each visit. FCM infusion occurred in a day care ward, where 
patients were monitored for three hours. Treatment efficacy was evaluated by blood 
samples drawn at 6, 12, 26 and 52 weeks after the start of treatment for the measurement 
of blood hemoglobin (Hb), serum iron, ferritin, total iron binding capacity (TIBC), 
transferrin levels, transferrin saturation, and C-reactive protein (CRP). The latter was 
measured to detect inflammation-induced pseudo-normalization of ferritin levels.




Ferritin was measured by electrochemiluminescence immunoassay (Roche Modular 
E170) and CRP was measured by immunoturbidimetric assay (Roche Modular P800). 
Serum iron (µmol/l) was determined by colorimetric measurements (Roche Modular 
P800). Transferin and TIBC were measured with the immunometric method (Roche 
Modular P800). 
Multivitamin background
To prevent bias caused by variation in multivitamin supplements, all participating 
women were instructed to use the RYGB-optimized multivitamin FFM (FitForMe 
WLS Forte®, Rotterdam, the Netherlands) that was provided free of charge during the 
study period. It contains ferrous fumarate, equivalent to 70mg of elemental iron a day. 
Ethics
This study was approved by the Medical ethics committee of Arnhem-Nijmegen and 
the local ethics committee of the Rijnstate Hospital, the Netherlands, and registered 




For sample size calculation, we assumed a 100% normalization of serum ferritin at 3 
months in the FCM-group, and an 80% normalization for the FF- and FG-groups. At a 
confidence interval of 95% and a power of 80%, this would require a sample size of 36 
patients per group. Considering a 10% dropout rate, each subgroup would require 40 
patients, and thus a total of 120 patients would be needed to perform this trial.
Data collection and Statistical analysis
Data were collected in Research Manager for all centers (Research Manager version 
5.12.1.0) and were analyzed using IBM® SPSS® (Version 21.0 for Windows). Results 
for numerical data were presented as mean values and standard deviation (SD) for normal 
distribution and as median and range for data not normally distributed. Categorical data 
were analyzed by chi-square test or Fisher’s Exact test. Continuous data were analyzed 
by ANOVA or the Kruskal Wallis test. Post-hoc analysis with Bonferroni adjustment was 
used for pairwise comparison. A p-value < 0.05 was considered statistically significant. 
Responses were analyzed by intention to treat. 
RESULTS
 
The study took place between December 2014 and June 2017. Forty-one (34.5%) 
patients were included in the FF-group, 39 (32.8%) in the FG-group and 39 (32.8%) 
in the FCM-group. One patient was excluded after randomization, because she had 
received the wrong iron supplement. Characteristics per treatment group at the time at 
which iron supplementation commenced are shown in table 1. Mean age was 40.8 ± 
7.9 years, weight was 87.1 ± 16.5 kg, corresponding with a BMI of 30.7 ± 5.5 kg/m2. 
Twenty-two patients had ID anemia (18.3%). Mean hemoglobin was 7.9 ± 0.6 mmol/l 
and median baseline ferritin was 13.0 (range 4-19) microgram/L. Patients were studied 
a median of 24.9 (range 1.8-57.1) months after RYGB surgery. At time of inclusion, one 
out of 111 patients had concomitant folic acid (0.8%) and 25 of 111 patients a vitamin 
B12 deficiency (20.3%) for which they received additional treatment. 
In the first three months, nine patients (7.6%) had a switch of oral iron supplement. 
Six because of intolerance for FG (nausea and taste disturbances), and three 
because of severe obstipation related to the use of FF. Five of these nine patients 
who had switched oral treatment were considered lost to follow-up, because they 
neither showed-up at control visits, nor answered to letters and telephone calls. 
Another seven patients were lost to follow-up for other reasons (5.9%), and three 
others were excluded because of pregnancy during the first three months of the 
study (figure 1). The overall lost to follow-up rate/exclusion was fifteen patients at 
three months, increased to eighteen at six months and twenty at twelve months. 




Figure 1. Number of patients at each time point
N, number; FF-group, patients treated with ferrous fumarate; FG-group, patients treated with ferrous gluconate; 


































































3 months 6 months 12 months 
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Age (years) 40.5 ± 8.9 40.1 ± 7.6 41.8 ± 7.0 -
Weight (kg) 90.5 ± 17.0 87.0 ± 17.1 83.9 ± 15.2 -
Time after RYGB (months) 25 (6-57) 24 (2-51) 31 (6-54) -
BMI (kg/m2) 31.6 ± 5.1 31.0 ± 6.0 29.6 ± 5.2 -
Anemia 9 (22%) 4 (10.3%) 9 (23.1%) -
Hemoglobin (mmol/l)* 7.9 ± 0.7 8.1 ± 0.5 7.8 ± 0.6 7.4 – 9.9
MCV (fl) 89 (72-97) 91 (80-101) 92 (72-101) 80 - 100
Ferritin (µg/l) 13 (4-19) 13 (6-19) 11 (6-18) 20 - 291
Iron (µmol/l) 12 (3-41) 16 (5-66) 12 (2-26) 10 - 30
Transferrin (g/l) 3.4 ± 0.5 3.3 ± 0.5 3.4 ± 0.4 2.0 – 3.6
TIBC (µmol/l) 76 ± 10 75 ± 12 76 ± 9 45.0 – 80.0
Transferrin saturation (%) 18 (4-54) 21 ± 8 16 ± 7 15 – 45%
CRP (mg/l) 1 (1-19) 1 (1-14) 1 (1-6) < 10
Premenopausal (N) 28 23 27 -
Patients’ characteristics at the time iron supplementation commenced. Data expressed in mean standard 
deviation for normal distributed data and in median with range for not normal distributed data. BMI, body 
mass index; CRP, C-reactive protein; FCM, ferric carboxymaltose group; Fumarate, ferrous fumarate group; 
Gluconate, ferrous gluconate group; l, liter; N, number; TYBC, total iron binding capacity; *, conversionfactor 
from mmol/l to g/dl multiply with 1.61. 
Treatment of persistent ID
Patients who were still deficient after three months of oral treatment were switched 
according to protocol from FF to FG or vice versa (N=5). Patients reporting intolerability 
to oral iron, or demonstrating no improvement in ferritin level were switched to IV 
treatment with FCM (N=2). The responses of these patients were not included in the 
follow-up report after three months. Only patients with normalization of ferritin levels 
at three months were included in the follow-up beyond three months.
Intention to treat analysis at three months
After three months of treatment, median ferritin levels had increased from 13 (4-19) 
to 26 (7-78) µg/l in the FF-group, from 13 (6-19) to 24 (6-80) µg/l in the FG-group 
and from 11 (6-18) to 115 (33-276) µg/l in the FCM-group (p < 0.001 for all three 
groups, figure 2). Ferritin levels measured at three months were still < 20 µg/l. In 
ten patients in the FF-group and in fourteen in the FG-group (29.4 % versus 42.4%, 




p=0.27), while all 37 patients in the FCM-group had a normalization of ferritin 
levels (p < 0.001). Pairwise comparisons showed that the normalization of ferritin 
levels in the PCM group was significantly different compared to both the FF and 
FG group. The normalization in the FF and FG group was not significantly different. 
Hb levels normalized in all patients who had developed ID anemia (N=5 in FF-group, 
N=2 in the FG-group and N=8 in the FCM-group). One patient in the FG-group 
developed a new anemia at 3 months.
Figure 2. Ferritin first three months




Long-term follow-up of patients with normalized ferritin levels
Out of the 80 patients who had a normalization of ferritin levels at three months, three 
were lost to follow-up (figure 1). Sixteen (20.8%) developed a recurrence of ID at six 
months: seven (29.2%) in the FF-group, six (31.6%) in the FG-group and three (8.1%) 
patients in the FCM-group. The number of patients developing ID in the FCM group 
was significantly lower than those in the oral iron groups (p=0.037). One patient in the 
FF-group developed ID anemia. As shown in figure 3, median ferritin at six months in 
the FF-group was 29 (9-123), in the FG-group 28 (9-82) and in the FCM group 88 (11-
205) µg/l, p < 0.001).
Figure 3. Mean ferritin levels
Median ferritin levels after initiating treatment with ferrous fumarate (grey dots), ferrous gluconate (black 
dots) and ferric carboxymaltose (white dots). At 6 months patients are shown who had sufficient ferritin levels 
at 3 monts. At 12 months patients ars shown who had sufficient ferritin levels at 6 monts (see text).




At twelve months, median ferritin in the FF-group was 22.5 (10-49), in the FG-group 
26.5 (9-82) and in the FCM 53 (8-158) µg/l, p < 0.001. Fifteen patients had a recurrence 
of ID, six (35.3%) in the FF-group, two (18.2%) in the FG-group and seven (21.2%) in 
FCM-group, p=0.43). One of six patients in FF-group became anemic and two of seven 
patients in the FCM-group became anemic (p > 0.05), but none in the FG-group. 
A last observation carried forward analysis showed that at 12 months a total of 69.7% 
of patients in the FF-group and 74.2% in the FG-group had a persisting or recurrent ID 
during the one year study, whereas a single infusion of FCM normalized ferritin levels 
in all patients, and 27.8% developed a recurrence of ID (figure 4). 
Figure 4. Cumulative iron deficiency
Percentage cumulative iron deficiency at 3, 6 and 12 months after initiating iron therapy (last observation 
carried forward).  FF, ferrous fumarate; FG, ferrous gluconate; FCM, ferric carboxymaltose.
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Adverse effects
In the FF-group, constipation was reported by five patients (12.2%), nausea by 
two (4.9%) vomiting by one (2.4%), gastric pain by two (4.9%) and non-specific 
abdominal pain by three (7.3%). In the FG-group, nausea was reported by nine 
patients (23.1%), vomiting in two (5.1%), constipation in three (7.7%), diarrhea in 
one (2.6%), gastric pain in one (2.6%) and non-specific abdominal pain in two (5.1%). 
One patient complained about dizziness and bad taste (2.6%). Generally reported 
side effects of FCM are hypertension, headache, dizziness, nausea, reaction at the 
injection site (such as pain, bruising, skin discoloration, extravasation, irritation), 
redness in the face and hypophosphatemia. In the present study, only two patients 
reported FCM-related adverse effects. One patient had transient headache with 
dizziness, dyspnea and fever (2.6%), and one developed transient diarrhea (2.6%). 
 
DISCUSSION
The present study compared the efficacy of the three most common treatments for ID 
that are used in the Netherlands. It showed that oral iron supplements for three months 
failed to normalize ferritin levels in 29% of the patients receiving FF, and in 42% of those 
receiving FG despite the use of a daily dose of 70mg iron in a multivitamin supplement. 
In contrast, all patients treated with intravenous FCM responded with a normalization of 
ferritin levels at three months after intravenous infusion. Additionally, recurrence of ID 
after discontinuation of three month oral treatment, occurred in 56.5% of the patients in 
the FF group and in 52.9% in the FG group, whereas only 27.8% had a recurrence in the 
group treated with intravenous FCM. The costs of three month oral treatment is lower 
than IV treatment (FF €9.90, FG €52.20, FCM €327,-) but probably fewer outpatient 
checks are needed in a year because the ferritin remains stable for a longer period.
Overall, a single course of oral treatment was effective in about two thirds of patients 
but failed in one third, whereas IV treatment normalized ferritin levels in all subjects. 
Bias by menopausal status is unlikely since the proportions of premenopausal women 
were comparable for the oral and IV groups. Reduced bioavailability and absorption, 
discontinuation of oral supplements because of intolerable side-effects, and limited 
compliance as suggested by the poor blister return procedure may all have played a role.
There is currently no guideline for treatment adjustment if oral therapy fails to normalize 
ferritin levels. It is important to treat ID because symptoms of fatigue and poor exercise 
tolerance may occur even in the absence of anemia. Kotkiewitcz et al. described an oral 
treatment failure rate of 8.5% of the whole cohort of post-bariatric patients and in 22% of 
the patients with ID anemia. In our study, a 3-month course of oral iron supplementation 
failed to achieve or maintain a normalization of ferritin levels during the 12 month 
study period in 69.7% of patients in the FF-group and 74.2% in the FG-group. A switch 
to another supplement might be a logical step if differences in bioavailability among 




oral supplements are substantial14. Mischler et al. performed a small RCT with a short 
follow-up to compare two types of oral supplements: oral non-heme iron (ferrous sulfate 
195mg/day, N=6) and oral heme-iron (Proferrin ES, HIP, 31.5 to 94.5mg/day, N=8) for 
eight weeks in fourteen women with ID after RYGB15. Treatment with HIP was not 
effective. No change was observed in any of the iron status biomarkers in the HIP-group, 
whereas four out of six patients in the ferrous sulfate group had a resolution of ID, with 
a normalization in Hb level in 75%. Studies comparing other oral iron supplements are 
currently not available. 
Recurrence of ID is common after discontinuation of oral therapy, and this raises the 
question of what the optimal dose for maintenance therapy might be. More than 50% 
of our patients who had a good response after oral treatment developed a recurrence 
in the nine months to follow, despite a maintenance dose of 70mg/day provided by the 
standard multivitamin supplement. Clearly, there is a need to develop a new and more 
effective maintenance treatment, either oral or intravenously.
 
Cuidin et al, compared oral versus intravenous maintenance treatment in a case-
controlled study with 40 patients comparing intravenous iron sucrose every three 
months with daily oral sucrosomial iron supplementation (28mg per day) in ID patients 
after RYGB16. All patients initially received 300mg IV iron at the start of the study to 
normalize ferritin levels, and were then switched into two groups: one that continued 
on three monthly IV iron, and one that was started on oral sucrosomial iron. Three 
months later Hb, ferritin and transferrin saturation was similar in both groups. This 
may serve to illustrate that oral iron maintenance therapy can be a realistic option in 
patients, in particular in those where a previous course of oral iron was successful 
in correcting ID. However, the optimal dose and timing of administration remains to 
be established. As shown in our study, a maintenance dose of 70mg iron/day is not 
sufficient, but at the moment there is no solid evidence of what the optimal maintenance 
dose might be. A doubling of the 70mg dose may be more appropriate, but could induce 
more adverse effects. Alternatively, it might be worthwhile to examine the efficacy 
of other treatment schedules. In non-bariatric women, there is evidence to suggest 
that a single dose of iron supplementation every other day is more effective than 
daily doses and that iron absorption of a single dose is not inferior to daily divided 
doses17. It remains to be shown whether these findings also apply to post-bariatric 
patients.  Recently a systematic review of 10,996 non-bariatric women, evaluated 
the effects of intermittent oral iron supplementation on anemia and its associated 
impairments among menstruating women7. Intermittent iron supplementation compared 
with no intervention or a placebo, reduced the risk of having anemia and increased 
hemoglobin and ferritin concentrations. Compared to daily regimens, intermittent 
regimens may also reduce the risk of having iron deficiency with adverse side effects7. 
Another important aspect of oral maintenance therapy is that it may have adverse 
effects on gastrointestinal function. High luminal concentrations of free iron have been 
associated with increased gut inflammation and adverse changes in gut microbiota18, 19. 
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The current study has several limitations. First, the lost to follow-up rate was relatively 
high, but an impact on study outcome is unlikely in view of the balanced distribution 
over the three treatment groups. There was no structured follow-up of patients on 
oral treatment with persisting ID at 3 months, patients who were still deficient after 
three months of oral treatment were switched from FF to FG or vice versa. Patients 
reporting intolerability to oral iron, or demonstrating no improvement in ferritin level 
were switched to IV treatment with FCM. However, this is unlikely to have affected the 
results, since five of these seven patients were lost to follow-up. Compliance proved 
to be an issue in this study. This was due to the poor return of empty blisters, but we 
estimated that compliance was limited in about 20%. This may be an additional argument 
to prefer IV treatment. The maintenance dose of 70mg in the multivitamins may have 
contributed to the development of the adverse events reported during oral treatment. It 
has been shown that increasing the dose of oral iron may increase the adverse events rate 
and decrease absorption in non-bariatric patients17. Furthermore, the cut-off value of the 
ferritin for the definition of iron deficiency may be debatable. A ferritin below 20µg/l (as 
in the present study) is very firm evidence for iron deficiency, but if less strict criteria 
are used, the prevalence of iron deficiency may be somewhat higher. Finally, the study 
was not blinded. Blinding would have made the study design very complex, with a high 
patient burden due to the required IV placebo treatments. 
CONCLUSION
Treatment and prevention of iron deficiency are a major challenge in post-RYGB women, 
in particular in premenopausal women. This study has shown that intravenous ferric 
carboxymaltose is much more efficient then oral treatment in resolving iron deficiency, 
as well as in delaying its recurrence but the costs are higher. The optimal route, dose and 
timing of maintenance therapy has not yet been established. 
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Background: After Roux-en-Y Gastric Bypass (RYGB), patients often develop a 
vitamin B12 deficiency. 
Objective: To investigate whether oral supplementation increases and normalizes low 
vitamin B12 concentrations (vitamin B12 > 200pmol/L) in RYGB patients, as compared 
to intramuscular injections.
Design: A randomized controlled trial in RYGB patients with subnormal serum B12 
concentrations was performed. One group (IM-B12) received bimonthly intramuscular 
hydroxocobalamin injections (2000 µg as loading dose and 1000 µg at follow-up) for 
six months. The second group (oral-B12) received daily doses of oral methylcobalamin 
(1000 µg). Serum vitamin B12 was determined at baseline (T0) and at 2 (T1), 4 (T2) and 
6 (T3) months after start of treatment. Secondary markers, methylmalonic acid (MMA) 
and homocysteine (Hcy) concentrations, were measured at T0 and at T3.  
Results: Fifty patients were included and randomized, 27 in IM-B12 and 23 in oral-B12. 
The median vitamin B12 concentration at T0 was 175 (114, 196) pmol/L for IM-B12 
and 167 (129, 199) pmol/L for oral-B12. Vitamin B12 normalized in all individuals and 
there was no significant difference in vitamin B12 between the two groups. MMA and 
Hcy concentrations decreased significantly after 6 months within each group ( P < 0.001 
and P < 0.001 for MMA and P=0.03 and P=0.045 for Hcy). There was no significant 
difference between the groups at 6 months for both MMA and Hcy (P=0.53 and P=0.79).
 
Conclusion: The efficacy of oral vitamin B12 supplementation was similar to that of 
hydroxocobalamin injections in the present study. Oral supplementation can be used as 
a alternative to hydroxocobalamin injections to treat RYGB patients with low values of 
serum vitamin B12.
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The Roux-en-Y Gastric Bypass (RYGB) is an excellent procedure for sustained weight 
loss in morbidly obese patients1. Despite the excellent results in terms of weight loss, the 
RYGB is also known to cause vitamin B12 deficiency in a significant number of patients 
in the first postoperative years (17-50%)2, 3, 4. This is due by an severely impaired vitamin 
B12 absorption.
When performing a RYGB, the stomach is reduced to a small pouch (30cc) and a 
considerable part of the intestinal tract is bypassed. Consequently, there (most often) is 
no gastric acid available  in the first part of the digestive tract and Intrinsic Factor (IF)5, 
6. IF is still produced in the remnant stomach, but is now isolated from the food stream 
and thus does not bind vitamin B12. Gastric acid and IF are required to release vitamin 
B12 from dietary protein and to form the IF-B12 complex needed for absorption. 
Vitamin B12 deficiency has been associated with neurological complications and 
macrocytic anemia, both requiring treatment7, 8. The American Society for Metabolic 
and Bariatric Surgery (ASMBS) advises to treat vitamin B12 deficiency (serum vitamin 
B12 < 200pmol/L) resulting from the RYGB parenterally, sublingually, subcutaneously, 
orally, or via intramuscular injections9. All our RYGB patients are advised to take daily 
specialized multivitamin supplements postoperatively to prevent multiple post-operative 
nutrient deficiencies. Although these specialized supplements effectively prevent most 
deficiencies, subnormal vitamin B12 levels and/or frank deficiency still occurs10, 
11 sometimes and additional treatment of vitamin B12 deficiency is warranted. The 
conventional treatment method for vitamin B12 deficiency in many countries includes 
regular intramuscular hydroxocobalamin injections, which is commonly regarded as 
the golden standard. However, these injections can be painful and require a considerable 
amount of time and effort from health care professionals. Oral supplementation is 
potentially more comfortable for patients making regular medical visits unnecessary. 
A number of studies have suggested that oral supplementation can effectively increase 
vitamin B12 concentrations12, 13. Three randomized controlled trials have concluded 
that oral supplementation in patients with normal gastrointestinal anatomy was equally 
effective as conventional intramuscular injections in the treatment of low cobalamin 
levels and/or deficiencies14-16. However, there remains a doubt as to whether oral 
supplements are equally effective compared to injections in RYGB patients whose 
nutrient absorption is severely altered. Therefore, this study prospectively investigated 
whether oral supplementation effectively increases and normalizes vitamin B12 
concentrations in vitamin B12 deficient RYGB patients, as compared to conventional 




A randomized controlled trial was conducted, comparing oral vitamin B12 
supplementation with intramuscular vitamin B12 injections. The present study was 
approved by the Medical Ethics Committee and the institutional review board. The 
study was registered at clinicaltrials.gov under number NCT02270749.
Participants
The trial was performed at the bariatric department of a general hospital that performed 
some 1200 bariatric procedures per year. Patients were recruited when they were 
diagnosed with a low value of vitamin B12 (< 200 pmol/L) during one of the standard 
control visits following RYGB surgery17. These control visits took place at 6, 12, 24 
and 36 months after surgery. During this screening process, patients were excluded 
when creatinine concentrations (> 150 µmol/L) or liver enzymes (> 2 times the upper 
limit) were increased, when they had previous gastrointestinal surgery other than 
RYGB, gastrointestinal disease, or psychiatric issues, used medication influencing bone 
metabolism, already used vitamin B12 supplement other than the advised multivitamin 
supplements or in the case of a known pregnancy.
Intervention
Different effective supplementation regimes have been described for treating vitamin 
B12 deficiency with intramuscular injections and oral supplementation9, 13, 16. Similar to 
results from these previous studies, clinical experience showed that a single intramuscular 
loading dose of 2000 µg and follow-up doses of 1000 µg hydroxocobalamin every two 
months intramuscularly was adequate. Therefore, patients in the first group (IM-B12) 
received a loading dose injection of 2000 µg hydroxocobalamin (Centrafarm services 
B.V., Etten-Leur, the Netherlands) at baseline followed by bimonthly injections of 1000 
µg hydroxocobalamin up until six months. Patients in the second group (oral-B12) 
received 1000 µg methylcobalamin (FitForMe Vitamin B12 ™, Rotterdam, the 
Netherlands)  orally, once daily, for six months. These oral supplements were tailored to 
meet the increased needs of RYGB patients, which did not contain other micronutrients.
Fasting blood samples were taken at baseline and at two month intervals up until six 
months (table 1). Serum vitamin B12 (pmol/L) was determined at each time point 
by electrochemiluminescence immunoassay (ECLIA) (Roche Modular E170). The 
secondary parameters serum MMA (µmol/L) and serum Hcy (µmol/L) were determined 
at baseline and after six months. MMA was analyzed by means of isotope dilution liquid 
chromatography-tandem mass spectrometry (ID-LC/MS/MS) and Hcy via enzymatic 
assay (Roche Modular P800 P5). Laboratory measurements in group IM-B12 were 
taken just prior to their bimonthly injection to make sure that through concentrations 
were measured and not peak concentrations. For group oral-B12, measurements were 
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taken just prior to the intake of their oral supplement. A research physician administered 
the injections and monitored compliance in group IM-B12. Patients returned the empty 
oral supplement packages for monitoring compliance in group oral-B12.
At baseline, weight (kg) was measured. Length and weight were used to calculate 
Body Mass Index (BMI) in kg/m2 and to determine Excess Weight Loss (%EWL). 
Furthermore, patients were requested to report any existing co-morbidities and their 
current medication and multivitamin use and were asked not to use other vitamin B12 
supplements other than advised in this study. 
Table 1. Study design
T=0 T=1 T=2 T=3 
Serum vitamin B12 X X X X
Serum Hcy X X
Serum MMA X X
Study design with primary and secondary outcome parameters after supplementation. Hcy, Homocysteine; 
MMA, methylmalonic acid; T0, time of inclusion; T1, 2 months after starting treatment; T2, 4 months after 
starting treatment; T3, 6 months after starting treatment
Outcomes 
The main outcome was the increase and normalization of serum vitamin B12 
concentrations (> 200 pmol/L) after two, four and six months after supplementation. 
Secondary outcomes were effects on serum homocysteine (Hcy) and serum 
methylmalonic acid (MMA) over six months. Elevated Hcy and MMA concentrations 
were indicative for vitamin B12 deficiency.
 
Sample size
The number of patients have been calculated with the assumption that there would 
be a  10% difference in low vitamin B12 levels between the groups. In the control 
group, treated with vitamin B12 injections, no vitamin B12 depletion remain (100% 
improvement). In the intervention group, which was treated with methylcobalamin, it 
was assumed that 10% of the low B12 levels would persist (90% improvement). With 
a confidence interval of 95%, an alpha of 5% and a power of 80% and a non-inferiority 




Participants were enrolled by the research physician. Fifty eligible patients signed 
informed consent in twofold and were invited for baseline measurements and were 
randomized in one of two treatment groups by computer (Research Manager version 
5.12.1.0, a validated program with block randomization, block size was 10). Patients 
were treated for their low vitamin B12 by the research physician with the supplement 
that came from the randomization procedure. 
Statistical analysis
Data were analyzed using IBM® SPSS® (Version 21.0 for Windows). Results were 
presented as mean values and standard deviation (SD) for normally distributed 
continuous variables. Otherwise, median and range were used. Normally distributed 
continuous variables were tested between the groups by independent samples T-test and 
within the groups with paired samples T-test. For not normally distributed continuous 
variables a Mann-Whitney U test was performed for differences between the groups 
and  a related-samples Wilcoxon signed rank test for within groups differences. Chi-
square test and Fisher’s exact test were performed for nominal data. An ANOVA test 
(2-factor repeated measures analysis) was performed to compare the serum vitamin B12 
concentrations after two, four and six months of treatment between the two treatment 
groups. A P-value < 0.05 was considered statistically significant.
RESULTS
Finding suitable patients for this study took longer than expected, which was due to the 
introduction of preventive specialized multivitamins for RYGB patients in our clinic. 
These tablets contained 350ug of vitamin B12 and reduced the expected amount of 
patients tested with a low vitamin B12 by two-thirds9, 10. Fifty patients were included, 
26 in group IM-B12 and 24 in group oral-B12. The baseline table described the 
characteristics of the patients that were included in the study (table 2). Compliance 
was defined as using the medication for at least six days a week. Patients who took less 
were categorized as non-compliant. In group oral-B12 there was a sufficient compliance 
in 19 patients. Two patients were non-compliant during the first part of the study but 
after two months took the methylcobalamin tablets correctly. One patient from group 
oral-B12 was non-compliant and forgot to take her medication daily in the first 2 
months of the study. This patient was switched to group IM-B12 with a treatment with 
hydroxocobalamin injections and completed the study. Due to the switch of treatment 
for this patient, group IM-B12 ultimately contained 27 patients and group 2 contained 
23 patients in the follow-up. 
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Age (y) 41.6 ± 9.8 46.0 ± 11.9 0.16
Male/Female (N(%)) 5/21 (19/81) 8/16 (33/67) 0.26
Weight (kg) 83.0 (65.1, 119.8) 95.7 (72.2, 136.7) 0.05
BMI (kg/m2) 29.2 ± 4.4 32.9 ± 4.5 0.01*
Time since surgery (mo) 23 (5, 49) 24 (4, 39) 0.48
DM type 2 (N, %) 1 (3.8) 2 (8.3) 0.60
Hypertension (N, %) 3 (11.5) 4 (16.7) 0.70
Hypercholesterolemia (N, %) 1 (3.8) 3 (12.5) 0.34
OSAS (N, %) 2 (7.7) 0 (0) 0.49
Arthrosis (N, %) 6 (23.1) 8 (33.3) 0.42
Vitamin B12 (pmol/L) 175 (114, 196) 167 (129, 199) 0.45
Normal Vit B12 (N, %) 0 (0) 0 (0) -
MMA (µmol/L) 0.31 (0.10, 1.53) 0.31 (0.13, 0.73) 0.74
Normal MMA, (N, %) 17 (65) 14 (58) 0.61
Hcy (µmol/L) 11.4 (6.5, 20.5) 11.3 (3.0, 27.6) 0.92
Normal Hcy (N, %) 22 (85) 19 (79) 0.72
Values are expressed as mean ± standard deviation or median with range. Nominal data are expressed by 
number and percentage. IM-B12, group treated with intramuscular hydroxocobalamin (2000 µg); Oral-B12, 
group treated with oral methylcobalamin (1000 µg); DM, diabetes mellitus; FFM, specialized multivitamin 
supplement; Hcy, Homocysteine; MMA, methylmalonic acid; N, amount;%, percentage; mo, months; OSAS, 
obstructive sleep apnea syndrome; PO, Per oral treatment; y, years; *, statistical significance. Independent 
samples T-test is used for normally distributed variables, Man-Whitney U test for not normally distributed 
variables and Chi-square test or Fisher’s exact test for nominal data.
Vitamin B12
The course of vitamin B12 concentrations in both groups is shown in figure 1. There was 
a significant increase, within each group two months after supplementation (P < 0.001 
and P < 0.001). The repeated measures analysis showed no interaction between time and 
the change from baseline. After six months of treatment, all patients had normal vitamin 
B12 concentrations (table 3). 
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Figure 1. Vitamin B12 concentrations
Median vitamin B12 concentrations with range throughout the study period in both treatment groups. Grey 
squares represents intramuscular B12 injection treatment(2000 µg, N=27) and black dots represent oral 
treatment with methylcobalamin (1000 µg, N=23); At 6 months the number of patients in the intramuscular 
injection group was 26. P-interaction for time by repeated measures ANOVA for vitamin B12 was not 
significant (P=0.75).






Vit B12 26 (100)# 23 (100) -
MMA 27 (100) 22 (96) 0.46
Hcy 25 (96)# 20 (87) 0.33
Normalization was defined as vitamin B12 ≥ 200pmol/l, MMA < 0.35µmol/L and Hcy < 13.4 µmol/L IM-
B12, group treated with intramuscular hydroxocobalamin (2000 µg); Oral-B12, group treated with oral 
methylcobalamin (1000 µg); Vit B12, vitamin B12; Hcy, Homocysteine; MMA, methylmalonic acid; N, 
amount; ;%, percentage; PO, Per oral treatment; P-values were analyzed by Fisher’s exact test. #, Number of 
patients is 26.
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The mean MMA concentration was significantly decreased after 6 months within each 
group (figure 2, P < 0.001 and P < 0.001).
There was no significant difference in change from baseline to 6 months between IM-
B12 and oral-B12 (median change was -0.15 (-1.34, 0.04) vs. -0.13 (-0.42, 0.18) µmol/l, 
P=0.53). After 6 months, MMA was normalized in all patients in the IM-B12 and in 
96% of the patients in the oral-B12 group (P=0.46). Overall, MMA increased during 
the study in 5 patients, of which 4 stayed in the normal range (MMA < 0.35 µmol/l) and 
were in group IM-B12. The patient who had a MMA > 0.35 µmol/l was in the oral-B12 
group. 
Figure 2. Methylmalonic acid concentrations
Median methylmalonic acid (MMA)concentrations with range at baseline and after 6 months of treatment. 
Grey squares represents intramuscular B12 injection treatment(2000 µg, N=27) and black dots represents 
oral treatment with methylcobalamin (1000 µg, N=23); Mean MMA concentrations decreased in both groups 
between 0 and 6 months (P < 0.001 and P < 0.001, related samples wilcoxon signed rank test).There was no 
significant difference between the groups in MMA change (P=0.53, Mann-Whitney U test). The white triangles 
represents the total patients with raised MMA concentrations at baseline and their MMA concentration at 6 
months after treatment (N=19), which decreased (P < 0.001, related samples Wilcoxon signed rank test).
 
Hcy
At baseline there was no significant difference in Hcy concentrations between men in 























mean Hcy concentration decreased significantly after 6 months in group IM-B12 and in 
group oral-B12 (figure 3, P=0.03 and P=0.045). There was no significant difference in 
change from baseline to 6 months between IM-B12 and oral-B12 (mean change  -1.50 
(-7.5, 4.4) vs. -1.70 (-10.0, 4.6) P=0.79). 
In the total group Hcy was higher in 18 patients (36%, including 8 patients in IM-B12 group 
and 10 in oral-B12 group, P=1.0) at T3 than at T0, of which 15 patients stayed at the normal 
range (Hcy < 16.4 µmol/l). One patient in group oral-B12 had a Hcy value of 16.8 µmol/l. 
Overall, 9 patients had an increased Hcy level at baseline, 4 in group IM-B12 and 5 in 
group oral-B12 (median 20.5 range 17.6, 27.6 µmol/l) and decreased at six months of 
treatment (N=8, median 15.0 range 10.1-22.6 P=0.012, figure 3).  After 6 months Hcy 
was normalized in 25 (96%) patients in the IM-B12 and in 20 (87%) patients in the 
oral-B12 group (P=0.33, table 3). 
Figure 3. Homocysteine concentrations
Median homocysteine (Hcy) concentrations with range at baseline and after 6 months of treatment. Grey 
squares represents intramuscular B12 injection treatment (2000 µg, N=27) and black dots represents oral 
treatment with methylcobalamin (1000 µg, N=23); At 6 months the number of patients in the intramuscular 
injection group was 26. Hcy decreased significantly in both groups (P=0.03 and P=0.045, related samples 
wilcoxon signed rank test). There was no significant difference between the groups (P=0.79, independent 
samples t-test). The white triangles represents the total patients with raised Hcy concentrations at baseline(N=9) 
and their Hcy concentration at 6 months after treatment (N=8), which decreased (P=0.012, related samples 
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In the IM-B12 group at baseline, 23 (88.5%) subjects used daily multivitamin 
supplementation. Fifty-four percent used the specialized multivitamin supplements for 
RYGB patients, containing higher doses of vitamin B12 (10,11) and 34.6% used standard 
multivitamins,  In the oral-B12 group 92% of patients used multivitamins. Fifty-four 
percent  used the specialized supplements and 37.5% used standard multivitamins 
(P=1.00 compared with multivitamin use in IM-B12).
Vitamin B12 concentrations were not significantly different between the specialized 
multivitamin-users and users of regular multivitamin supplements (median 175 (124-
196) pmol/l versus 164.5 (114, 199) pmol/l, P=0.36). Neither there was a significant 
difference in Hcy (median 11.8 (3.0, 25.8) µmol/l versus 10.3 (6.7, 27.6) µmol/l, 
P=0.56). The concentration of MMA was significant higher in regular multivitamin 




This study in RYGB patients with low vitamin B12 concentrations (N=50) showed 
that there was no significant difference in serum vitamin B12 and MMA concentrations 
between the two treatments after six months. In addition, both treatments achieved 
normalization of serum vitamin B12 concentration (> 200 pmol/l) in all patients 
within six months of treatment. Within the oral-B12 group one patient had persistently 
subnormal levels after two months  (T1) and one patient was low at four months (T2). 
These deficiencies were due to insufficient intake of the vitamin B12 tablet by these two 
patients (p > 0.05). Therefore, this study indicated that oral supplementation is similarly 
effective as intramuscular injections when compliance is sufficient.
The present study is the first randomized controlled trial, comparing intramuscular 
and oral vitamin B12 treatment in RYGB patients. The results of the current study 
are comparable to previous trials in subjects with low cobalamin levels and/or frank 
deficiencies but otherwise healthy subjects using different dosing schemes. Kuzminski 
et al. studied the effect 2000 µg cyanocobalamin per oral daily for four months 
compared to nine 1000 µg cyanocobalamin intramuscular injections (IM) spread over 
four months on serum vitamin B12 concentrations in vitamin B12 deficient subjects 
in a randomized controlled trial (RCT)16. In the current study both treatment groups 
reached 100% normalization, suggesting they are equally effective based on vitamin 
B12 concentrations. Castelli et al. gave their subjects either 1000 µg cyanocobalamin 
PO daily or nine 1000 µg cyanocobalamin IM injections spread over three months15. In 
both groups vitamin B12 concentrations had normalized after fifteen days, using an even 
higher cut-off value (> 258 pmol/L). Some patients with gastrointestinal abnormalities 
such as the RYGB were included in this study and both treatments were considered 
effective.
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Altogether, literature suggests that oral supplementation can form an adequate 
alternative in patients with a normal anatomy for regular intramuscular injections14-16. In 
the previous RCTs cyanocobalamin was used as supplementation, whereas the current 
study used hydroxocobalamin and methylcobalamin. These forms of vitamin B12 are 
very similar, and the form of choice for supplementation is currently, for the most part, 
dependent on the availability in the country where it is used. 
Vitamin B12 absorption can be impaired by certain medications. Acid inhibitors 
(e.g. omeprazole) result in reduced acid in the stomach. The lack of acid impairs the 
release of vitamin B12 from dietary protein so it can not bind IF and be absorbed in 
the ileum. Metformin therapy, an antihyperglycemic drug used against diabetes type 
2, has also been associated with reduced vitamin B12 concentrations18. Nevertheless, 
the mechanism is not entirely understood yet, and different mechanisms have been 
proposed. For example, metformin is suggested to interfere with intracellular calcium 
handling, disrupting calcium-dependent absorption of vitamin B12 in the ileum19. In 
the present study, eleven subjects used proton pomp inhibitors and six subjects used 
metformin. The RYGB most often resolves reflux issues and thereby reduces the need 
for acid inhibitors. Furthermore, the RYGB also helps patients to get rid of diabetes, 
which makes anti-hyperglycemic therapy redundant. 
Patients in both treatment groups received an adequate therapy for their low vitamin B12. 
Nevertheless, the current study also had its limitations. There is currently no consensus 
on how to diagnose vitamin B12 deficiency. As used in the present study, serum vitamin 
B12 concentrations are routinely used in clinics as a first line diagnostic test for vitamin 
B12 deficiency. However, there is some debate about which cut-off values apply to 
normal vitamin B12 concentrations. In the current study we used a cut-off  < 200 pmol/l 
based on the ASMBS guidelines17. Generally  serum vitamin B12 concentrations below 
148 pmol/l are thought to sensitively diagnose 97% of true vitamin B12 deficiencies20, 
21. A higher cut-off value can reduce the specificity for diagnosing clinical deficiency to 
approximately 65-90% with a cut-off value of 148 pmol/l (200 pg/ml)20, 21. The largest 
problem at present with using vitamin levels to diagnose deficiency is that in there are 
also false positive measurements. Serum vitamin B12 concentrations are maintained at 
the expense of its tissue stores, hence deficiency might be present when serum vitamin 
B12 is normal13. MMA And Hcy are elevated in case of vitamin B12 deficiency. For this 
reason, additional measurement of MMA and/or Hcy is recommended for diagnosing 
a clinical vitamin B12 deficiency. It should be noted though, that renal disease also 
increases MMA concentrations, and Hcy is not specific to vitamin B12 deficiency. 
MMA is considered the best marker for vitamin B12 deficiency, but due to poor assay 
availability and the high costs  in our country its clinical use is limited. In the present 
study additional Hcy and MMA measurements at two weeks or one month to see if in 
fact patients were corrected instead of just at six months, would have been helpful. Also 
we could not be sure what happened with the vitamin B12 concentration within the 
first 2 months between the two groups. Selecting patients based on serum vitamin B12 
concentrations combined with MMA values might improve a future study design. It is 
Efficacy of oral versus intramuscular vitamin B12 supplementation following Roux-en-Y Gastric Bypass, 
a randomized controlled trial
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also important to consider the costs of the laboratory tests. At this moment determination 
of serum vitamin B12 concentrations costs €9 euro. The current price to determine 
MMA concentrations in the Netherlands is €45 euro, Hcy concentrations €39 euro and 
the determination of HoloTC approximately costs €25 euro. 
Evidence is emerging for the use of another marker for vitamin B12 deficiency called 
active vitamin B12 or holotranscobalamin (HoloTC). HoloTC represents the amount of 
vitamin B12 available to the body’s cells. Literature suggests HoloTC is more suitable to 
diagnose vitamin B12 deficiency22. Although HoloTC appears to be a promising marker, 
its use is still explorative and further investigation is needed before its use as marker for 
clinical diagnosis for vitamin B12 deficiency is justified.
Although we performed a randomized controlled trial, the groups were not compared 
with placebo groups. Neither was the study blinded, which could give the study more 
strength. However, blinding this study would be clinically challenging and ethically 
bothersome, while this would mean that both groups would get injections and tablets at 
the same time. 
Another limitations is the design of the study which was based on two different factors 
between the intervention arms, the route of administration (oral versus intramuscular) 
and the form of B12 used (hydroxycobalamin versus methylcobalamin). Moreover, 
vitamin B12 was low in all studied patients but MMA was not elevated in all patients 
who were considered deficient at start. This study was set up for the most common type 
of deficiency found in bariatric centers with adequate follow-up, in which patients have 
only minor or no clinical symptoms, and serum levels are lowered. The severity of the 
deficiency could theoretically vary and could be a factor that influences the response to 
the two treatments. In severe deficient patients there could be a faster response in the 
intramuscular injection group. Therefore in patients with a severe deficiency where a 
fast response is required only intramuscular therapy should be considered. However, 
we compared MMA and Hcy before treatment and there was no significant difference, 
but we also see hardly no severe deficiencies in our clinics and there were none in this 
studied population.
This study indicated that both treatments could effectively increase and normalize serum 
vitamin B12 concentrations in RYGB patients with low vitamin B12 values during a 
period of six months. Having a choice of treatment is convenient to optimize care for 
RYGB patients. For example patients who are anxious about receiving injections can be 
offered the more comfortable but also more expensive oral supplementation treatment. 
Vice versa, patients with compliance issues can be prescribed bimonthly intramuscular 
injections in order to keep control of the treatment. A possible disadvantage that could 
develop in terms of compliance is when patients have to use more tablets for varies 
deficiencies.
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Nevertheless, it remains of the utmost importance to monitor vitamin B12 status 
throughout the patient’s life, especially in patients with oral supplementation, where 
compliance is harder to monitor. 
Efficacy of oral versus intramuscular vitamin B12 supplementation following Roux-en-Y Gastric Bypass, 
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To date, bariatric surgery, known as metabolic surgery, is the most effective treatment 
for weight loss with good results in the long-term in morbid obese patients (BMI > 
40 or > 35 with obesity related comorbidities)1-3. This is one of the main reasons why 
the amount of metabolic procedures has increased enormously in the recent decades4. 
The Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) are the most 
performed operations (figures 2 and 3 in chapter 1). More malabsorptive procedures 
like the biliopancreatic diversion with or without a duodenal switch (BPD/DS) (figure 
6 in chapter 1) are mostly reserved for super morbid obese patients (BMI > 60kg/m2).
Despite the many excellent results,. the most common complications are nutritional 
deficiencies. These result from several factors including reduced dietary intake and 
absorption due to the changed anatomy5-10. The fact that nutritional deficiencies can also 
have an enormous impact on a patient’s health  has been underestimated for a long time 
by both patients and health care professionals. 
The most common deficiencies after metabolic surgery, depending on the type of 
procedure, cut-off value and time after surgery, are iron (~62%), vitamin B12 (~20%), 
folic acid (~65%) vitamin B1 (~49%), vitamin D (~100%) and calcium (~100%)6-9, 11-
17. This incidence is even higher in BPD/DS procedures with an increased the risk of 
protein, fat-soluble vitamins A (5-69%), D, E, and K (50-60%), which is uncommon 
after other procedures18, 19. 
There are a number of scientific societies who have made an effort to come up with 
guidelines for the assessment and treatment of micronutrient deficiencies20-23. The most 
frequently used and best attempt, has so far been made by the American Society for 
Metabolic and Bariatric Surgery (ASMBS) who published their first guideline in 2008 to 
provide suggestions for conducting nutrition assessments, education, supplementation, 
and follow-up care21. These recommendations are however, based on scarcely available 
literature and expert opinions. In 2017 there was a second update with more detailed 
recommendations but most are still based on expert opinions as well as a literature 
review of empirical and clinical data. They were intended to set a standard of care but 
were lacking because of insufficient scientific evidence22 .At the end of 2019 a new 
guideline was produced which is an update of the version form 201717, 22. What is 
striking about this new guideline is that the recommendations for nutritional deficiencies 
have only been changed for vitamin B12 compared to the version from 2017, despite the 
large amount of recently published literature on this subject. Apparently, a void exists in 
understanding and treating micronutrient deficiencies.
The present thesis focusses on preventive supplementation of nutritional deficiencies, 
changes in uptake of micronutrients and the treatment of nutritional deficiencies once 
they have occurred.
Prior to metabolic surgery, many obese patients with morbid obesity already suffer from 
a deficient nutrient status most often this is due to an insufficient diet24-28. First it is 
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important to educate these patients preoperatively about the nutritional deficiencies and 
the resulting consequences that may occur. This should help to achieve a healthier intake 
and to remain compliant to multivitamins, calcium and vitamin D which are advised on 
a daily basis by their healthcare providers15, 22.
Additional action to assess nutritional deficiencies is blood testing. Preoperative 
detection of deficiencies is important, because postoperatively, supplementation is on 
average more challenging because of the reduced absorption capacity. After the first 
year in which patients are evaluated at least twice, a minimum of one annual blood 
examination to detect nutritional deficiencies is eminent22. 
To prevent nutritional deficiencies, the recommended preventive daily doses of 
micronutrients is on average higher than in over the counter (OTC) multivitamins. It is 
impossible to achieve adequate doses for some micronutrients with OTC supplements 
due to a too low dose or noncompliance for the advised two to three tablet dosage 
each day15, 17, 22. In 2006, there was no procedure specific specialized and standardized 
multivitamin available for metabolic patients. In order to develop these, a number of 
studies were performed in the bariatric research department of The Rijnstate Hospital, 
the Netherlands. In this research department Dogan and colleagues performed a double 
blind randomized controlled trial with a new multivitamin supplement with high doses 
of vitamins and minerals (Weight Loss Surgery Forte® (WLS Forte®, FitForMe, 
Rotterdam, the Netherlands) that needs to be ingested once a day. They concluded that 
the use of these specialized multivitamins led to less deficiencies in iron, vitamin B12 
and folic acid over the first twelve months postoperatively30. A three year follow-up 
study was later performed by Homan et al. that produced similar results31. Based on the 
positive results from the first study of Dogan et al, the ethical committee determined that 
it was not ethical to exclude patients from the use of the specialized supplement during 
the follow-up study. The follow-up study of Homan et al. had lost its randomization 
design and became an observational investigation. Approximately half of the patients still 
used the specialized multivitamins. Over time, significantly less deficiencies in ferritin, 
zinc, vitamin B12 and folic acid and less anemic patients were found. Additionally 
the supplement is safe in use, while no adverse events were reported. The important 
limitation of the trial design (described above) warrants a cautious interpretation of the 
data31. Caution about long-term side effects and risks of un-physiological doses.
 
Main findings
In chapter 2 we compared the differences between the standard and specialized 
supplements once more (WLS Forte®, FitForMe, Rotterdam, the Netherlands) in a large 
retrospective trial. We studied 1160 patients for three years in a prospectively collected 
cohort. Again, significantly less deficiencies in ferritin, vitamin b12, folic acid and 
vitamin D were found. Also the incidence of anemia de novo was low in the specialized 
group (12%) compared to other studies6, 10, 13. A point of note is that the users of the 




point of the ‘non-users’ group is that they used different kinds of OTC supplements. Also 
different limb-lengths after bariatric surgery could have played role on the postoperative 
outcomes31, 32.
Theoretically, lengthening of the biliopancreatic limb could lead to more deficiencies. 
Overall, when comparing the current studies that have been performed with the 
specialized multivitamin supplements, despite the limitations, conclusions are uniform, 
with superiority for the specialized supplements. Based on our investigations, we 
now recommend the specialized supplement to all our RYGB patients as standard 
care. Reported side effects are nausea, poor taste and experiencing gastric discomfort. 
Improvements are being made on to improve these points. 
SG has now become the most performed bariatric procedure worldwide and 
is regarded as quick, relatively easy and safe17, 33, 34. One of the reasons why a 
shift from RYGB to SG has occurred is because theoretically fewer nutritional 
deficiencies can occur34-36. Unfortunately, several studies show the same rate 
of shortages as with the RYGB. This is especially the case in deficiencies 
for iron, folic acid, vitamin B12 and vitamin D are frequently reported37-44. 
For this reason we conducted a double blind RCT on the effect of a specialized 
multivitamin supplement in SG patients (Chapter 3). In this RCT the amounts of 
vitamins that are normally present in an OTC product were compared with a specialized 
supplement (WLS Optimum 1.0, FitForMe, Rotterdam, the Netherlands) in 139 patients 
till 12 months after surgery.
WLS optimum contained higher doses of all vitamins and minerals. An intention-to-
treat analysis showed more folic acid deficiencies and higher serum vitamin B1 levels in 
the WLS optimum group. A per protocol analysis, excluding non-users, showed higher 
levels of folic acid, vitamin B1 and lower PTH in the WLS Optimum group. Overall, 
less anemia was found in the new supplement (2.6% vs. 17.5%). Non-compliance with 
multivitamin supplements was frequently encountered. This indicates that there is a 
clear need for even more patient education and further optimization of multivitamin 
supplementation for SG patients. 
After metabolic surgery, major physiological changes occur. A reduced uptake 
capacity for micronutrients is just one of these. Increased and decreased bowel 
movements are frequently reported postoperatively (constipation and even more 
often diarrhea) depending on the type of the surgical procedure. To optimize 
prevention and treatment of nutritional deficiencies, it is important to clarify 
these physiological changes and their impact on vitamin and mineral status. 
In the past a retrospective study from our group showed that loose stools and frequent 
bowel movements correlated with increased PTH levels45. The hypothesis is that this 
is due to the inability to bind and then absorb calcium when intestinal transit time 
increases. This has been shown earlier in animal studies but never before in humans46, 
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47. When calcium levels decrease, the body compensates by bone reabsorbing. Calcium 
and vitamin D deficiencies eventually lead to secondary hyperparathyroidism (SHPT). 
Raised PTH levels are a first sign that manifests in the follow-up laboratory assessments, 
while calcium and vitamin D levels are in the normal range for a longer period of time. 
Persistent SHPT leads to increased bone turnover resulting in a higher prevalence in 
osteoporotic fractures48-50. Therefore patients are advised to take calcium and vitamin D 
supplements daily51-53. In chapter 4 we studied  the association between the fecal score 
(semi-quantitative assessment of bowel habits by summation of stool frequency and 
consistency) and PTH levels in RYGB patients. Twelve months after surgery a positive 
correlation between loose and frequent stools and PTH levels was found45. In spite of 
supplementation with a fixed dose of calcium carbonate (500mg, three times daily) 
combined with vitamin D3 (400 IU, three times daily), secondary hyperparathyroidism 
(SHPT) was found in fourteen out of 75 patients. This might be partially due to low 
compliance to the rigid regime of calcium supplementation three times daily over an 
extended period of time.
Next to follow-up alone with laboratory assessments, monitoring of bowel habits help 
to optimize nutritional status. The question remains whether one should dose calcium 
individually. Theoretically, calcium supplementation could be increased in patients with 
frequent diarrhea. Constipation can be a side effect of calcium supplementation, but can 
be of great use in these cases of persistent diarrhea. The reverse also applies, calcium 
supplementation can aggravate constipation after bariatric surgery. When increasing 
the calcium supplements, it is important to monitor whether patients do not develop 
hypercalcemia. Another theory is that it might even be sufficient to supplement bariatric 
patients with relatively high doses of vitamin D, and leave calcium out. These are 
merely suggestions and will have to be investigated further in larger studies with proper 
monitoring of side effects over a longer period of follow-up.
Despite all efforts, prevention alone is often insufficient. Frequently, many simultaneous 
deficiencies arise and correcting them all at once often forms a major challenge. A well-
known example is supplementing deficits after a BPD/DS. This procedure can be regarded 
not only as severe malabsorptive for macronutrients, but also for micronutrients. In 
chapter 5 we monitored 34 patients after a BPD/DS for one year after we had corrected 
several deficiencies found at baseline. Despite severe adjustments of the supplement 
regime, many patients still (re)developed deficiencies in vitamins A, D, iron, calcium 
and zinc. Current observations suggests a minimum of 200 mg iron in women and 100 
mg in men, 100 mg zinc, 3100 mg calcium weekly vitamin A and D in 50000 IU. Prior to 
this study, only a few studies were performed focusing on BPD/DS procedures, of which, 
only two dealt with the supplementation of vitamins and minerals: one study concluded 
that regular multivitamins are insufficient and gave some rudimentary recommendations 
on how to supplement54-55. A second study only gave general directions, concluding 
that 200% of the recommended daily dose in 80% of patients after five years was still 
insufficient55. In our study we had a small heterogeneous group of patients, a varying time 




the advised OTC multivitamins. Nevertheless, deficiency rates, despite supplementation 
were 60% for iron, 44% for vitamin A, 53% for vitamin D and 62% for zinc. Fifty-one 
percent had a SHPT and 53% of patients had a hypervitaminosis for vitamin B6. We 
combined our results with those of others which led to a new supplementation regime.
Two of the most common deficiencies after a RYGB are iron and vitamin B12. This is 
mainly due to the reduced volume of the stomach, less stomach acid availability and the 
bypassing of the most important uptake part of the small intestines5, 6, 10-13, 17, 56. Factors like 
reduced intake, red meat intolerance and the use of (mandatory) proton pomp inhibitors 
also play a role. Postoperative iron deficiency (ID) has been reported in up to 66% of 
patients. Current knowledge about the optimal dose and route of iron supplementation 
for the prevention and treatment of ID after metabolic surgery is still limited. The 
American Society for Metabolic and Bariatric Surgery (ASMBS) recommends to treat 
post-bariatric ID with 150-200 mg elemental iron daily, up to 300 mg maximum17, 22. 
No distinction is made between RYGB and other bariatric procedures, which form of 
iron is used, and no advice is given how to adjust the iron maintenance dose, once 
they have finished their superimposed course of iron supplementation for the treatment 
of ID. Chapter 6 describes an open multicentric three-armed randomized controlled 
trial in 120 post-RYGB women with ID. One group was treated with ferrous fumarate 
one group with ferrous gluconate and one group with a single dose of intravenous 
ferric carboxymaltose. Three months after initiating treatment we frequently saw an 
insufficient respond of ferritin in the oral treatments (ferritine < 20µg/l). Patients were 
offered a WLS Forte, which contains 70mg of elementary iron a day. One year after 
the start of treatment we concluded that one single intravenous dose was much more 
effective to treat ID than three months of oral supplementation. A high rate of (re)-
deficiencies, especially in the two oral treatment groups (57 and 53%) occurred but also 
in up to 28% in de intravenous group, despite a preventive dose of 70mg elemental iron in 
multivitamins. The best maintenance therapy with oral supplementation in patients with 
a good response and for the patients who received the intravenous treatment to get less 
re-deficiencies should hold more than 70mg a day57-58. However, this inevitably leads to 
more patients with obstipation This study shows a high failure rate with the current oral 
therapy regimen. We must either start dosing higher or give a much higher maintenance 
dose after initial treatment. Another option is to switch directly to intravenous treatment 
with monitoring afterwards.
The treatment of vitamin B12 deficiencies was also never researched in a randomized 
controlled trial design in deficient patients post RYGB. Vitamin B12 deficiency occurs 
in 17-50%9, 13, 59. Chapter 7 describes a randomized controlled trial in 50 patients with 
low vitamin B12 levels (< 200pmol/l). One group received bimonthly intramuscular 
hydroxocobalamin.the second group received daily doses of oral methylcobalamin This 
study showed that oral supplementation is a good alternative for hydroxocobalamin 
injections in RYGB patients with low values of serum vitamin B12. 
As mentioned before, compliance with therapy is often a problem, not only in the 
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prevention but also in the treatment of deficiencies. Having a treatment alternative is 
convenient to optimize care for RYGB patients. For example, patients who are anxious 
about receiving injections can be offered the more comfortable but also more expensive 
oral supplementation treatment. Vice versa, patients with compliance issues can be 
prescribed bimonthly intramuscular injections in order to keep up with the treatment. 
A possible disadvantage of oral administration in terms of compliance is when patients 
have to use more tablets for varies deficiencies. Table 1 shows the main findings, 
implications and limitations for each chapter. 
Table 1. Main findings, implications and limitations per chapter
Chapter Main findings Implications Limitations
2 •	 Higher serum levels for 
ferritin, vitamin B12, 
vitamin D and folic acid 
when using a specialized 
multivitamin after RYGB
•	 Less new deficiencies of 
vitamins and minerals 
when using a specialized 
multivitamin after RYGB
•	 Daily use of a specialized 





•	 Unequal number of 
patients in the different 
groups
•	 Compliance is hard to 
assess
•	 Different types of OTC 
multivitamins
3 •	 High prevalence of 
nutritional deficiencies 
after SG
•	 Specialized multivitamin 
after SG had no clear 
advantages over standard 
supplementation
•	 A specialized multivita-
min with sufficient doses 
is needed after SG to 
prevent deficiencies
•	 Non validated tools for 
assessing compliance
•	 High rate of incompliant 
patients
4 •	 Fecal score is positively 
correlated with secondary 
hyperparathyroidism
•	 Pay attention to bowel 
movements postop-
erative, it can give an 
indication for calcium 
deficiencies
•	 The tool used for bowel 
habits is not validated
•	 Adherence for calcium 
was not assessed using a 
validated tool. 
5 •	 High rates of deficiencies 
after BPD/DS despite 
treatment
•	 Exceptionally high 
supplementation doses 
are needed in case of 
deficiency
•	 Further refinement and 
simplification of treat-
ment schedules is needed
•	 Improvement of com-
pliance to treatment is 
recommended
•	 Small heterogeneous 
group
•	 Retrospective
•	 Adherence for medica-
tion was not assessed 




6 •	 After three months of 
treatment persistent iron 
deficiency (ID) was 
observed in 29.4% and 
42.4% of the patients 
treated with ferrous 
fumarate and ferrous glu-
conate. None in the ferric 
carboxymaltose group
•	 Approximately half of 
the orally treated patients 
became re-deficient in 
the next 9 months
•	 Adverse effects were 
most common during 
oral treatment
•	 FCM is more effective 
and better tolerated than 
the oral treatments
•	 Intravenous iron supple-
mentation is more effec-
tive in ID after RYGB
•	 A cost-effectiveness 
study is needed to treat 
all patients with ID after 
RYGB
•	 The optimal route, dose 
and timing of mainte-
nance therapy has not yet 
been established.
•	 Not blinded
•	 Noncompliance rate of 
20%
•	 Relatively high rate of 
lost to follow-up
7 •	 Vitamin B12 normalized 
in all individuals and 
there was no significant 
difference in vitamin B12 
between the two groups
•	 Oral treatment can be 
used as an alternative 
to hydroxocobalamin 
injections to treat RYGB 
patients with low serum 
values.
•	 Vitamin B12 was low in 
all studied patients but 
MMA was not elevated 
in all patients who were 
considered deficient at 
start
•	 The exact duration of 
supplementation has to 
be further investigated
•	 Compliance can decrease 
in oral treatment regimes
•	 Methyl malonic acid is 
more specific for vitamin 
B12 deficiency but more 
expensive
•	 Not blinded
•	 Debatable cut-off value 
vitamin B12
Strengths and limitations
The strength of this thesis is the clear focus on the prevention and treatment of the 
most common nutritional deficiencies after metabolic surgery. Because the increase 
of metabolic patients, more and more patients with nutritional deficiencies arise after 
metabolic surgery. There is a great demand for the treatment and prevention strategy of 
vitamin and mineral deficiencies while it is a burden for both the patient as well as the 
healthcare professionals. To date, there are no adequate guidelines and only few trials are 
available that study the effect of (specialized) multivitamins on these metabolic surgery 
patients. In the current thesis, we used this knowledge gap and conducted research to the 
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effect of specialized multivitamins, as one of the first in the world. The main question 
of the thesis ‘How can nutritional deficiencies be prevented and treated once developed 
after metabolic surgery?’ has been largely answered for the most common deficiencies 
and types of metabolic surgery. We have found that the use of a specialized multivitamin 
for RYGB results in fewer shortages compared to standard supplements. Unfortunately, 
this did not apply after a GS and will therefore has to be further optimized. This thesis 
also provides treatment advices for deficiencies after a BPD / DS. Oral supplementation 
with vitamin B12 works as good as injections and  this thesis shows that the current 
advice for treating iron deficiency is not adequate and needs to be improved.
Different research forms in large and small research groups have been conducted and 
published in international reputable journals. The number of patients was almost always 
higher compared to other studies in de past. Another strength of this thesis is that it holds 
three separate randomized controlled trials.
Besides the strengths of the thesis, there are also limitations in de design we used in the 
studies. We examined patients who were subjected to metabolic surgery as a disease 
model. Because of the use of this disease model, many results from the studies cannot be 
used for the general population. Only the study of stool patterns and calcium metabolism 
was performed before and after metabolic surgery were patients were their own control 
group. None of the other studies included a control group. Without a control group it is 
difficult to establish the cause and effect relationship between the exposure and an injury. 
Multivitamins and medication were taken at home, without supervision. Except 
counting empty blisters during the outpatient visits, no validated instruments have been 
used to adequately investigate the treatment compliance which can cause bias. Also, a 
non-validated questionnaire was used for stool patterns. Additionally, two of the three 
randomized controlled trials were not blinded. 
FUTURE PERSPECTIVES
Future investigations in the relatively young specialism of metabolic surgery will 
initially focus on optimizing surgical techniques, weight regain and new (endo-luminal) 
interventions. Another research focus lies on expanding the indication limits for 
metabolic surgery (treatment of comorbidities, lowered BMIs, extension of age limits). 
Hopefully, the risk of nutritional deficiencies will also be taken into account. The most 
optimal metabolic intervention should include a high percentage of EWL / TBWL, 
resolving all comorbidities, with no complications (including deficiencies) limited 
weight regain on the long term.
In the domain of prevention of nutritional deficiencies, first of all focus should lie on 
educating patients and healthcare professionals. Promoting therapy compliance should 




have had a form of metabolic surgery60. This number is expected to increase very 
quickly. Many patients are discharged from hospital care after an average of two years 
monitoring of health status then transferred into the hands of their (often inexperienced) 
general practitioners (GPs). Follow-up will dramatically improve after better education 
and training for GPs in the field of nutritional deficiencies and possibly the development 
of an evidence based guideline. Cooperation between the first and second line of the 
health care system can also be improved in this area. 
In addition, further research is necessary to optimize the doses in daily preventive 
maintenance medication, multivitamins, adapted to each surgical technique, especially 
for GS and BPD/DS.
Metabolic surgery causes many physiological changes in the body with the added 
change in uptake of micronutrients. Further research of physiological changes and 
predictive values for a poor absorption capacity can promote the prevention of nutrient 
deficiencies like bowel movements for calcium uptake and hepcidin and transferrin for 
iron absorption.
If we have a clearer picture of these predictors, we can anticipate deficiencies and maybe 
even prevent them.
When prevention fails and patients develop deficiencies then the deficits will 
have to be supplemented. To achieve this as accurately as possible, thorough 
research must be performed into the treatment per micronutrient and operation 
type. Currently, many treatments are based on the knowledge gained from 
non-bariatric patients, but now there is a need for investigations based on 
the bariatric patient as this group continues to grow rapidly worldwide. 
The treatment of iron deficiencies in particular, is a challenge as is also shown 
in this thesis. The daily preventive dose in multivitamins may need to be increased 
to a higher level than 70mg/day. A high oral maintenance dose after an initial 
treatment should also be further investigated with the possible consequences that 
iron may have to be ingested in high doses for life with regard to bowel movement 
and the impact on the gut flora. Another option is to switch earlier to intravenous 
treatment, to be sure that the ferritin level will rise and patients do not have to take 
an extra dose of iron 2-3 times a day on top of their usual tablets. The number of 
tablets that are prescribed per day, correlates negatively with therapy compliance. 
GENERAL CONCLUSION
In addition to the considerable benefits of metabolic surgery, the most common 
complication is the development of nutritional deficiencies. A specialized multivitamin 
supplement ensures fewer deficiencies in patients who have undergone metabolic 
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surgery. But unfortunately it fails to provide complete protection against becoming 
deficient. Regimes and dosages will still have to be developed for new upcoming 
metabolic procedures. Lifelong follow-up of this patient group is important to monitor 
their compliance and to be able to detect deficiencies as soon as possible before serious 
complications can arise. International guidelines help clinicians to more uniformly 
prevent and treat deficiencies. However, publishing a guideline alone is not always 
adequate for helping individual patients and with changing procedure preference and 





1. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004;14:1157-64.
2. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for 
 Diabetes - 5-Year Outcomes. N Engl J Med 2017;376:641-651.
3. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-
 -3-year outcomes. N Engl J Med 2014;370:2002-13.
4. Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery and Endoluminal Procedures: IFSO 
 Worldwide Survey 2014. Obes Surg 2017;27:2279-2289.
5. Alvarez-Leite JI. Nutrient deficiencies secondary to bariatric surgery. Curr Opin Clin Nutr Metab Care 
 2004;7:569-75.
6. Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what 
 have we learned? Obes Surg 2005;15:145-54.
7. Duran de Campos C, Dalcanale L, Pajecki D, et al. Calcium intake and metabolic bone disease after 
 eight years of Roux-en-Y gastric bypass. Obes Surg 2008;18:386-90.
8. Johnson JM, Maher JW, DeMaria EJ, et al. The long-term effects of gastric bypass on vitamin D 
 metabolism. Ann Surg 2006;243:701-4; discussion 704-5.
9. Vargas-Ruiz AG, Hernandez-Rivera G, Herrera MF. Prevalence of iron, folate, and vitamin B12 
 deficiency anemia after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2008;18:288-93.
10. Dalcanale L, Oliveira CP, Faintuch J, et al. Long-term nutritional outcome after gastric bypass. Obes 
 Surg 2010;20:181-7.
11. Lupoli R, Lembo E, Saldalamacchia G, et al. Bariatric surgery and long-term nutritional issues. World J 
 Diabetes 2017;8:464-474.
12. Thibault R, Huber O, Azagury DE, et al. Twelve key nutritional issues in bariatric surgery. Clin Nutr 
 2016;35:12-7.
13. Aarts EO, van Wageningen B, Janssen IM, et al. Prevalence of Anemia and Related Deficiencies 
 in the First Year following Laparoscopic Gastric Bypass for Morbid Obesity. J Obes 2012;2012:193705.
14. Brolin RE, Gorman JH, Gorman RC, et al. Are vitamin B12 and folate deficiency clinically important 
 after roux-en-Y gastric bypass? J Gastrointest Surg 1998;2:436-42.
15. Dogan K, Homan J, Aarts EO, et al. Long-term nutritional status in patients following Roux-en-Y 
 gastric bypass surgery. Clin Nutr 2018;37:612-617.
16. Dolan K, Hatzifotis M, Newbury L, et al. A clinical and nutritional comparison of biliopancreatic 
 diversion with and without duodenal switch. Ann Surg 2004;240:51-6.
17. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative 
 Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 
 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of 
 Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity 
 Medicine Association, and American Society of Anesthesiologists. Endocr Pract 2019.
18. Homan J, Betzel B, Aarts EO, et al. Vitamin and Mineral Deficiencies After Biliopancreatic Diversion 
 and Biliopancreatic Diversion with Duodenal Switch--the Rule Rather than the Exception. Obes Surg 
 2015;25:1626-32.
19. de Luis DA, Pacheco D, Izaola O, et al. Zinc and copper serum levels of morbidly obese patients before 
 and after biliopancreatic diversion: 4 years of follow-up. J Gastrointest Surg 2011;15:2178-81.
20. Busetto L, Dicker D, Azran C, et al. Practical Recommendations of the Obesity Management Task Force 
158
 of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical 
 Management. Obes Facts 2017;10:597-632.
21. Allied Health Sciences Section Ad Hoc Nutrition C, Aills L, Blankenship J, et al. ASMBS Allied Health 
 Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis 2008;4:S73-108.
22. Parrott J, Frank L, Rabena R, et al. American Society for Metabolic and Bariatric Surgery Integrated 
 Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg 
 Obes Relat Dis 2017;13:727-741.
23. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, 
 metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by 
 American Association of Clinical Endocrinologists, The Obesity Society, and American Society for 
 Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013;21 Suppl 1:S1-27.
24. Kaidar-Person O, Person B, Szomstein S, et al. Nutritional deficiencies in morbidly obese patients: a 
 new form of malnutrition? Part A: vitamins. Obes Surg 2008;18:870-6.
25. Damms-Machado A, Friedrich A, Kramer KM, et al. Pre- and postoperative nutritional deficiencies in 
 obese patients undergoing laparoscopic sleeve gastrectomy. Obes Surg 2012;22:881-9.
26. Kaidar-Person O, Rosenthal RJ. Malnutrition in morbidly obese patients: fact or fiction? Minerva Chir 
 2009;64:297-302.
27. Malek M, Yousefi R, Safari S, et al. Dietary Intakes and Biochemical Parameters of Morbidly Obese 
 Patients Prior to Bariatric Surgery. Obes Surg 2019.
28. Sanchez A, Rojas P, Basfi-Fer K, et al. Micronutrient Deficiencies in Morbidly Obese Women Prior to 
 Bariatric Surgery. Obes Surg 2016;26:361-8.
29. Dogan K, Aarts EO, Koehestanie P, et al. Optimization of vitamin suppletion after Roux-en-Y gastric 
 bypass surgery can lower postoperative deficiencies: a randomized controlled trial. Medicine 
 (Baltimore) 2014;93:e169.
30. Homan J, Schijns W, Aarts EO, et al. An optimized multivitamin supplement lowers the number of 
 vitamin and mineral deficiencies three years after Roux-en-Y gastric bypass: a cohort study. Surg Obes 
 Relat Dis 2016;12:659-667.
31. Boerboom A, Homan J, Aarts E, et al. A long biliopancreatic and short alimentary limb results in more 
 weight loss in revisional RYGB surgery. Outcomes of the randomized controlled ELEGANCE REDO 
 trial. Surg Obes Relat Dis 2019;15:60-69.
32. Homan J, Boerboom A, Aarts E, et al. A Longer Biliopancreatic Limb in Roux-en-Y Gastric Bypass 
 Improves Weight Loss in the First Years After Surgery: Results of a Randomized Controlled Trial. Obes 
 Surg 2018;28:3744-3755.
33. Welbourn R, Hollyman M, Kinsman R, et al. Bariatric Surgery Worldwide: Baseline Demographic 
 Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg 
 2019;29:782-795.
34. Kehagias I, Zygomalas A, Karavias D, et al. Sleeve gastrectomy: have we finally found the holy grail of 
 bariatric surgery? A review of the literature. Eur Rev Med Pharmacol Sci 2016;20:4930-4942.
35. Ben-Porat T, Elazary R, Goldenshluger A, et al. Nutritional deficiencies four years after laparoscopic 
 sleeve gastrectomy-are supplements required for a lifetime? Surg Obes Relat Dis 2017;13:1138-1144.
36. Ruiz-Tovar J, Llavero C, Zubiaga L, et al. Maintenance of Multivitamin Supplements After Sleeve 
 Gastrectomy. Obes Surg 2016;26:2324-30.
37. Coupaye M, Riviere P, Breuil MC, et al. Comparison of nutritional status during the first year after 




38. Guan B, Yang J, Chen Y, et al. Nutritional Deficiencies in Chinese Patients Undergoing Gastric Bypass 
 and Sleeve Gastrectomy: Prevalence and Predictors. Obes Surg 2018;28:2727-2736.
39. Kwon Y, Kim HJ, Lo Menzo E, et al. Anemia, iron and vitamin B12 deficiencies after sleeve 
 gastrectomy compared to Roux-en-Y gastric bypass: a meta-analysis. Surg Obes Relat Dis 
 2014;10:589-97.
40. Moize V, Andreu A, Flores L, et al. Long-term dietary intake and nutritional deficiencies following 
 sleeve gastrectomy or Roux-En-Y gastric bypass in a mediterranean population. J Acad Nutr Diet 
 2013;113:400-10.
41. Aarts EO, Janssen IM, Berends FJ. The gastric sleeve: losing weight as fast as micronutrients? Obes 
 Surg 2011;21:207-11.
42. Caron M, Hould FS, Lescelleur O, et al. Long-term nutritional impact of sleeve gastrectomy. Surg Obes 
 Relat Dis 2017;13:1664-1673.
43. Kikkas EM, Sillakivi T, Suumann J, et al. Five-Year Outcome of Laparoscopic Sleeve Gastrectomy, 
 Resolution of Comorbidities, and Risk for Cumulative Nutritional Deficiencies. Scand J Surg 
 2019;108:10-16.
44. van Rutte PW, Aarts EO, Smulders JF, et al. Nutrient deficiencies before and after sleeve 
 gastrectomy. Obes Surg 2014;24:1639-46.
45. Aarts EO, Berends FJ, Janssen IM, et al. Semiquantitative assessment of bowel habits and its 
 relation with calcium metabolism after gastric bypass surgery: a retrospective study. J Obes 
 2011;2011:156164.
46. Cai J, Zhang Q, Wastney ME, et al. Calcium bioavailability and kinetics of calcium ascorbate and 
 calcium acetate in rats. Exp Biol Med (Maywood) 2004;229:40-5.
47. Suzuki S, Ramos EJ, Goncalves CG, et al. Changes in GI hormones and their effect on gastric emptying 
 and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005;138:283-90.
48. Mellstrom D, Johansson C, Johnell O, et al. Osteoporosis, metabolic aberrations, and increased risk for 
 vertebral fractures after partial gastrectomy. Calcif Tissue Int 1993;53:370-7.
49. Melton LJ, 3rd, Crowson CS, Khosla S, et al. Fracture risk after surgery for peptic ulcer disease: a 
 population-based cohort study. Bone 1999;25:61-7.
50. Klein KB, Orwoll ES, Lieberman DA, et al. Metabolic bone disease in asymptomatic men after partial 
 gastrectomy with Billroth II anastomosis. Gastroenterology 1987;92:608-16.
51. Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium 
 metabolism after malabsorptive bariatric surgery. J Gastrointest Surg 2004;8:48-55; discussion 54-5.
52. Malone M. Recommended nutritional supplements for bariatric surgery patients. Ann Pharmacother 
 2008;42:1851-8.
53. Williams SE, Cooper K, Richmond B, et al. Perioperative management of bariatric surgery patients: 
 focus on metabolic bone disease. Cleve Clin J Med 2008;75:333-4, 336, 338 passim.
54. Topart P, Becouarn G, Salle A, et al. Biliopancreatic diversion requires multiple vitamin and 
 micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis 2014;10:936-41.
55. Nett P, Borbely Y, Kroll D. Micronutrient Supplementation after Biliopancreatic Diversion with 
 Duodenal Switch in the Long Term. Obes Surg 2016;26:2469-74.
56. Salgado W, Jr., Modotti C, Nonino CB, et al. Anemia and iron deficiency before and after bariatric 
 surgery. Surg Obes Relat Dis 2014;10:49-54.
57. Fernandez-Gaxiola AC, De-Regil LM. Intermittent iron supplementation for reducing anaemia and its 
 associated impairments in adolescent and adult menstruating women. Cochrane Database Syst Rev 
160
 2019;1:CD009218.
58. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given 
 on consecutive versus alternate days and as single morning doses versus twice-daily split dosing 
 in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 
 2017;4:e524-e533.










Meer dan de helft van de Nederlandse bevolking lijdt momenteel aan overgewicht 
(BMI≥ 25kg/m2) en 15% behoort tot de groep met obesitas (BMI≥30kg/m2).Wereldwijd 
zijn er meer dan 1,9 miljard volwassenen met overgewicht (39% van de volwassen 
wereldbevolking), waarvan 650 miljoen (14%) met obesitas. Bariatrische chirurgie, ook 
wel metabole chirurgie genoemd, is tot op heden de enige effectieve behandeling voor 
gewichtsverlies en -behoud op de lange termijn. Hierbij nemen ook de gerelateerde 
comorbiditeiten zoals diabetes mellitus type 2, hart-en-vaatziekten, artrose en slaapapnoe 
significant af. Het Rijnstate Ziekenhuis te Arnhem is al jaren een toonaangevend 
centrum voor metabole chirurgie in Nederland. Aanvankelijk werden veel maagbanden 
geplaatst ter behandeling van morbide obesitas, maar eigen wetenschappelijk onderzoek 
liet zien dat deze behandeling bij veel patiënten op de lange termijn in termen van 
gewichtsverlies en afname van comorbiditeiten niet tot de gewenste resultaten leidde. 
Elke patiënt met (morbide) obesitas is anders en er moet zorgvuldig worden afgewogen 
met welke ingreep het beste resultaat verwacht kan worden. Er moet telkens een 
afweging gemaakt worden tussen de voor- en nadelen die te verwachten zijn per patiënt. 
Het is dan ook logisch dat er verschillende ingrepen ontwikkeld zijn. Na de afname van 
het aantal maagbandplaatsingen maakte in Nederland de laparoscopische Roux-en-Y 
Gastric Bypass (RYGB) een snelle opmars, enkele jaren later gevolgd door de Gastric 
Sleeve (GS) welke nu ook wereldwijd de meest uitgevoerde metabole ingrepen zijn 
(figuur 2 en 3 Introduction). Daarnaast zijn er ook andere bariatrische procedures die 
bijvoorbeeld gebruikt kunnen worden bij extreme obesitas (veelal BMI > 60 kg/m2). 
Voorbeelden hiervan zijn de biliopancreatische diversie met of zonder duodenal switch 
(BPD/DS, figuur 6 Introduction). Andere ingrepen die nu een opmars maken en in de 
toekomst naar verwachting vaker verricht zullen worden zijn de SADI-S en de mini 
gastric bypass (figuur 4 en 5 Introduction).
In de afgelopen 25 jaar is steeds duidelijker geworden dat metabole chirurgie ook 
nadelen kent op de lange termijn. De meest voorkomende complicatie is het ontstaan van 
vitamine- en mineralendeficiënties wat lange tijd onderbelicht bleef. Deze deficiënties 
waren wel bekend in de geneeskunde, vooral na ondervoeding en alcoholmisbruik, maar 
niet in deze spectaculaire mate. Ook werd duidelijk dat de standaard behandelingen om 
de deficiënties te behandelen in hun normale dosis volstrekt ontoereikend waren. De 
‘American Society for Metabolic and Bariatric Surgery’ (ASMBS) adviseert (pas) sinds 
2008 aan alle postoperatieve patiënten levenslang dagelijks multivitaminepreparaten, 
vitamine D en calciumsupplementen te gebruiken. Ook wordt geadviseerd om jaarlijks 
laboratorium onderzoek te verrichten om tekorten aan vitamines en mineralen tijdig op 
te sporen.
Tijdens metabole chirurgie wordt de maag aanzienlijk verkleind en meestal 
gecombineerd met een omleiding van de darmen (bypass). Belangrijke absorptie locaties 
voor micronutriënten worden zodoende overgeslagen of worden te snel gepasseerd door 
een verhoogde motiliteit van de darm. Door de vermindering van het maagvolume bij 
veel procedures is er minder maagzuur en intrinsic factor beschikbaar welke nodig 
zijn om aan substraat gebonden micronutriënten te kunnen splitsen en om te zetten 
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naar een opneembare variant. Daarnaast is er veelal een fysieke restrictie, waardoor 
patiënten na metabole chirurgie minder eten. Regelmatig ontstaat ook een intolerantie 
voor bijvoorbeeld rood vlees hetgeen bijdraagt aan het ontwikkelen van vitamine- 
en mineralendeficiënties. Andere bijdragende factoren zijn bijvoorbeeld braken, 
aanhoudende slechte eetgewoontes, het gebruik van protonpompremmers, slechte 
therapietouw voor multivitaminepreparaten en een veranderde smaak. Een grote rol is 
daarnaast weggelegd voor de leef- en eetgewoonten voor metabole chirurgie waarbij 
zeer frequent tekorten gevonden worden. In deze patiënten wordt meestal een slecht 
voedingspatroon, minder blootstelling aan zon en een hoog vetpercentage gevonden.
De meest voorkomende postoperatieve deficiënties (o.a. afhankelijk van het type 
ingreep) worden gezien in het ferritinegehalte (66%), vitamine B12 (50%), foliumzuur 
(15%) vitamine B1 (49%), vitamine D (25-73%) en calcium (10%). De meer extreme 
operaties waarbij slechts enkele meters functionele dunne darm resteren zoals de BPD/
DS geven ook kans op deficiënties voor vitamine A (5-69%), E, en K (50-60%). 
Vitamines en mineralen spelen een belangrijke rol in enzymreacties voor homeostase, 
metabolisme en neurologische functies. Deficiënties van deze micronutriënten kunnen 
leiden tot serieuze complicaties op hematologisch, neurologisch en musculoskeletaal 
gebied. Het is daarom noodzakelijk om meer kennis te krijgen over micronutriënten 
voor en na metabole chirurgie, deficiënties te voorkomen en als ze ontstaan ze zo 
adequaat mogelijk te behandelen. 
Doel van het proefschrift
De studies in dit proefschrift richten zich in eerste instantie op de preventie van het 
ontwikkelen van vitamine- en mineralentekorten na metabole chirurgie. In het verleden 
werd een lijn met gespecialiseerde multivitaminepreparaat ontwikkeld door dr. E.O. 
Aarts samen met FitForMe (Rotterdam, Nederland), gebaseerd op literatuur en eigen 
onderzoek. De preparaten verschillen in samenstelling gebaseerd op de specifieke 
behoeften per operatie die patiënten ondergingen, omdat reguliere multivitaminen niet 
sufficiënt bleken. In dit gespecialiseerde preparaat zijn veel doseringen aangepast of 
opgehoogd. In het eerste onderzoek door collega’s Dogan et al werd al aangetoond dat 
op de korte termijn het preparaat effectiever is dan standaard multivitaminen. 
In het huidige proefschrift wordt het effect van dit preparaat verder uitgediept op de 
lange termijn, zowel voor de RYGB als voor een nieuw supplement voor de SG operatie.
Het tweede doel van dit proefschrift is gebaseerd op het verkrijgen van inzicht in een 
gedeelte van de veranderende fysiologie na metabole chirurgie. Zo wilden we meer 




Het derde doel was om te onderzoeken wat de beste behandeling is indien er een 
tekort ontstaat voor ijzer of vitamine B12, maar ook hoe de tekorten na een BPD/DS te 
behandelen zijn.
Beschrijving van de hoofdstukken
In hoofdstuk 2 wordt een groot retrospectief cohort besproken van 1160 RYGB 
patiënten. Het gebruik van een standaard multivitaminepreparaat werd vergeleken 
met een speciaal ontwikkeld preparaat zoals beschreven in de studie van Dogan et 
al. Er werd gekeken naar de serumwaardes van verschillende micronutriënten en 
het aantal deficiënties na 1, 2 en 3 jaar postoperatief. Er was een significant hogere 
serumwaarde voor ferritine, vitamine B12, vitamine D en foliumzuur in de groep met 
het gespecialiseerde multivitaminepreparaat. Ook ontstonden er veel minder nieuwe 
deficiënties in deze groep. 
Het aantal GS operaties neemt fors toe wereldwijd. Voor deze ingreep werd een speciaal 
multivitaminepreparaat ontwikkeld (met aangepaste doseringen). In hoofdstuk 3 wordt 
een gerandomiseerde dubbelblind gecontroleerde studie beschreven in 139 patiënten 
waarbij het speciaal ontwikkelde supplement werd vergeleken met een standaard 
multivitaminepreparaat tot 1 jaar postoperatief. Het bleek dat de aangepaste doseringen 
nog niet adequaat genoeg waren. De doseringen zijn geoptimaliseerd en worden 
binnenkort onderzocht in een vervolgstudie. 
Postoperatief verandert de opname van micronutriënten sterk. Daarnaast verandert 
frequent het ontlastingspatroon. We stelden de vraag of het veranderen van het 
ontlastingspatroon van invloed was op de calciummetabolisme na het ondergaan van 
een RYGB. In hoofdstuk 4 wordt in 75 RYGB-patiënten preoperatief en vervolgens 
6 en 12 maanden postoperatief het ontlastingspatroon in kaart gebracht (fecal score: 
FS) en vervolgens vergeleken met laboratoriumuitslagen voor calciummetabolisme. 
FS is positief gecorreleerd met een secundaire hypoparathyreoïdie. Mogelijk kan het 
reguleren van het ontlastingspatroon bijdragen aan minder calciumtekorten. 
Hoofdstuk 5 beschrijft retrospectief de behandeling van vitamine- en 
mineralendeficiënties die ontstaan na een BPD/DS (N=34). Vitamine B1, B6, B9 en 
B12 deficiënties konden voorkomen worden met een gemiddelde dagdosis van 2.75mg, 
980µg, 600µg, en 350µg. Veel patiënten ontwikkelden tekorten aan vitamine A, D, 
ferritine, calcium en zink ondanks grote dosisaanpassingen. 
Huidige observaties suggereren dat de dagelijkse minimale dosering ijzer ter preventie 
200 mg bij premenopauzale vrouwen en 100 mg bij mannen moet zijn. Voor zink is dit 
100mg, voor calcium 3000mg en voor opgelost vitamine A en vitamine D een wekelijkse 
dosering van tenminste 50,000IE. 
In hoofdstuk 6 wordt een multicentrische gerandomiseerde studie uitgevoerd bij 120 
vrouwen die een ijzerdeficiëntie hebben ontwikkeld na RYGB. In deze studie werd 
het effect van ferrofumaraat (3 maanden 3d200mg oraal), ferrogluconaat (3 maanden 
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2d695mg oraal) en ferricarboxymaltose (eenmalig 1000mg intraveneus) met elkaar 
vergeleken wat betreft effectiviteit op het ferritine gehalte en vervolgd voor 1 jaar. 
Na 3 maanden bleek 39-42% van de vrouwen met orale behandeling nog steeds een 
ijzerdeficiëntie te hebben en 0% in de intraveneuze groep. In de groep vrouwen die geen 
ijzerdeficiënte meer had na 3 maanden orale suppletie, bleek na 9 maanden meer dan 
50% een re-deficiëntie te hebben ondanks dagelijks gebruik van multivitamine (70mg 
ijzer). Voor de intraveneuze groep betrof dit 28%. Ook werden er veel bijwerkingen 
ervaren bij orale therapie tegenover nauwelijks bijwerkingen in de intraveneuze groep. 
Tot slot wordt in hoofdstuk 7 een gerandomiseerde studie uitgevoerd waarbij 50 patiënten 
met een vitamine B12 deficiëntie na RYGB behandeld werden met 2 verschillende 
therapieën; een intramusculaire vitamine B12 injectie (hydroxocobalamine elke 2 
maanden) of oraal (methylcobalamine 1000ug/dag) gesuppleerd worden met vitamine 
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Collecting, handling and storing data in a transparent and reliable manner is an important 
issue. This thesis is based on the results of human studies, which were conducted in 
accordance with the principles of the Declaration of Helsinki. The medical and ethical 
review board Committee on Research Involving Human Subjects Region Arnhem 
Nijmegen, Nijmegen, the Netherlands has given approval to conduct the prospective 
studies. These studies were also registered in clinicaltrials.gov. All participants gave 
written informed consent to participate in the studies. Retrospective studies were 
approved by the Local Ethical Committee of the Rijnstate Hospital. The research data 
were archived by FAIR-principles 1 (improve Findability, Accessibility, Interoperability 
and Reuse of research data). 
Data were captured and processed in Microsoft® Office Excel, Research manager® 
and IBM® SPSS Statistics. All files were stored at on a local server of the department 
of surgery in Rijnstate Hospital, of which an update was daily performed. The files 
were only accessible for scientific members of our research group and locked with a 
password.
The Rijnstate Hospital Vitalys Clinic was responsible for trial design, trial set‐up, trial 
management and all statistical aspects of the trial. 
All data generated or analyzed in this thesis are included in published articles and its 
additional files are available from the associated corresponding authors on request.
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 25-OHD  25-Hydroxyvitamin D
 %TBWL Pecentage Total Body Weight Loss
 %EWL  Percentage ExcessWeight Loss
A
 AGB  Adjustable Gastric Band
 ASMBS  American Society for Metabolic and Bariatric Surgery
B
 BMI  Body Mass Index
 BPD  Biliopancreatic Diversion
 BPD/DS  Biliopancreatic Diversion with Duodenal Switch
C
 Ca  Calcium
 Cacorr  Calcium corrected for albumin
 CRP  C-Reactive Protein
D
 DM  Diabetes Mellitus
F
 FCM  Ferric carboxymaltose
FF  Ferrous fumarate
 FG  Ferrous gluconate
 FS  Fecal Score
H
 Hb  Hemoglobin
 Hcy  Homocysteine
 HoloTC  Holotranscobalamin
 Ht  Hematocrite
I
	 ID	 	 Iron	Deficiency
 IF  Intrinsic Factor
 IFSO  International Federation for the Surgery of Obesity and                      
   Metabolic Disorders
 IM-B12  Group treated with intramuscular hydroxocobalamin
 IV  Intravenous
L
 LSG  Laparoscopic Sleeve Gastrectomy
M
 MCV  Mean Cell Volume
 MGB  Mini Gastric Bypass
 MMA  Methylmalonic Acid
N
 N  Number
O
 oMVS  Optimized multivitamin supplement
 Oral-B12 Group treated with oral methylcobalamin
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 OSAS  Obstructive Sleep Apnea Syndrome
P
 PPI  Proton Pump Inhibitor
 PTH  Parathyroid Hormone
R
 RCT  Randomized Controlled Trial
 RDA  Recommended Daily Allowance
 RHA  Rijnstate Hospital Arnhem
 RYGB  Roux-en-Y Gastric Bypass 
S
 SADI-S  Single Anastomosis Duodeno Ileal bypass with Sleeve
 SD  Standard Deviation
 SG  Sleeve Gastrectomy
SHPT  Secondary Hyperparathyroidism
sMVS  Standard Multivitamin Suppelement
T
 TIBC  Total Iron Binding Capacity
W
 WHO  World Health Organization
 WLS Forte®   Weight Loss Surgery Forte® (optimized multivitamin  
   supplement)
 WLS Optimum® Weight Loss Surgery Optimum® (optimized multivitamin  
   supplement)
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Na 6 jaar is het dan eindelijk zo ver, het proefschrift is af! Alle tijd en energie die 
hierin gestoken zijn, zijn uiteraard niet alleen van mij afkomstig. Er zijn veel mensen 
betrokken geweest gedurende mijn promotietraject, zowel op de werkvloer als ook 
in mijn privéleven. Ik wil dan ook iedereen bedanken die op welke manier dan ook 
heeft bijgedragen aan dit eindresultaat. Er zijn een aantal mensen die een speciale rol 
hebben gespeeld gedurende mijn promotietraject en die ik hiervoor in het bijzonder wil 
bedanken.
Allereerst wil ik de vele patiënten bedanken voor het deelnemen aan mijn studies. 
Zonder hen zou het nooit gelukt zijn deze uit te voeren. Door jullie bijdrage hebben we 
grote stappen kunnen zetten in de preventie en behandeling van vitamine-en mineralen 
tekorten na metabole chirurgie.
Beste Frits (dr.Berends, co-promotor), bedankt dat ik als net afgestudeerde arts en als 
eerste vrouwelijke onderzoeker in jullie onderzoeksteam en toonaangevend bariatrisch 
centrum (Vitalys) mocht komen werken. Ik had veel te leren en ben ontzettend dankbaar 
voor de kansen die ik gekregen heb. Bedankt voor je waardevolle bijdrage aan het 
schrijven van de artikelen en dit proefschrift.
Beste Edo (dr. Aarts, co-promotor), waar moet ik beginnen, woorden zullen 
tekortschieten. Allereerst, bedankt voor je dagelijkse begeleiding van begin tot het einde 
van mijn promotietraject. Je hebt enorm veel tijd en werk hierin gestoken. Ook de laatste 
jaren toen ik 182km zuidelijker ben gaan wonen, was je zeer laagdrempelig bereikbaar 
en altijd snel met je reacties. 
Ignace (drs. Janssen), samen met Frits waren jullie de twee grote heren van Vitalys. 
Een man met een groot hart, zeer gedreven. Jij hebt een belangrijke rol gespeeld in de 
loop van de tijd. Je hebt ervoor gezorgd dat ik mijn promotietraject heb voortgezet nadat 
ik had gekozen voor de huisartsenopleiding. Je wist me als geen ander te motiveren 
en dacht mee hoe dit aan te pakken. Je was erg betrokken en bleef  vertrouwen in me 
houden, bedankt hiervoor!
 
Geachte professor van Laarhoven (promotor), bedankt dat u mijn promotor wilde zijn en 
het vertrouwen dat u in mijn promotietraject had. Bedankt voor uw belangrijke bijdrage 
aan de studies en de totstandkoming van dit proefschrift. 
Geachte professor Drenth (promotor), heel fijn dat u bent aan gesloten als promotor 
van mijn proefschrift dit heeft een grote meerwaarde gehad. Ik ben u dankbaar voor de 
betrokkenheid, de waardevolle ondersteuning en uw snelle reacties. Uw kritische blik 
heeft het proefschrift enorm verbeterd.
Beste dr. De Boer, beste Hans, als endocrinoloog in het Rijnstate speel(de) jij een zeer 
belangrijke rol binnen de bariatrische chirurgie. Mijn onderzoeken richtten zich met 
name op  de complicaties die betrekking hadden op jouw specialisme. Hierdoor hebben 
196
we veel samengewerkt en bij deze wil ik je bedanken voor al je kennis, de prettige 
samenwerking en je zeer belangrijke input in mijn onderzoeken. Als afsluiter wil ik je 
ook bedanken voor het grondig doorlezen van mijn proefschrift en je deelname aan de 
verdediging. Geniet van je welverdiende pensioen. 
Beste leden van de manuscript commissie, prof. dr.G.A.P.J.Rongen, prof. dr. A.J. Kiliaan 
en prof. dr. ir. J. Seidell, bedankt voor het kritisch doorlezen en beoordelen van dit 
proefschrift en jullie bereidheid om zitting te nemen in de corona. 
Prof. dr. E.J. Hazebroek, prof. dr. Kaasjager, dr. Koehestanie, bedankt voor het 
bestuderen van mijn proefschrift en de zitting in de corona (een woord dat dit jaar helaas 
ook een heel andere betekenis heeft gekregen). Prof. dr. Kaasjager, ook bedankt voor de 
fijne samenwerking in het verleden. 
Beste chirurgen en arts-assistenten uit het Rijnstate, als arts-onderzoeker maakte ik al snel 
onderdeel uit van jullie groep. Van de overdracht in de ochtend, tot de refereeravonden 
en uitjes met de maatschap. Ook sprong ik zo nu en dan bij op de afdeling als er krapte 
was in de bezetting. Het was fijn om hier deel van uit te maken, waarvoor dank! 
Beste collega’s van de Nederlandse Obesitas Kliniek te Velp, het volledige voor- en 
natraject van de metabole chirurgie viel onder jullie zorg. Tijdens mijn onderzoeksperiode 
heb ik daarom regelmatig met jullie samengewerkt en hierbij wil ik jullie bedanken voor 
het prettige verloop. 
Collega’s van het Rode Kruis Ziekenhuis en OLVG West, mijn laatste RCT heb ik samen 
met jullie uitgevoerd. Het was met jullie niet ingewikkeld om multicentrisch onderzoek 
te verrichten, de samenwerking verliep vlot en een ritje richting de Randstad was altijd 
leuk om te doen, dankjulliewel. 
Beste medewerkers van de trial-apotheek en het klinisch chemisch laboratorium, in 
het grootste gedeelte van de totstandkoming van dit proefschrift hebben jullie ook een 
grote rol gehad. Bedankt voor de samenwerking, het overleggen en het laagdrempelig 
bereikbaar zijn.
Beste collega’s van het wetenschapsbureau en leerhuis, alle trials in het Rijnstate worden 
bij jullie geregistreerd en voorzien van kritische feedback. Ook hebben jullie mijn 
waardevolle ondersteuning geboden zoals het beschikbaar stellen van het programma 
Researchmanager. Bedankt hiervoor.
Mijn speciale dank gaat uit naar Lian Roovers, epidemioloog. Jouw kennis en bijdrage 
op statistisch gebied was van onschatbare waarde tijdens mijn promotietraject!
Beste Jens en Bark, zes jaar geleden sloot ik als eerste vrouwelijke onderzoeker aan bij 
jullie mannenclubje in plaats van Kemal. Dit was even wennen. Jullie hebben inmiddels 
de promotie afgerond, goed werk! Bedankt voor de gezellige tijd en jullie bijdrage aan 




Laura Deden, na een hoog testosterongehalte op de assistentenkamer was ik blij dat jij 
ons bariatrisch onderzoeksteam kwam versterken als technisch geneeskundige. Bedankt 
voor de hele fijne samenwerking in de afgelopen jaren, de wandelingen in de middag en 
dat je nu mijn paranimf bent. Succes met je verdere carrière als technisch geneeskundige, 
een jong vak wat zeker een belangrijke rol in de toekomst gaat vervullen.
Na Laura kwam later ook Mellody erbij en maakte de gezelligheid (en leuke ritjes) 
compleet. Bedankt voor de samenwerking en veel succes met de huisartsenopleiding en 
je promotietraject. Ook Abel volgde in 2016. Bedankt voor je inzet voor de ijzersuppletie 
trial en ook jij succes met de huisartsenopleiding en promotie, dat gaat zeker lukken!
Laura Heusschen, graag wil ik je bedanken voor de samenwerking en succes wensen 
voor de toekomst. Ik kijk met grote belangstelling uit naar je verdere onderzoeken over 
vitamines en mineralen na metabole chirurgie.
Lieve collega’s van de huisartsenopleiding en opleiders, de opleiding tot huisarts 
was een zeer leerzame periode op het gebied van medische kennis, communicatie en 
persoonlijke groei. We hebben veel van elkaar kunnen leren en ook veel (werk)plezier 
gehad. 
Beste Jean-Paul, bedankt voor je collegialiteit en je flexibiliteit in de huisartsenpraktijk. 
Zo verloopt het plannen en afronden van de zaken rondom dit proefschrift soepeler.
Alle co-auteurs, bedankt voor de belangrijke input die jullie hebben gehad voor het 
voltooien van de wetenschappelijke onderzoeken en de fijne samenwerking.
Beste Kristy, ontzettend knap hoe jij je hebt opgewerkt als manager van Vitalys. Bedankt 
voor al je ondersteuning, je vertrouwen in mij en de gezelligheid tijdens congressen en 
alle andere uitjes. 
Martin Kirch, de man van de financiën. Dankjewel voor je ondersteuning, oprechte 
vriendelijkheid en laagdrempelige bereikbaarheid voor overleg ondanks je drukke 
agenda.  
Beste Nadine, Gül, Linda en Annemieke, als verpleegkundig specialist en morbide 
obesitas verpleegkundigen hebben jullie een belangrijke taak te vervullen binnen 
Vitalys. Patiënten kunnen blij zijn met jullie. Het was heel fijn samenwerken! 
Beste dames van Vitalys (Ada, Anja, Caroline, Ellen, Frieda, en Peggy), bij binnenkomst 
had ik al snel door dat ik in een warm bad was beland. Wat een fijn team zijn jullie en 
wat vind ik het jammer dat ik niet dichterbij woon om even een kop koffie of thee te 
komen drinken! Ellen, speciale dank aan jou voor het database werk. Bedankt dames 
voor de gezellige tijden en samenwerking. 
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Allerliefste meiden, oftewel ‘vrouwluuj’ (Jolijn, Nadja, Claudia, Mary, Simone en 
Claudia (ja 2 keer), met ons clubje van 7 zijn we samen opgegroeid en hebben we veel 
meegemaakt. Bedankt voor de ontelbare gezellige avonden/dagen/weekenden/vakanties 
en ga zo maar door. Het plezier en de ontspanning met jullie is de drijfveer om door te 
gaan met de serieuze zaken in het leven. Jolijn, heel erg fijn dat je mijn paranimf wil 
zijn. Met jouw hulp gaat het helemaal goed komen. 
Fia, Yvo, Sjef en Annie, kostbare familieleden die ik er in de loop van de jaren bij 
heb gekregen. Al die jaren hebben jullie mij ondersteund en zijn jullie altijd oprecht 
geïnteresseerd geweest in mij en mijn werkzaamheden. Behalve hiervoor ook dank voor 
al het andere wat jullie voor Noël en mij doen en hebben gedaan! 
Lieve pap en mam, mijn carrière heb ik voor een groot deel aan jullie te danken. Jullie 
hebben alles gedaan wat jullie konden doen om mij mijn droom te laten verwezenlijken. 
Hiervoor ben ik jullie eeuwig dankbaar en dat zal ik nooit vergeten. ‘Ich hot van uuch’. 
Tot slot, lieve Noël, nog voordat ik vertrok uit Bocholtz om in Nijmegen te gaan studeren 
waren wij al samen. Nu 13 jaar later nog steeds mijn liefde en mijn soulmate. Jij was en 
bent er altijd voor me en volgt mij in mijn keuzes, niks is jou te veel. Wat hebben we veel 
meegemaakt in die jaren. Je hebt het nodige geduld moeten opbrengen door mijn vele 
werken, ook in onze kostbare vrije tijd samen. Na het afronden van mijn promotie en 
de huisartsenopleiding komt er meer tijd vrij voor leuke dingen en staat ons een mooie 
toekomst te wachten. Ik hou van je. 


